Immunotherapeutic proteins containing an FC domain component with a mutation at position 429
Mutant IgG molecules with mutations at position 429 in the CH3 domain enhance complement activation and oligomer formation, addressing the limitations of existing mAbs by improving therapeutic efficacy in treating various diseases, including cancers and autoimmune disorders.
Patent Information
- Application Number
- JP2024527530
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-15
- Filing Date
- 2022-10-26
- Publication Date
- 2024-12-03
AI Technical Summary
Existing monoclonal antibodies (mAbs) used in treating inflammatory diseases and cancers have limitations in enhancing therapeutic efficacy due to insufficient modifications in the Fc region, particularly in terms of complement-dependent cytotoxicity (CDC) and FcγR interactions.
Development of mutant immunoglobulin G (IgG) molecules with specific mutations at position 429 in the CH3 domain, allowing for enhanced activation of the complement system and formation of oligomers, including hexamers, to improve therapeutic efficacy against diseases such as cancer, infectious diseases, and autoimmune disorders.
The mutant IgG molecules exhibit improved complement-dependent cytotoxicity and antigen binding, leading to enhanced therapeutic effects in treating conditions like acute lymphoblastic leukemia, adenocarcinoma, COVID-19, drug-resistant malaria, systemic lupus erythematosus, and type 1 diabetes.
Smart Images

Figure 2024544531000034 
Figure 2024544531000035 
Figure 2024544531000036
Abstract
Description
[Technical field]
[0001] The present disclosure relates to immunotherapeutic proteins, including, for example, modified immunoglobulin molecules (i.e., antibodies), for use in methods of treating a disease or condition.
[0002] Preferred Documents This application claims priority from Australian Provisional Patent Application No. 2021 / 903609, entitled "Modified immunoglobulin and method of use thereof(3)", filed November 11, 2021, and from Australian Provisional Patent Application No. 2022 / 901632, also entitled "Modified immunoglobulin and method of use thereof(3)", filed June 15, 2022. The contents of both of these applications are incorporated herein by reference in their entireties. [Background technology]
[0003] Monoclonal antibodies (mAbs) have become one of the most important and successful types of therapy, revolutionizing the treatment of inflammatory diseases such as cancer and autoimmune diseases. Many mAbs engineered on the backbone of the IgG antibody class specifically exploit the powerful effector functions of the immune system by engaging both the target antigens through their variable Fab domains and Fcγ receptors (FcγRs) through their heavy chains, which contain a constant Fc portion (Fc or Fc fragment), leading to the activation of inflammatory or killer cells, among others. In addition, the Fc of the antibody can also activate blood proteins called complement (which involves the antibodies coming together in a process known as "self-association" or "on-target assembly"), resulting in complement-dependent effector functions, such as complement-dependent cytotoxicity (CDC). These various actions work separately, but in a complementary manner, allowing natural antibodies to destroy "targets" such as cancer cells and virus-infected cells (or the viruses themselves), as well as bacteria, parasites, and other pathogens. However, they may also be advantageously utilized through the action of engineered mAbs (i.e., therapeutic mAbs) for various medical therapies, such as, for example, cancer therapy and treatment of infectious and inflammatory diseases and disorders.
[0004] Given the above, it is perhaps not surprising that considerable research effort has been applied to unravel the details of Fc interactions (e.g., with FcγR and complement proteins, such as C1q and the membrane attack complex (MAC) proteins C4-C9) and to identify modifications (e.g., mutations) that can be made to Fc to potentially enhance the efficacy of therapeutic mAbs. However, such Fc mutations have so far been largely absent from therapeutic mAbs, with the best known being antibodies in which the heavy chain glycans have been engineered to lack fucose, thereby resulting in enhanced FcγRIII interactions, e.g., obinituzumab and margetuximab (containing six point mutations in the heavy chain of an IgG1 antibody), as well as other antibodies in clinical trials but not yet approved, such as a triple mutation in the Fc fragment of IgG1, i.e., amino acid substitutions at positions 345 (i.e., E345R), 430 (i.e., E430G), and 440 (i.e., S440Y) (also known as “IgG-RGY” (see WO 2014 / 006217)), or a single mutation only at position 430 (i.e., E430G) of the Fc of IgG1 (de Jong RN et al., PLoS Biol 2014:2311-2315, 2014). 14(1):e1002344, 2016) and various HexaBody™ mAbs (GenMab BV, Copenhagen, Denmark). This E430G mutation has been shown to enhance the ability of IgG1 antibodies to form hexamers on target molecules, and IgG1 mutants containing the E430G mutation have been reported to exhibit strongly enhanced CDC contingent on antigen binding on target cells (de Jong et al., 2016 supra). Thus, it will be apparent to one of skill in the art that there is a need in the art for modifications that enhance the therapeutic efficacy of immunotherapeutic proteins (e.g., mAbs). Summary of the Invention
[0005] In the work leading to the present disclosure, the inventors have produced a series of mutant antibodies (particularly mutant immunoglobulin G (IgG) molecules) that contain point mutations at various positions, for example, in and around the interface of the CH2 and CH3 domains of the heavy chain polypeptide. It has been found that some molecules containing mutations at position 429, a "buried" or inaccessible site in the IgG1 structure (see FIG. 1) that is believed to be occupied by a histidine (His / H) residue, exhibit enhanced activation of the complement system, for example, by the classical complement pathway, including binding of C1q, formation of the membrane attack complex, and complement-dependent cytotoxicity, in assays of complement function. In addition, the inventors have obtained evidence showing that some molecules containing an Fc region component with a mutation at position 429 are capable of forming oligomers, either in solution or upon binding to a relevant target. The present disclosure is directed to immunoglobulins and other molecules comprising an Fc region component (e.g., fusion proteins comprising a partner polypeptide having beneficial functions and / or characteristics), including mutations at position 429 (or positions corresponding thereto) of the Fc region component, and their potential uses in therapy against, for example, cancer (e.g., acute lymphoblastic leukemia (ALL) and adenocarcinoma), infectious diseases (e.g., COVID-19, emerging viral infections, and parasitic infections such as infections with drug-resistant malaria), and inflammatory diseases and disorders (e.g., autoimmune diseases including systemic lupus erythematosus (SLE) and type 1 diabetes (T1D)).
[0006] Thus, in a first aspect, the present disclosure provides an immunotherapeutic protein comprising one or more immunoglobulin heavy chain polypeptides comprising an Fc region component comprising at least a CH3 domain (or at least a CH4 domain), wherein the one or more polypeptides comprise an amino acid substitution at a position corresponding to H429 (Eu numbering) in the amino acid sequence of a human IgG1 heavy chain.
[0007] The immunotherapeutic protein may comprise a dimeric immunotherapeutic protein, such as an immunoglobulin molecule (e.g., an antibody) comprising first and second immunoglobulin heavy chain polypeptides comprising an Fc region component comprising CH2 and CH3 domains (such that the first and second polypeptides may form an Fc fragment or an Fc-like fragment upon dimerization). In some embodiments, such a dimeric immunotherapeutic protein may be provided in an oligomeric form, such as, for example, a hexamer comprising six copies of the dimeric immunotherapeutic protein.
[0008] In other embodiments, the immunotherapeutic protein comprises a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a CH4 domain), such that the immunotherapeutic protein may be in the form of a fusion protein or protein conjugate. Such a fusion protein or protein conjugate may, in some embodiments, comprise a dimeric immunotherapeutic protein comprising a first and a second immunoglobulin heavy chain polypeptide comprising an Fc region component comprising a CH2 and a CH3 domain (such that the first and second polypeptides may form an Fc fragment or an Fc-like fragment by dimerization). In some embodiments, such a dimeric immunotherapeutic protein may be provided in an oligomeric form, such as, for example, a hexamer comprising six copies of the dimeric immunotherapeutic protein.
[0009] In some preferred embodiments, the immunotherapeutic protein comprises an H→Y or H→F amino acid substitution at the position corresponding to H429 in the amino acid sequence of a human IgG1 heavy chain.
[0010] In a second aspect, the disclosure provides the use of an immunotherapeutic protein as defined in the first aspect for treating or preventing a disease or condition in a subject, the disease or condition may for example be selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases, and proliferative diseases.
[0011] In a third aspect, the disclosure provides the use of an immunotherapeutic protein as defined in the first aspect in the manufacture of a medicament for treating or preventing a disease or condition, wherein the disease or condition is selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases, and proliferative diseases.
[0012] In a fourth aspect, the disclosure provides a method for treating or preventing a disease or condition comprising administering to a subject an effective amount of an immunotherapeutic protein as defined in the first aspect, wherein the disease or condition is selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases, and proliferative diseases.
[0013] In a fifth aspect, the present disclosure provides a pharmaceutical composition or medicament comprising an immunotherapeutic protein as defined in the first aspect, and a pharma- ceutically acceptable carrier, diluent, and / or excipient. [Brief description of the drawings]
[0014] [Figure 1]FIG. 1 provides a diagrammatic representation of the structure of the Fc of human IgG1, showing that the H429 residue is located at an inaccessible site within the Fc fragment. The representation is of human IgG1-Fc (PDB:1Fc1) reproduced from Deisenhofer J., Biochemistry 20:2361-2370, 1981, using space-filled rendering. (A) In the side view of the Fc, the A chain is shown in black, the B chain in light grey, and the N-linked glycans in dark grey. The boxed region of chain A is shown expanded in panels B and C, (B) expanded boxed region of panel A shows in grey the solvent accessible amino acids of chain B labelled according to the Eu numbering of human IgG1: methionine at position 428 (M428), glutamic acid 430 (E430), alanine 431 (A431), leucine 432 (L432), histidine H435, which are located above histidine 429 (H429), and the ambiguous histidine 429 (H429) that is buried in Fc, (C) view of panel B after the solvent accessible residues shown in panel B have been unrendered, i.e., removed from the view. The buried H429, shown in grey CPK, is now only revealed underneath the adjacent solvent accessible residues that overlie these shown in panel B. The accessible surface area (ASA) for the residues calculated using PISA (i.e., the "Protein Interfaces, Surfaces and Assemblies" service PISA, http: / / www.ebi.ac.uk / pdbe / prot_int / pistart.htm, and Krissinel E and K Henrick. J Mol Biol 372:774-797,2007) indicates that H429 is inaccessible, recording a value of 0.0. [Diagram 2]Figure 1 provides a representation of immunoglobulin (antibody) and antibody-like (Ab-like) molecules showing the modular nature of antibodies. Left panel: provides a representation of a prototypic immunoglobulin structure. Immunoglobulins comprise a chain of variable (V) and constant (C) domains arranged in a heavy (H) chain, and optionally a self-assembling light (L) chain. The domains are further specified by the chain (e.g., CH3 is the third constant domain of the heavy chain). The heavy (H) chain usually further comprises a separate connecting or hinge sequence between the Fab and Fc segments. Some H chains comprise three constant H domains as shown in the panel (with residue H429 shown in the CH3 domain), while other H chains comprise four constant H domains (e.g., IgM and IgE), with CH4 being the domain equivalent to CH3 in other antibodies (e.g., IgG and IgA). Antibodies from many species comprise a light (L) chain. In antibodies that lack light chains, two H chains dimerize (H2) and usually comprise the antibody. On the other hand, in antibodies that contain light (L) chains, two antibody H chains usually dimerize, with an L chain associated with each H chain (i.e., H2L2). Some antibodies that lack strong H chain interactions (such as human IgG4) can sometimes be antibody "half molecules" that contain a monomeric H chain and one L chain (H1L1). The Fc fragment (or Fc) of an immunoglobulin is a dimer formed by covalent and / or non-covalent interactions between portions of each H chain (i.e., the two Fc regions of the H chain, each containing the hinge, CH2, and CH3 domains of the heavy chain). Right panel: Provides a representation showing that the modularity of immunoglobulins allows flexibility in the production of Ab-like molecules and fusion proteins (containing immunoglobulin portions). All molecules shown contain "H-like" chains that contain at least the CH3 domain. In particular, the depicted Ab-like molecules each consist of a V domain for target antigen recognition joined by a linking sequence to a CH3 domain of an Fc region, for example from an IgG (which in variations of the molecule shown can be the equivalent CH4 domain from IgE or IgM). The CH3 domain can carry a mutation such as that described herein at position 429 (Eu numbering).The V and CH3 domains may be linked by sequences that may include heterologous linking sequences, synthetic linking sequences, and / or other homologous or heterologous sequences or domains linking the V and CH3 domains (e.g., as depicted in the examples shown in the figures, the V and CH3 domains may be linked by CH1-CH2 or CH2, with or without a heterologous or synthetic linking sequence or an additional short polypeptide sequence such as an immunoglobulin hinge sequence), and the CH1, CH2, and hinge sequence modules may be provided in various combinations and orders, not limited to the examples shown. The molecules shown are each in a monomeric form that can dimerize to form homodimeric or heterodimeric forms. Similarly, for the fusion proteins shown, these each consist of a target recognition moiety (depicted as "X") joined by a linking sequence to, for example, at least the CH3 domain of the Fc region from IgG (or the equivalent CH4 domain of IgE or IgM). Again, the CH3 domain may include a mutation such as that at position 429 (Eu numbering), and the target recognition moiety and the H chain module (e.g., the CH3 domain, the CH2-CH3, or the CH3-CH2 components) are linked by a sequence which may include a heterologous or synthetic linking sequence and / or other homologous or heterologous sequences or domains linking the V domain and the CH3 domain (e.g., CH1-CH2 or CH2, with or without a heterologous or synthetic linking sequence or an additional short polypeptide sequence such as an immunoglobulin hinge sequence). [Diagram 3]Illustrating the conservation of domain structure and sequence homology in Immunoglobulin G (IgG) and Immunoglobulin A (IgA) molecules. A sequence comparison of the hinge and constant domains of human immunoglobulin heavy (H) chain sequences is provided depicting the domain-based structure of the H chain (i.e., CH1-hinge-CH2-CH3 as defined by IgG1; Eu numbering shown for the first amino acid of each IgG1 domain and hinge (inverted triangle) is therefore shown as follows: CH1 domain, amino acids 118-215; hinge amino acids 216-230; CH2 domain amino acids 231-340; and CH3 domain amino acids 341-447). Other IgG subclasses IgG2, IgG3, IgG4, and IgA subclasses IgA1 and IgA2 have corresponding domain structures with amino acid sequence homology. Also shown is the conservation of the histidine residue at position 429 of human IgG1 across other IgG and IgA subclasses (indicated by arrows). Amino acid sequences were derived from translation of the open reading frames of sequences from the European Nucleotide Archive (https: / / www.ebi.ac.uk / ena / browser / ). Accession numbers for the heavy chain sequences are: IgG1 heavy chain, J00228-IGHG1; IgG3 heavy chain, X03604-IGHG3; IgG4 heavy chain, K01316-IGHG; IgG2 heavy chain, J00230-IGHG2; IgA1 heavy chain, J00220-IGHA1; and IgA2 heavy chain, J00221-IGHA2. Alignments were performed using Clustal, except for the hinges, which were aligned manually. [Figure 4]The histidine at position 429 in IgG1 is shown to be conserved in all immunoglobulin classes. Comparison of the amino acid sequences of the IgG1 CH3 domain and the corresponding domains of other human immunoglobulin classes shows that histidine 429, indicated by the arrow, is conserved in the CH3 domain of the other IgG subclasses IgG2, IgG3, and IgG4, as well as the IgA subclasses IgA1 and IgA2, and IgD, and in the equivalent domain (CH4) of IgE and IgM. The IgG1 CH3 domain is defined and numbered according to Eu numbering, and the first amino acid in the CH3 domain is indicated by an inverted triangle above a glycine. The amino acid sequence shown was derived from a translation of the open reading frame of the sequence from the European Nucleotide Archive (https: / / www.ebi.ac.uk / ena / browser / ). The accession numbers for the heavy chain sequences are: IgG1 CH3 domain, J00228-IGHG1; IgG3 CH3 domain, X03604-IGHG3; IgG4 CH3 domain, K01316-IGHG4; IgG2 CH3 domain, J00230-IGHG2; IgA1 CH3 domain, J00220-IGHA1; IgA2 CH3 domain, J00221-IGHA2; IgE CH4 domain, IGHE-CH4-J00222; IgM CH4 domain, IGHM-CH4-X57331; and IgD CH3 domain, IGHD-K02879. [Diagram 5]1 shows the results of purification of ACE2-Fc H429Y fusion protein according to the present disclosure: (A) Anion exchange (IEX) chromatography of flACE2-Fc-WT with the ACE2-Fc-containing peak highlighted by * (flow-through (ft), elution fractions, and wash), (B) SDS-PAGE of the flow-through (ft) and IEX peak fractions with flACE2-Fc H429Y migrating above the 250 kDa marker and low molecular weight (mw) impurities marked with †, (C) Size exclusion chromatography (SEC) of IEX fractions containing flACE2-Fc-WT (comparison) using a Superose 6 column showing oligomers (oli), monomers (mn), and low mw impurities (†), and (D) SEC of IEX fractions containing flACE2-Fc H429Y showing a high proportion of oligomeric species. Monomeric (mn) species are considered to be single molecules containing two copies of each ACE2-Fc fusion polypeptide self-associated through the Fc region moiety (ie, monomeric molecules). [Figure 6]1 provides graphical results showing the SARS-CoV-2 RBD binding activity of ACE2-Fc fusion proteins according to the present disclosure. ACE2-Fc fusion protein binding to immobilized RBD-Ig was determined by ELISA for: (A) trACE2-Fc-WT, (B) flACE2-Fc-WT, and (C) and EflACE2-Fc-WT, and the following variants thereof: F ACE2-Fc protein with a mutated H429F Fc region component Yoli SEC-purified ACE2-Fc protein with a mutated H429Y Fc region component (oligomeric protein) Ymn SEC-purified ACE2-Fc protein with a mutated H429Y Fc region component (monomeric protein; contains two copies of ACE2-Fc fusion protein dimerized through the Fc region component) kif trACE2-Fc-WT protein produced in the presence of the mannosidase inhibitor, kifunensine. (D) Summary of EC50 binding constants for trACE2-Fc-WT, flACE2-Fc-WT, and variant proteins showing higher apparent RBD binding affinity for flACE2-Fc-WT than for trACE2-Fc-WT, and weaker binding affinity for the flACE2-Fc-H429Y monomer (Ymn; i.e., containing two copies of flACE2-Fc-H429Y fusion protein dimerized through the Fc region moiety). Welch's unpaired t-test p=0.0332 (*), <0.0001 (****). [Figure 7]1 provides results showing that flACE2-Fc H429Y fusion protein according to the present disclosure forms pH-dependent oligomers. SEC of flACE2-Fc H429Y purified by IEX was dialyzed against (A) PBS 7.4 or (B) 100 mM citrate, 100 mM NaCl pH 5, and then SEC was performed in the same buffer. SEC at pH 5 resulted in a greater proportion of monomeric (mn) fusion protein than separation at pH 7.4. (C) Native PAGE of ACE2-Fc H429Y (1 μg). Lane 1, SEC pH 5 oligomer (oli); lane 2, SEC pH 5 monomer (mn); lane 3, SEC pH 7.4 oligomer; lane 4, SEC pH 7.4 monomer; lane 5, SEC pH 5 monomer redialyzed against PBS pH 7.4 and purified by SEC, and the mn fraction collected as in panel D. (D) SEC chromatogram of pH 5.0 oligomer analyzed in lane 1 of panel C, redialyzed against PBS pH 7.4 and SEC performed in PBS pH 7.4. (E) Improved RBD-Ig binding activity of flACE2-Fc-H429Y monomer (Ymn) prepared at pH 5. The monomer is considered to be a single molecule containing two copies of each ACE2-Fc fusion polypeptide dimerized through the Fc region moiety (i.e., a monomeric molecule). [Figure 8]Results are provided showing that the SARS-CoV-2 neutralization potency of ACE2-Fc fusion proteins according to the present disclosure is affected by the ACE2 scaffold (i.e., truncated or full-length) and Fc mutations. Neutralization potency of ACE2 polypeptides, as well as three groups of ACE2-Fc-WT fusion proteins and variant proteins, was determined by titration to a cytotoxic effect (CPE) endpoint in a microneutralization assay. The fusion proteins are trACE2-Fc, flACE2-Fc and EflACE2-Fc WT, as well as Fc variants, H429F, F; H429Y oligomer on SEC, Yoli and H429Y monomer on SEC, Ymn (containing two copies of the fusion protein dimerized through the Fc region moiety). The trACE2-Fc fusion protein contains glycan-modified trACE2-Fc-kif. Neutralization endpoints mean ± SEM, ANOVA with Dunnett's multiple comparison test compared to ACE2 and ACE2-Fc WT. p=0.1234(ns), 0.0332(*), 0.0021(**), 0.0002(***), <0.0001(****). [Figure 9] 1 provides the results of an assay to evaluate the interaction of ACE2-Fc fusion proteins with FcγR according to the present disclosure. Ramos-S cells were opsonized with ACE2-Fc WT fusion protein and variant proteins (5 μg / ml). Biotinylated (A) dimeric rsFcγRIIa or (B) dimeric rsFcγRIIIa probes, followed by streptavidin-APC, were bound to the opsonized cells, and binding, described as median fluorescence intensity (median FI), was determined by flow cytometry. FcR binding activity of ACE2-Fc fusion proteins was readily detected (three replicates, mean ± SEM), except for ACE2-Fc H429Y fusion protein, which was greatly reduced. [Figure 10]Provide the results of the assay to evaluate the ability of ACE2-Fc fusion protein according to the present disclosure to mediate cell activation via FcγRIIIa.The results demonstrate that flACE2-Fc protein is a potent activator of FcγRIIIa, except for the Fc H429Y mutant of any ACE2 form that cannot stimulate.Defucosylated trACE2-Fc-kif is also a potent activator of FcγRIIIa. Ramos-S target cells were opsonized with (A) trACE2-Fc, (B) flACE2-Fc, and (C) EflACE2-Fc, WT, and variant proteins including H429F, F;H429Y, oligomer, Yoli;H429Y monomer, Ymn (containing two copies of the fusion protein dimerized through the Fc region moiety), or trACE2-Fc kif produced from trACE2-Fc WT in Expi293 cells in the presence of the mannosidase inhibitor, kifunensine. In some experiments, Ramos-S target cells were opsonized separately with the anti-CD20 mAb rituximab, RIT. These opsonized targets were incubated with FcγRIIIa-NF-κB-RE nanoluciferase reporter cells, and FcγRIIIa activation was measured by induction of nanoluciferase (RLU). Data were fitted to agonist response curves to estimate EC50. (D) EC50 (nM) values from the curve fits are shown. Mean ± SEM, n > 4, ANOVA with Dunnett's multiple comparison test compared to trACE2-Fc WT. p = 0.0021 (**), 0.0002 (***), < 0.0001 (****). [Figure 11]We provide results showing that ACE2-Fc fusion proteins according to the present disclosure, comprising Fc region components with H429F and H429Y mutations, robustly fix complement and direct complement-dependent cytotoxic killing of Ramos-S target cells, as determined using ELISA analysis of complement fixation activity of trACE2-Fc (A, C, E) or flACE2-Fc (B, D, F) bound to SARS-CoV-2 RBD-biotin captured by plate-bound avidin: C1q binding to ACE2-Fc fusion protein variants (2.0 μg / ml) at different concentrations of avidin-captured RBD on the plate (A, B); titration of C1q (C, D) or C5b-9 (E, F) binding by serially diluted ACE2-Fc fusion protein variants (2.5 μg / ml) bound to avidin-captured RBD-biotin (mean ± SEM); two independent ELISA experiments. (G) Flow cytometric analysis of complement-dependent cytotoxicity (CDC) (% killing) of opsonized Ramos-S cells was determined using the presence of a 1 / 3 dilution of normal human serum as a source of complement (EC50 (nM) values from curve fitting are shown). [Figure 12]Results of an assay are provided showing that IgG1 antibodies containing an Fc region component with the H429F mutation in the CH3 domain strongly fix complement and exhibit identical antigen binding. (A, B) TNP-BSA antigen was adsorbed to wells of an ELISA plate at different concentrations (20 μg / ml to 0.625 μg / ml) and reacted with a single concentration (2 μg / ml) of chimeric anti-TNP human IgG1 and IgG2 mAbs containing unmodified wild-type (WT) heavy chains, or 2 μg / ml of anti-TNP mAb containing an IgG1 heavy chain with the Fc component mutation H429F (TNP-IgG1-H429F). Antibody-opsonized TNP-BSA coated wells were treated with (A) purified human C1q and (B) human serum as a source of complement, and the formation of the membrane attack complex (C5b-C9) was detected with an anti-C5b-C9 rabbit polyclonal antibody. (C) provides results from an ELISA showing the antigen-binding activity of the chimeric anti-TNP mAbs used in panels A and B, including unmodified (TNP-IgG1-WT and TNP-IgG2-WT mAbs) and the H429-modified mAb, TNP-IgG1-H429F. After coating the ELISA plate with TNP-BSA, the anti-TNP mAbs were titrated and antibody binding was detected with HRP-conjugated anti-human IgG. All mAbs showed similar antigen-binding activity. [Figure 13]Results are provided showing C1q fixation and MAC (C5b-9) formation by mAbs containing IgG1 heavy chains with glutamic acid, glutamine, or serine modifications at position 429 of the heavy chain. TNP-BSA (20 μg / ml) was adsorbed to wells and reacted with chimeric human anti-TNP mAbs, titrated over a concentration range of 4 μg / ml to 0.125 μg / ml. mAbs tested contained unmodified wild-type (WT) heavy chains of IgG1 (TNP-IgG1-WT) (panels A-D) or IgG2 (TNP-IgG2-WT) (panels A-C), or IgG1 H chains containing the mutations TNP-IgG1-H429Q or TNP-IgG1-H429E (A, C) and TNP-IgG1-H429S (B, D). Antibody-opsonized TNP-BSA coated wells were treated with human serum as a source of complement. Fixation of C1q (A, B) was detected with anti-C1q rabbit polyclonal antibody, and (C, D) formation of the membrane attack complex (C5b-C9) was detected with rabbit anti-C5b-C9 polyclonal antibody. [Figure 14] Results of flow cytometric quantification of SEC-purified mAb binding to target cell surface antigens are provided. The binding activity of unmodified (WT) Rituximab, Daratumumab-WT, 11B8-WT mAbs and their CH3 modified variants carrying mutations H429F or H429Y (SEC (IgG H2L2) peak fraction p1 and IgGoli peak fraction p2) was assessed by flow cytometry on Ramos lymphoma cells expressing CD20 and CD38. The binding activity of unmodified Trastuzumab-WT, Pertuzumab-WT, and their CH3 heavy chain variants carrying mutation H429F was assessed on SK-OV-3 cells expressing HER2. [Figure 15]Figure 1 provides elution chromatograms of Protein A affinity purification profile of Rituximab-WT, Trastuzumab-WT, and their variants with modifications in CH3 of the heavy chain. IgG was recovered from the column after elution with sodium citrate buffer pH 3.0. (A) Elution profile of anti-CD20 Rituximab-based mAb. Rituximab-WT IgG and each variant IgG eluted as a single homogenous peak, (B) Elution profile of anti-HER2 Trastuzumab-based mAb. Trastuzumab-WT IgG and each variant IgG eluted as a single homogenous peak. [Figure 16]Size exclusion chromatography (SEC) profiles are provided that reveal that H429 mutations can alter the physical properties of IgG. After protein A affinity purification, the mAb was further purified by SEC at pH 7.2. (A) The SEC profiles of unmodified Rituximab-WT (WT) and Rituximab-H429F (H429F) mutant consist of a single homogeneous IgG peak (right part of the vertical dashed line) with minimal oligomeric species (left part of the vertical dashed line). Thus, for example, the SEC profile of unmodified Rituximab-WT shows, as expected, a single major species corresponding to IgG (H2L2), which migrates with the expected mass of 150 kDa for non-reduced IgG and is resolved into its 50 kDa heavy (H) chain and 25 kDa light (L) chain species after reduction in DTT, as confirmed by SDS-PAGE analysis (Figure 17A). On the other hand, Rituximab-H429Y mAb contained both non-oligomeric and oligomeric IgG. (B) SEC profiles of Protein A purified anti-HER2 trastuzumab wild type (WT) (i.e., the unmodified form of trastuzumab) and its variants containing H429F or H429Y amino acid substitutions. A single peak of non-oligomeric IgG to the right of the vertical dashed line was observed for trastuzumab-WT and H429F mutant mAbs, whereas trastuzumab-H429Y mutant IgG (H429Y) contained both non-oligomeric and oligomeric IgG. The non-oligomeric IgG peak of trastuzumab-H429Y matched the peaks of unmodified trastuzumab-WT, or its H429F variant, and the equivalent rituximab-based mAb in panel (A). The SEC profile of oligomeric IgG in trastuzumab-H429Y was consistent with that in rituximab-H429Y in panel (A). [Figure 17]Images obtained from SDS-PAGE of SEC-purified mAbs are provided. mAbs purified by SEC were analyzed by SDS-PAGE in 5-15% gradient gels with or without reduction of disulfide bonds. (A) Under non-reducing conditions, the non-oligomeric IgG peaks of Rituximab-WT (WT IgG) and Rituximab-H429F (HF IgG) migrated as a single species with the expected molecular size of ∼150 kDa for IgG (i.e., H2L2). After reduction in DTT, the 150 kDa IgG was resolved into heavy (H) chains of ∼50 kDa and light (L) chains of ∼25 kDa, as expected. Before reduction, the non-oligomeric IgG (HY IgG(H2L2)) and oligomeric (HY IgG(oli)) forms of Rituximab-H429Y mAb (see FIG. 16) both migrated similarly as a single 150 kDa IgG, i.e., H2L2 species. After reduction, both forms migrated as a heavy (H) chain of approximately 50 kDa and a light (L) chain of approximately 25 kDa, WT=wild type, HF=H429F, HY=H429Y; M=molecular weight marker, their masses (kD) are indicated on the left, (B) Under non-reducing conditions, the IgG peaks of Trastuzumab-WT (WT IgG) and Trastuzumab-H429F (HF IgG) migrated as a single species at the expected molecular size of approximately 150 kD for IgG, i.e., H2L2. After reduction with dithiothreitol (DTT), the 150 kDa IgG was resolved into heavy (H) chains of approx. 50 kDa and light (L) chains of approx. 25 kDa, as expected. Before reduction, both non-oligomeric IgG (HY IgG(H2L2)) and oligomeric (HY IgG(oli)) forms of trastuzumab-H429Y mAb migrated similarly as single 150 kDa IgG species under non-reducing conditions, and after reduction, migrated identically as the expected approx. 50 kDa heavy (H) chains and approx. 25 kDa light (L) chains, WT=wild type, HF=H429F, HY=H429Y; M=molecular weight markers, their masses (kD) are shown on the left. [Figure 18]Results of experiments are provided showing that oligomeric and non-oligomeric forms of H429Y modified IgG antibody exhibit comparable CDC potency and that their formation is pH sensitive. (A) SEC of Rituximab-H429Y at pH 7.2 showing the presence of two major IgG forms (see also FIG. 16A). Non-oligomeric IgG (H2L2) (right of vertical dashed line, indicated as p1) and oligomeric form of IgG (IgG(oli)) (left of vertical dashed line, indicated as p2) were collected separately for further evaluation of complement-dependent cytotoxicity (CDC) potency. (B) Oligomeric (p2) and non-oligomeric (p1) IgG forms from panel A, as well as SEC-purified unmodified Rituximab-WT IgG, were titrated and CDC potency was determined by flow cytometry using Ramos lymphoma cells and normal human serum diluted 1 / 3 as a source of complement. The extent of killing of Ramos cells opsonized with non-oligomeric Rituximab-H429Y p1 (open squares), oligomeric Rituximab-H429Y p2 (triangles), or unmodified Rituximab-WT (filled circles) was determined. Control background CDC of complement in the absence of mAb (no mAb C' only) is shown as filled diamonds. (C) Formation of IgG oligomers is sensitive to pH. Protein A purified trastuzumab-H429Y was analyzed by size exclusion chromatography (SEC) at either pH 7.2 (left panel) or pH 5.0 (right panel). At pH 7.2, both oligomers (IgG(oli)) and non-oligomeric IgG were present, whereas at pH 5.0, only a single peak corresponding to non-oligomeric IgG was present. [Figure 19]Results are presented showing that the H429F mutation in the CH3 domain of the IgG H chain strongly promotes C1q binding and complement-dependent cell-mediated cytotoxicity. Flow cytometric detection of C1q binding (fluorescence intensity) to Ramos lymphoma cells opsonized with unmodified rituximab-WT (A) or modified rituximab-H429F mAb (B), or SK-OV-3 ovarian cancer cells opsonized with trastuzumab-WT (C) or modified trastuzumab-H429F mAb (D) are depicted. mAb-opsonized cells were treated with normal human serum as a source of complement, and C1q binding was detected by staining with an anti-C1q rabbit polyclonal antibody. C1q binding to mAb-opsonized cells is shown in unshaded histograms, and C1q background binding controls (i.e., cells treated with serum complement in the absence of mAb) are shown in grey shaded histograms. Median fluorescence intensity (MFI) values for each histogram are shown in brackets. (E) Complement-dependent cytotoxicity (CDC; i.e., % killing detected using Zombie Green) of Ramos lymphoma cells opsonized with Rituximab-WT (black circles) or its mutated variant mAb Rituximab-H429F (black squares) was determined by flow cytometry using normal human serum as a source of complement. CDC is significantly enhanced by the mutation at position 429 in Rituximab-H429F compared to Rituximab-WT mAb. [Figure 20] 1 shows the results of Protein A affinity chromatography of type II anti-CD20 11B8-WT mAb and mutant mAbs containing the H429 substitution. The mAbs were 11B8-WT mAb (WT) produced with a wild-type human IgG1 heavy chain. 11B8-H429F (H429F) was produced with a modified IgG1 heavy chain in which the amino acid histidine at position 429 in the CH3 domain of the Ig heavy chain was replaced with phenylalanine. [Figure 21]Size-exclusion chromatography (SEC) purification and SDS PAGE analysis of 11B8-WT mAb and 11B8-H429F (H429F) mutant are shown. (A) Chromatogram of mAb purified by SEC at pH 7.2; monomeric non-oligomeric IgG is shown to the right of the vertical dotted line, (B) SDS-PAGE analysis (5-15% gradient gel) of SEC-purified monomeric IgG mAb from panel A. Before reduction (non-reduced), all SEC-purified antibodies migrated at the expected molecular size of IgG, i.e., H2L2, of approximately 150 kDa. After reduction with DTT (reduced), all of the antibodies were resolved into heavy (H) chains of approximately 50 kDa and light (L) chains of approximately 25 kDa, as expected. WT=wild type, HF=H429F, M=molecular weight markers, their masses (kD) are shown on the left. [Figure 22] Results are provided showing that H429 modification of the CH3 domain confers CDC potency to type II anti-CD20 mAbs. CDC by 11B8-WT mAb (filled circles) or CH3 mutant 11B8-H429F mAb (filled squares). Complement-dependent lysis was determined using Ramos lymphoma cells opsonized with mAb at the indicated concentrations and normal human serum diluted 1 / 3 as a source of complement. CDC (% killing) was determined by flow cytometry using Zombie Green. Control background CDC in the absence of mAb (only C' without mAb) is shown as black diamonds. 11B8-WT mAb was unable to mediate CDC, whereas 11B8-H429F mutant mAb mediated potent complement-dependent lysis of lymphoma cells (WT=wild type). [Diagram 23] FIG. 1 shows the results of Protein A affinity chromatography of anti-CD38 daratumumab-WT mAb and daratumumab-H429F mAb. The elution chromatograms showed that each of the antibodies eluted as a single, consistent homogenous peak. [Figure 24]Size-exclusion chromatography (SEC) purification and SDS-PAGE analysis of daratumumab-WT mAb and mutant mAb, daratumumab-H429F. (A) Chromatograms of SEC-purified mAbs. In each case, the mAbs contained a single non-oligomeric IgG peak (right part of vertical dashed line) and an absence of oligomeric species (left part of vertical dashed line). (B) SDS-PAGE analysis (5-15% gradient gel) of SEC-purified IgG from panel A. Before reduction (non-reduced), all of the antibodies migrated at the expected molecular size of ∼150 kDa for IgG (i.e., H2L2); after reduction with DTT (reduced), all of the antibodies resolved into heavy (H) chains of ∼50 kDa and light (L) chains of ∼25 kDa, as expected. WT=wild type, HF=H429F, M=molecular weight markers, their masses (kD) are indicated on the left. [Diagram 25] Results are provided showing that the H429F substitution greatly enhances complement-dependent lysis of lymphoma cells by daratumumab-WT. The graph shows the level of CDC (% killing) by daratumumab-WT mAb (filled circles) and daratumumab-H429F (filled squares). Background lysis (filled triangles) was determined in the absence of mAb, but in the presence of complement only. CDC was determined by flow cytometry using Zombie Green. Daratumumab-H429F mAb mediated more potent complement-dependent lysis of lymphoma cells than unmodified daratumumab-WT. [Figure 26]Results are provided showing that the H429F substitution confers complement-dependent lysis of myeloma and leukemia cells resistant to lysis by anti-CD38 mAb. CDC by complement-dependent lysis was determined using: (A) KMS-12-PE myeloma cells opsonized with daratumumab-WT mAb (filled circles) or daratumumab-H429F mutant mAb (filled squares) at the indicated concentrations. Background lysis (filled triangles) was determined in the absence of mAb but in the presence of complement only, and (B) SUP-15 acute lymphoblastic leukemia (ALL) cells opsonized with daratumumab-WT mAb (solid circles) and daratumumab-H429F mutant mAb (solid squares) at the indicated concentrations. Background lysis (filled triangles) was determined in the absence of mAb but in the presence of complement only. CDC (% killing) was determined by flow cytometry using Zombie Green. [Figure 27] Figure 1 shows the results of Protein A affinity chromatography of anti-HER2 mAb Pertuzumab-WT and CH3 variant. The elution chromatograms showed that each of the antibodies eluted as a single, consistent homogenous peak. [Figure 28]Figure 1 shows the results of size-exclusion chromatography (SEC) purification and SDS-PAGE analysis of anti-HER2 mAb Pertuzumab-WT and CH3 H429F variant. (A) Chromatogram of SEC-purified mAb. After Protein A affinity chromatography, the mAb was further purified by size-exclusion chromatography (SEC) at pH 7.2. Chromatographic profiles are shown for unmodified Pertuzumab-WT and for the Fc-modified variant, Pertuzumab-H429F (H429F). In each case, Protein A-purified mAb contained a single non-oligomeric IgG peak (right part of vertical dashed line) and an absence of oligomeric species (left part of vertical dashed line). (B) SDS-PAGE analysis (5-15% gradient gel) of SEC-purified IgG from panel A. Before reduction (non-reduced), all of the SEC-purified antibodies migrated at the expected molecular size of approx. 150 kDa for IgG (i.e., H2L2). After reduction with DTT (reduced), all of the antibodies were resolved into heavy (H) chains of approximately 50 kDa and light (L) chains of approximately 25 kDa, as expected. WT=wild type, HF=H429F, M=molecular weight markers in kilodaltons (kD). [Figure 29]Results are provided showing cooperation and functional synergy in mixtures of mAbs containing amino acid substitutions at position H429; in particular, the results show that H429F modified mAbs can be combined to enhance C1q binding to target cells. (A) Flow cytometry histograms of C1q binding to HER2-expressing SK-OV-3 cells opsonized with trastuzumab-H429F alone, pertuzumab-H429F alone, or a 1:1 mixture of trastuzumab-H429F and pertuzumab-H429F (unfilled histograms). Black histograms show background binding of C1q to non-opsonized cells. Median fluorescence intensity (MFI) values for each histogram are also shown. C1q binding was detected using an anti-C1q specific polyclonal rabbit antibody, and (B) titration of enhanced functional cooperation. SK-OV-3 cells were opsonized with titrated individual anti-HER2 mAbs, Trastuzumab-WT, Pertuzumab-WT, Trastuzumab-H429F, Pertuzumab-H429F, or with 1:1 mixtures of Trastuzumab-WT with Pertuzumab-WT or Trastuzumab-H429F with Pertuzumab-H429F. Vertical double arrows illustrate the extensive cooperation in mixtures of Pertuzumab-H429F with Trastuzumab-H429F, which is antibody concentration limiting, compared to C1q binding of either mAb alone. [Diagram 30]1 provides graphical results showing that the synergy and functional synergy of H429-modified mAbs enhances complement-dependent killing (CDC) of target cells. The indicated rituximab-based mAbs were titrated alone (light grey columns) or in the presence of fixed concentrations of the indicated anti-CD38 or anti-CD20 mAbs (dark columns): (A) rituximab-WT titrated in the presence of 0.025 μg / ml daratumumab-WT, (B) rituximab-HF titrated in the presence of 0.025 μg / ml daratumumab-H429F, (C) rituximab-HF titrated in the presence of 0.5 μg / ml 11B8-H429F. CDC (% killing) was determined by flow cytometry using Zombie Green. The dotted horizontal lines in (B,C) indicate the percentage of CDC killing obtained in the absence of rituximab-based mAbs (0 μg / ml) but in the presence of only (B) 0.025 μg / ml daratumumab-H429F or (C) 0.5 μg / ml 11B8-H429F. The black arrows in (B,C) indicate the enhanced CDC of the mixture of mAbs over that of the individual mAbs (i.e., CDC of either rituximab-H429F alone (light columns) or 0.025 μg / ml daratumumab-H429F or 0.5 μg / ml 11B8-H429F (dark columns, 0 μg / ml rituximab) at the indicated concentrations). [Diagram 31]1 provides the results of flow cytometry analysis of the CDC potency of Rituximab antibodies containing the H429F mutation on normal peripheral blood CD19+ B lymphocytes. The results show that Rituximab-H429F mAb exhibits more potent CDC killing of normal peripheral blood B cells compared to unmodified Rituximab-WT. After treatment of peripheral blood mononuclear cells with the indicated mAbs and human complement, the percentage of live or dead B cells was determined by staining with anti-CD19 to identify B cells and Zombie Green (ZG) to identify dead cells. Cytological findings show Zombie Green median fluorescence intensity (ZG MFI) of gated CD19 B cells (CD19 median fluorescence intensity (CD19 MFI)). For each cellular finding, the percentage of dead cells (ZG positive) for each cellular finding is shown in the upper section Q1 for Rituximab-WT (30.4% ZG positive), Rituximab-H429F (85.6% ZG positive), and the corresponding negative control mAbs Trastuzumab-WT (3.05% ZG positive) and Trastuzumab-H429F (3.11% ZG positive), and the percentage of live B cells is shown in the lower section Q2. [Diagram 32] We provide results showing that the effect of H429 modification on antibody function is not restricted to IgG1 but extends to other immunoglobulin types, where we assessed the CDC potency on Ramos lymphoma cells of rituximab antibodies formulated with wild-type (WT) or H429F (HF) modified heavy chains of (A) IgG3 or (B) IgG4 subclasses. [Diagram 33] Results are provided showing that effective CDC of target cells mediated by mAbs is dependent on the presence of both monoclonal antibodies and serum complement. CDC (% killing) of Ramos cells by rituximab-H429F, daratumumab-H429F, or 11B8-H429F, or SUP-15 cells by daratumumab-H429F is shown. A = percent killing in the presence of both the indicated mAb and human serum as a source of complement, B = lysis in the presence of mAb alone at the same concentration as in A, and C = lysis in the presence of complement alone. [Diagram 34]Results are provided showing that the H429F substitution confers complement-dependent lysis of leukemia cells resistant to lysis by the unmodified anti-CD38 mAb Isatuximab. CDC by complement-dependent lysis was determined using SUP-15 acute lymphoblastic leukemia (ALL) cells opsonized with Isatuximab-WT mAb (dashed line with black circles) and Isatuximab-H429F mutant mAb (solid line with black squares) at the indicated concentrations. Background lysis (open circles) was determined in the absence of mAb but in the presence of complement only (C' only, no mAb). Background lysis induced by mAb at 5 μg / ml in the absence of complement was determined for Isatuximab-WT mAb (open inverted triangles) and Isatuximab-H429F mutant mAb (white open squares). CDC (% killing) was determined by flow cytometry using Zombie Green. [Diagram 35]1 provides the results of flow cytometry quantification of binding to Colo205 colorectal cells of purified DR5-specific mAbs containing unmodified wild-type (WT) heavy chains of human IgG1 or IgG2 subclasses, or containing human IgG1 or human IgG2 subclass heavy chains modified by replacing histidine 429 with phenylalanine (H429F). Panels are shown as follows: (A) Binding of BDR5-1WT containing a wild type heavy chain of human IgG1 subclass or BDR5-1HF mAb containing an IgG1 heavy chain containing the H429F modification, (B) Binding of BDR5-2WT containing an unmodified heavy chain of human IgG2 subclass or BDR5-2HF mAb containing an IgG2 heavy chain containing the H429F modification, (C) Binding of TDR5-1WT mAb containing an unmodified heavy chain of human IgG1 subclass or TDR5-1HF mAb containing an IgG1 heavy chain containing the H429F modification, and (D) Binding of TDR5-2WT containing an unmodified heavy chain of human IgG2 subclass or TDR5-2HF mAb containing an IgG2 heavy chain containing the H429F modification. The mAbs were serially titrated two-fold and binding activity to Colo205 cells was quantified by flow cytometry using a goat anti-hIgG Fc FITC-labeled anti-IgG secondary reagent. In all panels, the level of non-specific binding of fluorescent conjugates to cells is indicated (▲conjugate), MFI = median fluorescence intensity. [Diagram 36]1 provides the results of flow cytometry quantification of binding of purified DR5-specific mAbs to target Ramos lymphoma cells, containing unmodified wild-type (WT) heavy chains of human IgG1 or human IgG2 subclasses, or containing human IgG1 or human IgG2 heavy chains modified by replacing histidine 429 with phenylalanine (H429F). Panels are shown as follows: (A) Binding of BDR5-1WT with an unmodified heavy chain of human IgG1 subclass or BDR5-1HF mAb with an IgG1 heavy chain containing the H429F modification, (B) binding of BDR5-2WT with an unmodified heavy chain of human IgG2 subclass or BDR5-2HF mAb with an IgG2 heavy chain containing the H429F modification, (C) binding of TDR5-1WT with an unmodified heavy chain of human IgG1 subclass or TDR5-1HF mAb with an IgG1 heavy chain containing the H429F modification, and (D) binding of TDR5-2WT with an unmodified heavy chain of human IgG2 subclass or TDR5-2HF mAb with an IgG2 heavy chain containing the H429F modification. mAbs were serially titrated two-fold and binding to Ramos cells was quantified by flow cytometry using a goat anti-hIgG Fc FITC-labeled anti-IgG secondary reagent. In all panels, the level of non-specific binding to cells was determined using an irrelevant IgG antibody (negative IgG) and background binding of fluorescent anti-IgG conjugate to cells is shown (▲conjugate); MFI = median fluorescence intensity. [Figure 37]1 provides the results of flow cytometric quantification of binding of purified DR5-specific mAbs, containing unmodified wild-type (WT) H chains of human IgG1 or human IgG2 subclasses, or containing human IgG1 or human IgG2 heavy chains modified by replacing histidine 429 with phenylalanine (H429F), to target KMS-12-PE myeloma cells. Binding activity is shown for DR5-specific mAbs, BDR5 and TDR5, containing unmodified wild-type H chains of human IgG1 subclass (BDR5-1WT, TDR5-1WT) or human IgG2 subclass (BDR5-2WT, TDR5-2WT), or containing Fc mutant H chains of IgG1 subclass (BDR5-1HF, TDR5-1HF) or IgG2 subclass (BDR5-2HF, TDR5-2HF) containing the H249F mutation. KMS12-PE cells were incubated with the mAbs at 5 μg / ml. Binding activity was quantified by flow cytometry using an anti-IgG secondary reagent labeled with FITC goat anti-hIgG Fc. Background controls for binding of anti-IgG conjugate alone are shown (conjugate) along with background fluorescence of cells alone (cells). [Figure 38]
[0023] Figure 1 provides results showing survival of Colo205 colorectal cells in the presence of purified DR5-specific mAbs comprising unmodified wild-type H chains of human IgG1 or human IgG2 subclasses, or comprising Fc-mutated H chains of human IgG1 or human IgG2 subclasses containing the H429F mutation. Ten thousand cells were cultured in each well of a 96-well plate in the presence of 20 μg / ml of each of the following mAbs: TDR5-1WT mAb comprising unmodified wild-type H chains of human IgG1 subclasses, or TDR5-1HF mAb comprising H chains of human IgG1 subclasses containing the H429F mutation, or TDR5-2WT mAb comprising unmodified wild-type H chains of human IgG2 subclasses, or TDR5-2HF mAb comprising H chains of human IgG2 subclasses containing the H429F mutation. Additionally, Colo205 cells were separately cultured in the presence of 10 μg / ml TDR5-2HF and 10 μg / ml BDR5-2HF mAb mixture (TDR5-2HF+BDR5-2HF), both of which contained Fc-mutated human IgG2 H chains carrying the H429F mutation. Cell viability was quantified using a CCK8 colorimetric cell viability assay, in which the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell viability and viability. Maximum cell viability was determined by culturing cells in the absence of antibody (no antibody). Viability is expressed as follows: [experimentally determined absorbance 450 nm of mAb or control treatment - background absorbance 450 of cell culture medium], mean absorbance 450, and four replicates are shown. [Figure 39]
[0023] Figure 1 provides results showing survival of Ramos lymphoma cells in the presence of purified DR5-specific mAbs containing unmodified wild-type or Fc mutant heavy chains of human IgG1 or IgG2 subclasses containing the H429F mutation. Ten thousand cells were cultured in each well of a 96-well plate in the presence of 20 μg / ml of each of the following mAbs: TDR5-1WT mAb, which contained an unmodified wild-type heavy chain of human IgG1 subclass, or TDR5-1HF mAb, which contained an H chain of human IgG1 subclass containing the H429F mutation, TDR5-2WT mAb, which contained an unmodified wild-type heavy chain of human IgG2 subclass, or TDR5-2HF mAb, which contained an H chain of human IgG2 subclass containing the H429F mutation. Additionally, Ramos cells were separately cultured in the presence of 10 μg / ml TDR5-2HF and 10 μg / ml BDR5-2HF mAb mixture (TDR5-2HF+BDR5-2HF), both of which contained Fc-mutated human IgG2 H chains carrying the H429F mutation. Cell viability was quantified using a CCK8 colorimetric cell viability assay, in which the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell viability and viability. Maximum cell viability was determined by culturing cells in the absence of antibody (no antibody). Viability is expressed as follows: [experimentally determined absorbance 450 nm of mAb or control treatment - background absorbance 450 of cell culture medium], mean absorbance 450, and four replicates are shown. [Diagram 40]Results are provided showing survival of Colo205 colorectal cells in the presence of a mixture of purified DR5-specific mAbs, the mAbs containing wild-type or Fc-modified H chains of the same IgG subclass. BDR5 and TDR5 mAbs contained unmodified wild-type H chains of human IgG1 or human IgG2 subclasses, or heavy chains of IgG1 or IgG2 subclasses containing the H429F modification. Colo205 cells, 30,000 cells per well of a 96-well plate, were cultured in the presence of serial 2-fold dilutions of a 1:1 mixture of mAbs containing the same H chain. A starting concentration of 1 μg / ml was included in the mixture at 0.5 μg / ml of each mAb. The mixtures used were therefore: BDR5-1WT mAb comprising an unmodified wild-type IgG1 H chain mAb mixed with TDR5-1WT comprising an unmodified wild-type IgG1 H chain (BDR5-1WT+TDR5-1WT); BDR5-2WT mAb comprising an unmodified wild-type IgG2 H chain mAb mixed with TDR5-2WT comprising an unmodified wild-type IgG2 H chain (BDR5-2WT+TDR5-2WT); BDR5-1HF mAb comprising an IgG1 H chain containing the H429F modification mixed with TDR5-1HF mAb comprising an IgG1 H chain containing the H429F modification (BDR5-1HF+TDR5-1HF); BDR5-2HF mAb comprising an IgG2 H chain containing the H429F modification mixed with TDR5-2HF mAb comprising an IgG2 H chain containing the H429F modification (BDR5-2HF+TDR5-2HF). Cell viability was quantified using a CCK8 colorimetric cell viability assay in which the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell viability and survival. Maximum cell viability was determined by incubation of cells in the absence of antibody (no antibody) and maximum death was determined by incubation of cells with sodium dodecyl sulfate (SDS). Survival is expressed as follows: [experimentally determined absorbance 450 nm of mAb or control treatment - background absorbance 450 of cell culture medium]. [Diagram 41]Results are provided showing survival of Colo205 colorectal cells in the presence of different pairwise combinations of purified DR5-specific mAbs, the mAbs containing wild-type or Fc-mutated heavy chains of different IgG subclasses. The MAbs contained heavy chains of human IgG1 or human IgG2 subclasses, containing wild-type heavy chains or heavy chains modified by the H429F modification. Colo205 cells, 10,000 cells per well of a 96-well tissue culture plate, were cultured in the presence of a 1:1 mixture of mAbs serially diluted 2-fold from 1 μg / ml. The starting concentration of 1 μg / ml included 0.5 μg / ml of each mAb in the mixture. The mixture of wild-type mAbs used was: As seen in Figure 40, BDR5-2WT containing wild type human IgG2 H chain mixed with TDR5-1WT containing unmodified wild type human IgG1 H chain (BDR5-2WT+TDR5-1WT), BDR5-1WT containing wild type human IgG1 H chain mixed with TDR5-2WT containing unmodified wild type human IgG2 H chain (BDR5-1WT+TDR5-2WT), and a control mixture of BDR5-2WT containing unmodified wild type human IgG2 H chain mixed with TDR5-2WT containing unmodified wild type human IgG2 H chain (BDR5-2WT+TDR5-2WT). The mixture of DR5 mAb containing H429F Fc mutant H chain was: As seen in Figures 38 and 40, BDR5-2HF containing H429F Fc mutated human IgG2 H chain mixed with TDR5-1HF containing H429F Fc mutated human IgG1 H chain (BDR5-2HF+TDR5-1HF), BDR5-1HF containing H429F Fc mutated human IgG1 H chain mixed with TDR5-2HF containing H429F Fc mutated human IgG2 H chain (BDR5-2HF+TDR5-2HF), positive killing control mixture of BDR5-2HF containing H429F Fc mutated human IgG2 H chain mixed with TDR5-2HF containing H429F Fc mutated IgG2 H chain (BDR5 2HF+TDR5-2HF). Cell viability was quantified using a CCK8 colorimetric cell viability assay, where the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell viability and viability.Maximum cell viability was determined by incubation of cells in the absence of antibody (No Antibody) and maximum death was determined by incubation of cells with sodium dodecyl sulfate (SDS). Survival is expressed as: [experimentally determined absorbance 450 nm of mAb or control treatment - background absorbance 450 of cell culture medium]. [Diagram 42] 1 provides results showing survival of Colo205 cells in the presence of pairwise mixtures of BDR5 and TDR5 mAbs at different ratios. Ten thousand Colo205 cells were cultured for 48 hours in the presence of individual mAbs BDR5-1WT or TDR5-1WT containing wild-type IgG1 H chain, or individual mAbs BDR5-1HF or TDR5-1HF containing H chain with H429F modification, or mixtures of BDR5-1HF with TDR5-1HF mAb at the following ratios: 90:10, 75:25, 50:50, 25:75, and 10:90. In the mixtures shown in the plot, BDR5-1HF mAb is designated as B-1HF and TDR5-1HF is designated as T-1HF. Controls include maximum cell survival in the absence of mAb (no antibody) or maximum death control in the presence of sodium dodecyl sulfate (SDS). Cell viability was quantified using a CCK8 colorimetric cell viability assay, where the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell viability and viability. Viability is expressed as: [experimentally determined absorbance 450 nm of mAb or control treatment - background absorbance 450 of cell culture medium]. [Diagram 43]1 provides results showing survival of Ramos lymphoma cells in the presence of pairwise mixtures of BDR5 and TDR5 mAbs at different ratios. 10,000 Ramos cells were cultured for 48 hours in the presence of individual mAbs BDR5-1WT or TDR5-1WT containing wild-type H chains, or individual mAbs BDR5-1HF or TDR5-1HF containing H chains with H429F modification, or mixtures of BDR5-1HF with TDR5-1HF mAb at the following ratios: 90:10, 75:25, 50:50, 25:75, and 10:90. In the mixtures shown in the plot, BDR5-1HF mAb is designated as B-1HF and TDR5-1HF is designated as T-1HF. Cell viability was quantified using a CCK8 colorimetric cell viability assay, in which the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell survival and viability. Maximum cell viability was determined by incubation of cells in the absence of antibody (No Antibody) and maximum death was determined by incubation of cells with sodium dodecyl sulfate (SDS). Survival is expressed as: [experimentally determined absorbance 450 nm of mAb or control treatment - background absorbance 450 of cell culture medium]. [Diagram 44] Results are provided that detect different epitopes and quantify the binding of DR5-specific mAbs containing wild-type or Fc-mutated heavy chains of the human IgA2 subclass to Colo205 cells. The mAbs used as tissue culture supernatants from appropriately transfected Expi293 cells contained unmodified wild-type IgA2 heavy chains (BDR5-A2WT) and (TDR5-A2HF) of the human IgA2 subclass, or Fc-mutated IgA2 heavy chains carrying the H429F mutation (BDR5-A2HF) and (TDR5-A2WT). The background fluorescence, determined by measuring the binding of the fluorescent conjugate alone (no antibody), is shown along with the nonspecific fluorescence of cells alone (cells). [Diagram 45]FIG. 45 provides results showing survival of Colo205 cells in the presence of two different DR5-specific mAbs containing heavy chains of human IgA2 subclass. Colo205 cells, 10,000 cells per well of a 96-well plate, were cultured for 48 hours in the presence of serial two-fold dilutions of tissue culture supernatant from Expi293 cells producing the DR5 IgA mAbs used in FIG. 44. The mAbs used were: BDR5-A2WT, which contained wild-type heavy chains of human IgA2 subclass; TDR5-A2WT, which contained wild-type heavy chains of human IgA2 subclass; BDR5-A2HF, which contained heavy chains of human IgA2 subclass carrying the H429F modification; TDR5-A2HF, which contained heavy chains of human IgA2 subclass carrying the H429F modification. Cell viability was quantified using a CCK8 colorimetric cell viability assay, where the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell survival and viability. Maximum cell viability was determined by incubation of cells in the absence of antibody (No Antibody) and maximum death was determined by incubation of cells with sodium dodecyl sulfate (SDS). Survival is expressed as: [experimentally determined absorbance 450 nm - background absorbance of cell culture medium 450]. [Figure 46]13 provides results showing enhanced killing of Ramos lymphoma cells by a mixture of H429F modified mAbs detecting different molecular targets. Ramos cells at 10,000 cells per well were cultured in the presence of anti-CD38 mAb Isatuximab containing an IgG1 WT H chain (Isa-WT), or anti-DR5 mAb BDR5-1 containing an IgG1 WT H chain (BDR5-1WT), or a 1:1 mixture of both mAbs (Isa-WT+BDR5-1WT), separately, or with Isatuximab containing an H chain carrying the H429F modification (Isa-HF), and BDR5-1 containing an H chain carrying the H429F modification (BDR5-1HF), or a 1:1 mixture of both (Isa-HF+BDR5-1HF), as described in Example 7. All mAbs were present in the cultures at 10 μg / ml, and for mixtures, 10 μg / ml of each mAb for a total mAb concentration of 20 μg / ml. After 48 hours of culture, cell viability was quantified using a CCK8 colorimetric cell viability assay in which the absorbance (absorbance 450 nm) of the supernatant of CCK8-treated cells is a measure of cell survival and viability. Maximum cell viability was determined by culturing cells in the absence of antibody (no antibody) and by maximal cell death by incubation of cells with SDS prior to CCK8 treatment of cells. Viability is expressed as follows: [experimentally determined absorbance 450 nm - background absorbance 450 of cell culture medium], mean absorbance 450, and four replicates are shown. [Figure 47] Results are provided showing that the H429F substitution confers complement-dependent lysis (CDC) of leukemia cells that are resistant to lysis by the unmodified anti-CD38 mAb mezagitamab. CDC by complement-dependent lysis was determined specifically using Ramos lymphoma cells opsonized with mezagitamab-WT mAb or mezagitamab-H429F mutant mAb at the indicated concentrations. Background lysis was determined in the absence of mAb, but in the presence of complement only (C' only). CDC (% killing) was determined by flow cytometry using Zombie Green. [Figure 48]We provide results showing that additional mutations of K439E or S440K in the Fc region component can suppress the enhanced CDC of H429F-modified rituximab, and that the combination of rituximab-H429F / K439E with rituximab-H429F / S440K restores efficient CDC killing of Ramos cells. (A) Ramos lymphoma cells were opsonized with individual Rituximab-WT (WT) or Rituximab-H429F (H429F) mAbs, or with Rituximab-H429F containing the additional heavy chain mutation K439E (H429F / K439E), or with Rituximab-H429F containing the additional heavy chain mutation S440K (H429F / S440K), or with a pairwise mixture of Rituximab-H429F / K439E and Rituximab-H429F / S440K (H429F / K439E+H429F / S440K). Background lysis was determined in the absence of mAb but in the presence of complement only (No mAb C' only). CDC (% killing) of the mAbs was measured by flow cytometry using Zombie green in the presence of a 1 / 3 dilution of human serum. We found that the enhanced CDC mediated by the H429F modification of Rituximab was suppressed by either the K439E or the Fc:Fc interaction inhibiting S440K mutations, but was fully restored by a mixture of both IgG variants. (B) For binding analysis, proteins were serially titrated 2-fold and binding activity (to Ramos cells) was quantified by flow cytometry using a FITC-conjugated anti-hIgG-Fc secondary reagent. The levels of nonspecific background binding of fluorescent conjugates to cells are shown (conjugates only); MFI = median fluorescence intensity. All mAbs gave nearly identical binding to CD20. [Figure 49]Figure 1 provides the results of flow cytometric analysis of binding (A,C) and CDC (B,D) of purified flACE2-Fc fusion protein (A,B) and SARS-CoV spike-specific mAb (C,D) using Ramos-S cells. For binding analysis, proteins were titrated two-fold in series and binding activity (to Ramos-S cells) was quantified by flow cytometry using a FITC-conjugated anti-hIgG-Fc secondary reagent. The level of non-specific background binding of fluorescent conjugates to cells is shown (conjugate); MFI = median fluorescence intensity. For CDC analysis, proteins were titrated two-fold in series and human serum was used as a source of complement. CDC lysis was quantified using Zombie Green. Background lysis by complement in the absence of antibody was determined and is shown (only C' without mAb). [Figure 50]1 provides graphical results from flow cytometry analysis showing that the cooperative and functional synergy of H429F modified flACE2-Fc fusion protein and H429F modified anti-SARS-CoV-2 mAb further enhances complement dependent killing (CDC). (A) mAb S2P6-H429F (S2P6-HF) or S2P6-WT were titrated alone or in the presence of a fixed concentration of flACE2-Fc-H429 fusion protein (1 μg / ml final concentration) (S2P6-HF+flACE2-Fc-HF), which mediated 23.4% CDC killing (indicated by open diamond symbols) when used alone, or in the presence of a fixed concentration of flACE2-Fc-WT (1 μg / ml final) (S2P6-WT+flACE2-Fc-WT), which mediated 5.0% killing (black diamonds) when used alone. Background lysis by complement in the absence of mAb or Fc fusion protein (C' only) is shown, with the arrow indicating an example of maximal synergy. (B) CDC killing potency of H429F modified flACE2-Fc was evaluated on Ramos-S cells. mAbs CC40.8-H429F (CC40.8-HF) and CV3-25-H429F (CV3-25-HF) were used alone (final concentration of 2.5 μg / ml) or mixed with flACE2-Fc-H429F (CC40.8-HF+flACE2-Fc-HF; CV3-25-HF+flACE2-Fc-HF; note that the final concentration of mAb was 2.5 μg / ml and the final concentration of flACE2-Fc-H429F was 1 μg / ml). Killing potency was evaluated in a flow cytometry assay using Zombie Green. Also shown is the % CDC killing mediated by flACE-2-Fc-WT and background lysis by complement in the absence of mAb or Fc fusion protein (C' only). Values of four replicates and SEM are shown. The mean % killing value is shown above each column. [Figure 51]Results are provided showing that ACE2-Fc fusion proteins of three formats, namely trACE2-Fc, flACE2-Fc, and EflACE2-Fc, containing Fc region components with wild-type sequence or H429F mutation, bind equally to Ramos-S target cells, as determined using flow cytometry analysis with goat anti-hIgG Fc FITC-labeled anti-IgG secondary reagent: (A) trACE2-Fc (mean ± SEM, n = 3), (B) flACE2-Fc (mean ± SEM, n = 3), and (C) EflACE2-Fc (WT n = 3, H429F n = 1). In all panels, the level of non-specific binding of fluorescent conjugates to cells is shown (conjugate only); MFI = median fluorescence intensity. EC50 (nM) values from curve fitting are shown. [Figure 52] Results are provided showing that ACE2-Fc fusion proteins in three formats (trACE2-Fc, flACE2-Fc, and EflACE2-Fc) containing Fc region components with wild-type sequence or H429F mutation strongly fix complement and direct complement-dependent cytotoxicity (CDC) of Ramos-S target cells, as determined using flow cytometric analysis of CDC of opsonized Ramos-S cells using diluted normal human serum as a source of complement: (A) trACE2-Fc (mean ± SEM, n = 3), (B) flACE2-Fc (mean ± SEM, n = 3), (C) EflACE2-Fc (WT n = 3, H429F n = 1). In all panels, the level of nonspecific complement killing in the absence of ACE2-Fc fusion proteins is shown with complement alone (C' only). EC50 (nM) values from curve fitting for H429F protein are shown. A match could not be determined for the WT protein (nd). [Figure 53]Provides representations of immunoglobulin (antibody) and immunoglobulin (antibody)-like molecules showing the modular nature of antibodies. (A) Left panel: Definitions of immunoglobulin molecule chains and components are as shown and defined in the left panel of FIG. 2. Center panel: Provides an example of an Ab-like fusion protein, showing that the modular nature of immunoglobulins allows flexibility in the production of Ab-like molecules (as provided in FIG. 2). In the particular depicted Ab-like fusion protein, the target recognition structure (shown as X1) is the same in all chains, as in the case of the Ab-like molecule described in Example 14 (wherein the EflACE2 polypeptide is linked separately to both the H and L chain constant domains in the CH1 domain, allowing assembly into the H2L2 Ab-like fusion protein). Right panel: Depicts possible Ab-like fusion proteins containing fusions to different target recognition structures (or enzymes and / or reporter molecules) in any combination of specificities (e.g., "X1 X1 X1 X1", "X1 X1 X1 X2", "X1 X1 X2 X2", "X1 X1 X2 X3", "X1 X2 X3 X4", "X1", "X2", "X3", and "X4" represent different target recognition structures (or enzymes or reporter molecules)). (B) SDS-PAGE analysis of EflACE2-Ab-like-WT fusion protein eluted from Protein A affinity matrix with 0.4 M arginine (pH 4) showing that a fully disulfide-linked molecule consistent with H2L2Ab-like organization was achieved (lane 1). This molecule contains an EflACE2 polypeptide fused to an immunoglobulin constant heavy chain (EflACE2-CH) that self-assembles with the equivalent EflACE2 polypeptide fused to an immunoglobulin light chain constant domain (EflACE2-CL). Upon reduction with dithiothreitol, these two chains (i.e., EflACE2-CH (ACE2-CH) and EflACE2-CL (ACE2-CL; lane 2) are separately degraded. (C, D) Results are provided showing that the EflACE2-Ab-like-H429F fusion protein (H429F) strongly directed CDC of Ramos-S target cells, whereas the corresponding fusion protein with the wild-type sequence (WT) of the H chain was ineffective.CDC of opsonized Ramos-S cells was determined using the presence of a 1 / 3 dilution of normal human serum as a source of complement. This potent CDC mediated by the EflACE2-Ab-like-H429F fusion protein was not due to a different level of opsonization compared to the EflACE2-Ab-like-WT fusion protein, as their binding to Ramos cells expressing the SARS-CoV-2 spike was comparable for both proteins. Binding was determined using flow cytometric analysis using goat anti-hIgG Fc FITC-labeled anti-IgG secondary reagent. MFI = median fluorescence intensity; background binding of anti-Ig fluorescent conjugates shown as (conjugate only). [Figure 54] 1 shows the results of purification of EflACE2-Ab-like-Fc-H429F fusion protein using Protein A and arginine elution: (A) Protein A chromatography using a Hitrap™ Protein A column with gradient elution from 30 mM arginine (pH 4) to 35% 130 mM arginine (pH 4), (B) size exclusion chromatography (SEC) of pooled and concentrated Protein A fractions containing EflACE2-Ab-like-Fc-H429F using a Superose 6 Increase 10 / 300 column with the indicated oligomeric material (HMW), and (C) SDS-PAGE analysis of pooled Protein A eluates and pooled SEC monomer fractions under non-reducing (no DTT, dithiothreitol) and reducing (with DTT) conditions. [Figure 55]Results are provided showing survival of Colo205 colorectal cells in the presence of purified DR5-specific mAbs containing IgG1 H chains with a single H429F mutation (HF) or L234A, L235A, and H429F (LA / LA / HF) mutations. mAbs were titrated individually or mixed together (BDR5-1LA / HF+TDR5-1LA / LA / HF) and compared to a mixture of BDR5-1HF+TDR5-1HF, both mAbs in the mixture containing IgG1 H chains with only the H429F modification, and Colo205 cells, 10,000 cells per well of a 96-well plate, were cultured in the presence of serial 2-fold dilutions of the indicated mAbs. Individual mAbs were titrated from 1 μg / ml. For the mixture titration, a starting concentration of 1 μg / ml was included with 0.5 μg / ml of each mAb in the mixture. Cell viability was quantified using a CCK8 colorimetric cell viability assay in which the absorbance (absorbance 450 nm) of the cell culture supernatant is a measure of cell survival and viability. Maximum cell viability was determined by culturing cells in the absence of antibody (no antibody) and maximum death was determined by culturing cells with sodium dodecyl sulfate (SDS). Survival is expressed as: [experimentally determined absorbance 450 nm of mAb or control treatment - background absorbance 450 of cell culture medium]. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The present disclosure is directed to immunotherapeutic proteins comprising one or more polypeptides that include an Fc region component, wherein the one or more polypeptides comprise an amino acid substitution (mutation) at a position corresponding to H429 (within the CH3 domain) (Eu numbering) of the amino acid sequence of the human immunoglobulin G1 (IgG1) heavy (H) chain.
[0016] The amino acid numbering used herein is based on the so-called Eu numbering system, which is related to the sequence numbering used to describe the human IgG1 myeloma protein called Eu (Edelman GM et al., Proc Natl Acad Sci USA 63(1):78-85, 1969). According to this system, for example, H429 (i.e., histidine at position 429) of IgG1 occurs at position 429 in the Eu sequence. Thus, in any immunoglobulin molecule, such as an antibody or fragment thereof, or an antibody-like molecule, an amino acid at a given position number is related to or corresponds to the corresponding amino acid residue position number in the Eu sequence.
[0017] The heavy (H) chains of immunoglobulins, such as IgG1, are modular, multifunctional, yet monomeric polypeptides. (The prototypical immunoglobulin or antibody structure with the H429 mutation may be considered to consist of a dimeric protein containing two monomeric heavy (H) chain polypeptides, each optionally associated with a light (L) chain, thus occurring in an H2L2 format (see FIG. 2). However, other forms of immunoglobulin molecules may be formed, including when one heavy chain (H1) is associated with one light (L1) chain in an H1L1 format, and other forms in which two heavy (H) chains may dimerize in the absence of a light (L) chain to produce an H2-formatted heavy chain complex (FIG. 2). When the light (L) and heavy (H) chains are associated in an H1L1 format, the molecule can dimerize in this configuration to obtain a typical immunoglobulin structure designated as H2L2. This is exemplified by the typical human IgG class immunoglobulin, in which two heavy (H) chains are covalently linked to each other and a light (L) chain is covalently linked to each heavy (H) chain.
[0018] The dimeric form of the H1L1 immunoglobulin molecule (i.e., the H2L2 protein) is the basic structural "unit" of all human Ig classes (i.e., IgG, IgE, IgD, IgA, and IgM) and, in fact, is also the basis of most mammalian immunoglobulin classes, noting that exceptions to this format are known (e.g., camelid immunoglobulins can form heavy chain dimers without light chains (abbreviated as H2)). Thus, for example, human immunoglobulin G (IgG) molecules exist physiologically in solution as a single H2L2 unit. However, other covalently linked higher order oligomers of the basic H2L2 unit exist in nature, and are particularly common to IgM and IgA.
[0019] For example, IgM can form pentameric or hexameric rings of covalent bonds of the H2L2 format, with each H2L2 unit having a disulfide bond to the adjacent H2L2 unit, forming pentameric oligomers (H2L2)5 or hexameric oligomers (H2L2)6 (Eskeland T and TB Christensen, Scand J Immunol 4(3):217-228, 1975), and of note is the hexameric form of IgM, which is the most potent effector of the classical complement pathway (one of the two major effector systems of the innate immune system initiated by immunoglobulins), activated by avid binding of the soluble hexameric protein C1q (Eskeland T and TB Christensen, 1975 supra; Randall TD et al., Proc Natl Acad Sci USA 89:962-966, 1992; Hughey CT et al., J Immunol 161:4091-4097, 1998, and Randall TD et al., Eur J Immunol 20:1971-1979, 1990). IgM is also well recognized as the most potent agglutinin due to its covalent oligomerization resulting in the presence of 10-12 specific and identical antigen-binding variable domains in each IgM pentamer or hexamer. Since each antigen-recognition structure (e.g., Fab fragment) has a defined affinity for a target antigen site or epitope with a strength defined by its monovalent binding to one target structure, the presence of multiple antigen-recognition structures (e.g., the 12 antigen-binding variable domains of each IgM hexamer) within one molecule confers stronger or more avid binding of the oligomeric immunoglobulin. Thus, oligovalent binding results from the combined strength of the individual antigen-recognition interactions of the IgM oligomer and its target antigen epitope. In comparison, the avidity of IgG, which has two antigen recognition structures (Fab) per H2L2 unit, arises solely from the interaction of these two antigen recognition structures.
[0020] Immunoglobulins can also be considered as modular, multifunctional proteins in which the target recognition structure is connected to the functional activation structure by a flexible linker (i.e., the antigen recognition structure provided by the V domain of the Fab is linked to the Fc region by a flexible hinge), and in the case of a typical immunoglobulin, each H chain and each L chain contains different domains that can be considered as structural or functional modules (Figure 2). The H chains, in particular, contain a variable sequence antigen target recognition domain (V H The heavy chain of the Ig class, e.g., IgG or IgA, contains a first constant domain (V), followed by a series of constant domains that are unique to the heavy chain of the Ig class, e.g., IgG or IgA, and sequence analysis indicates that these constant domains are related across immunoglobulin classes (see Figures 3 and 4). H The H chain is followed by a first constant domain (CH1), which is connected to a second constant domain (CH2) by a flexible polypeptide acting as a linker known as a hinge region, which is then followed by a third constant domain (CH3), and thus a typical H chain is a separate structural molecule from the amino terminus (i.e., the NH2-terminal V H The light (L) chain consists of a variable antigen target recognition domain (V-CH1-hinge-CH2-CH3 (Figure 2)) and is exemplified by the human IgG1 H chain sequence (SEQ ID NO: 3 and 114) and is conserved across all human heavy chains (Figures 3, 4) exemplified by human IgG3 (SEQ ID NO: 4 and 115), IgG4 (SEQ ID NO: 5 and 116), IgG2 (SEQ ID NO: 6 and 117), IgA1 (SEQ ID NO: 7 and 118), IgA2 (SEQ ID NO: 8 and 119), and IgE (SEQ ID NO: 9), IgM (SEQ ID NO: 10), and IgD (SEQ ID NO: 11), and mammalian immunoglobulins in general. Similarly, the light (L) chain consists of a variable antigen target recognition domain (V-CH1-hinge-CH2-CH3 (Figure 2)), which is exemplified by the human IgG1 H chain sequence (SEQ ID NO: 3 and 114) and is conserved across all human heavy chains (Figures 3, 4) exemplified by human IgG3 (SEQ ID NO: 4 and 115), IgG4 (SEQ ID NO: 5 and 116), IgG2 (SEQ ID NO: 6 and 117), IgA1 (SEQ ID NO: 7 and 118), IgA2 (SEQ ID NO: 8 and 119), and IgE (SEQ ID NO: 9), IgM (SEQ ID NO: 10), and IgD (SEQ ID NO: 11), and mammalian immunoglobulins in general. L domain), followed by a constant domain specific to the light chain class.
[0021] Given their modular nature, immunoglobulins provide a versatile platform for the generation of a diverse range of immunotherapeutic or diagnostic molecules, including bivalent antibodies, e.g., classical hybridoma-derived mAbs, heavy chain antibodies comprising dimers of heavy chains (e.g., camelid antibodies; Hamers-Casterman C et al., Nature 363:446, 1993), antibody-like (Ab-like) molecules (including some fusion proteins comprising at least a CH3 domain (or at least a CH4 domain)), and other immunoglobulin derivatives known to those skilled in the art, as summarized in the "Periodic Table of Antibodies"; https: / / absoluteantibody.com / periodic-table-of-antibodies / #, the entire disclosures of which are incorporated herein by reference). Other specific examples include antibodies and antibody fragments, such as single chain Fv antibody fragments, asymmetric bispecific antibodies (WO2012 / 058768), chain exchange engineered domains (SEEDs or Seed Bodies) that are asymmetric and bispecific antibody-like molecules (WO2007 / 110205), dual variable domain immunoglobulins (US 7,612,181), knob-into-hole antibody formats (WO1998 / 050431), duobody molecules (WO2011 / 131746), IgG-like bispecifics (Shen J et al., J Immunol Methods 318(1-2):65-74,2007), and fusion proteins that include Fc or Fc region components, such as scFv fusions and dual scFv fusions.
[0022] A number of terms are used herein that are well known to those of skill in the art. Nonetheless, for purposes of clarity, a number of these terms are defined below.
[0023] As used herein, the term "antibody" should be understood to include (unless otherwise specified) polyclonal antibodies (pAbs), monoclonal antibodies (mAbs), chimeric antibodies, humanized antibodies, antibody mixtures (e.g., recombinant polyclonal antibodies), such as those generated by methods well known to those skilled in the art for producing multiple antibodies with different specificities from a single host cell line (e.g., Oligoclonics® technology: Merus BV, Utrecht, The Netherlands) or transgenic animals. Furthermore, it should be understood that the antibodies can be of any immunoglobulin class (i.e., isotype) or allotype. Thus, for example, the antibodies disclosed herein can be of an isotype selected from the well-known immunoglobulin isotypes, or can contain components from more than one isotype (e.g., as may be the case for some chimeric antibody types). Antibodies also include "mixed" chain, e.g., antibodies in which the H chain comprises different H2 or H2L2 units (i.e., H x and H y (H x H y Or L x H x H y L y ).
[0024] The term "antibody-like molecule" (Ab-like molecule) should be understood to refer to a protein that is not an antibody and that minimally comprises a target recognition structure (e.g., an antigen recognition sequence (e.g., a receptor or ligand such as a variable (V) domain or complementarity determining region (CDR) of an immunoglobulin) linked to at least the CH3 domain (or CH4 domain) of an immunoglobulin heavy (H) chain (providing a molecule having a "H-like" chain), including, for example, a receptor fusion protein comprising at least the CH3 domain (or at least the CH4 domain) of an H chain. Examples of Ab-like molecules include those described above (FIG. 2, FIG. 53A, and / or the Periodic Table of Antibodies). In some examples, H-like chains including at least a CH3 domain are considered to include an Fc region component, which may be, for example, a complete Fc region, or just the CH3 domain, or a CH2-CH3 or CH3-CH2 component. In other examples, such H-like chains may further include, for example, an immunoglobulin hinge sequence. The H-like chain may allow for dimerization, such that the antibody-like molecule may be provided, for example, in homodimeric or heterodimeric forms. As depicted in FIG. 53, in some embodiments, the Ab-like molecule may include an H2L2 format, and may include fusion proteins including the same or different target recognition structures (or enzymes and / or reporter molecules), such as, for example, "X1 X1 X1 X1", "X1 X1 X1 X2", "X1 X1 X2 X2", "X1 X1 X2 X3", or "X1 X2 X3 X4", where X1, X2, X3, and X4 represent different target recognition structures (or enzymes or reporter molecules).
[0025] The term "fusion protein" is well known to those of skill in the art and refers to a protein expressed from a DNA construct that contains two or more open reading frames in a desired order, such that the protein may be considered a hybrid or chimeric protein. In some simple examples, a fusion protein comprises a protein of interest (or a fragment) linked ("fused") to the amino terminus (N-terminus) or carboxyl terminus (C-terminus) of a partner polypeptide, such as a carrier protein (e.g., human serum albumin, HSA). As used herein, the term "fusion protein" will also be understood to refer to certain types of antibody-like molecules, such as fusion proteins that include a target recognition structure (e.g., an antigen recognition sequence (e.g., a receptor or ligand, such as a variable (V) domain or complementarity determining region (CDR) of an immunoglobulin) linked to at least the CH3 domain (or at least the CH4 domain) of an immunoglobulin heavy (H) chain (see the example shown in FIG. 2). Such fusion proteins can be, for example, mixtures of antibodies (e.g., bispecific antibodies) and antibody-like molecules, such that the fusion protein includes, for example, Fc fragments with different Fc regions (chains) (e.g., Fc1x and Fc2y). The Fc regions may include combined Fc regions, each of which may optionally be linked to a different target recognition structure (e.g., ligand 1 and ligand 2). One of skill in the art will appreciate that the target or antigen recognition structure may be linked to a polypeptide that may include, for example, an entire H chain or may include, for example, a complete Fc region, or an H-like chain that may include only a CH3 domain, or a CH2-CH3 or CH3-CH2 component, including at least a CH3 domain (or the equivalent CH4 domain of IgE or IgM). In other examples, such H-like chains may further include, for example, an immunoglobulin hinge sequence and / or a CH1 domain. The CH1 domain may provide, for example, a suitable site for linking a target or antigen recognition structure.
[0026] The term "Fc fragment" (Fc or Fc portion), as used herein, refers to a dimer formed by covalent and / or non-covalent interactions between portions of an immunoglobulin heavy (H) chain (i.e., a dimer formed between two Fc regions of a H chain (each comprising the CH2 and CH3 domains of the heavy chain and optionally a hinge sequence)), which is responsible for most of the activation of immune effector functions of immunoglobulins: in particular, killing of target cells by antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis (ADCP) or trogocytosis. Cell-based effector responses initiated by antibodies and cell surface-located Fc receptors, which lead to the modulation and inhibition of innate and adaptive immune cell activity by inhibitory Fc receptors, include activation of the complement system via its classical pathway, effector responses of the innate immune system initiated by antibodies through a cascade of proteins found in blood or biological fluids that are important in the destruction of pathogens, and killing of targets by direct lysis through complement dependent cytotoxicity (CDC) and / or by phagocytosis of targets through specific receptors for components of complement (C'ADCP). The Fc fragment also provides sites of association between immunoglobulin molecules that allow assembly of immunoglobulin molecules into higher order oligomers (self-association) through covalent bonds between domains in the Fc region of one immunoglobulin's heavy chain with the Fc region of an adjacent immunoglobulin's heavy chain (e.g., as found in the pentameric and hexameric forms of IgM), and sites of non-covalent self-association, such as that found in IgG when bound to an antigen, which leads to oligomerization, including hexamer formation (Diebolder CA et al., Science 343(6176):1260-1263, 2014), and certain effector functions, among other properties.
[0027] As used herein, the term "Fc region component" should be understood to refer to a portion of the Fc region of an immunoglobulin heavy (H) chain, including at least the CH3 domain (or at least the CH4 domain), in which H429 is located, but preferably including the CH2 and CH3 domains, and optionally further including an immunoglobulin hinge sequence (which may in turn include all or a portion of the lower hinge, core hinge, and upper hinge sequences) that can form (e.g., by dimerization) an Fc fragment or an Fc-like fragment. An "Fc-like fragment" should be understood to refer to an Fc fragment-like structure, but which includes a fragment or component of an Fc region (e.g., including the CH3 domain (or CH4 domain) alone or the CH3 domain in combination with the CH2 domain, and optionally further including an immunoglobulin hinge sequence (which may in turn include all or a portion of the lower hinge, core hinge, and upper hinge sequences).
[0028] As used herein, the term "treating" includes prevention and alleviation of established symptoms of a disease or condition. As such, the act of "treating" a disease or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of a disease or condition developing in a subject suffering from or prone to the disease or condition, (2) inhibiting the disease or condition (i.e., in the case of maintenance therapy, arresting, reducing, or delaying the onset or recurrence of the disease or condition, or at least one clinical or subclinical symptom thereof), and (3) relieving or attenuating the disease or condition (i.e., causing regression of the disease or condition, or at least one clinical or subclinical symptom thereof).
[0029] As used herein, the phrase "manufacturing a medicament" includes the use of one or more immunotherapeutic proteins at any stage in the manufacture of a medicament that is directly defined as a medicament in the first aspect or that contains one or more immunotherapeutic proteins as defined in the first aspect.
[0030] The term "effective amount" is an amount sufficient to achieve a beneficial or desired clinical result. An effective amount can be administered in one or more administrations. Typically, an effective amount is sufficient to treat a disease or condition or otherwise alleviate, ameliorate, stabilize, reverse, slow, or delay the progression of a disease or condition. By way of example only, an effective amount of an immunotherapeutic protein, such as a mutant IgG1 antibody, can include, for example, about 0.1 to about 250 mg / kg body weight per day, more preferably about 0.1 to about 100 mg / kg body weight per day, and even more preferably about 0.1 to about 25 mg / kg body weight per day. Notwithstanding the above, however, it will be understood by those skilled in the art that the effective amount can vary and can depend on a variety of factors, including the age, weight, sex, and / or health of the subject being treated, the activity of the particular immunotherapeutic protein, the metabolic stability and length of action of the particular immunotherapeutic protein, the route and time of administration of the particular immunotherapeutic protein, the rate of excretion of the particular immunotherapeutic protein, and, for example, the severity of the disease or condition being treated.
[0031] As shown in the examples provided below, it has been found that mutant antibodies containing a point mutation at position H429 can confer significant functional changes. For example, IgG mutants with an H429F substitution exhibit an enhanced ability to activate complement-dependent cytotoxicity (CDC) in complement assays (i.e., assays of complement function). It has also been found that fusion proteins containing an Fc region moiety with a point mutation at position 429 (i.e., H429F) fused to an angiotensin-converting enzyme 2 (ACE2) ectodomain (which can act as a "decoy" to block virus interaction and cellular entry of coronaviruses into host cells) can provide an enhanced ability to provide an antiviral effect through CDC of infected cells, while similar fusion proteins with an H429Y substitution exhibit enhanced virus neutralization with little or no complement activation (as immunotherapeutic proteins containing H429Y modified Fc moieties exhibit abrogated binding and activation of FcγRs, particularly FcγRIIIa). Without wishing to be bound by theory, it is believed that these effects may be due to oligomerization of the proteins into oligomers through self-association of the antibody / fusion protein either in solution or upon binding to the relevant target molecule (e.g., the antigen against which the antibody variant is directed) through "on-target" oligomerization.
[0032] In this regard, it is further noted that, although monomeric IgG1 and IgG3 are capable of delivering CDC, the levels of CDC can be considered low or "poor" compared to those achieved with native pentameric or hexameric IgM. Furthermore, IgG antibodies such as IgG1 and IgG3, unlike IgM, are also relatively poor agglutinins due to their bivalency. Thus, by allowing oligomerization, particularly after the immunoglobulin binds to an antigen (i.e., "on-target" oligomerization), and possibly enhancing the known weak inherent self-association ability of the Fc of immunoglobulins such as IgG, immunotherapeutic proteins according to the present disclosure may provide a more optimal platform for complement system activation and other functions enhanced by self-association by forming oligomers. This oligomerization may particularly and / or optimally involve the formation of hexamers, which has been visualized in the crystal structure of the anti-HIV antibody b12 (Saphire EO et al., Science 293:1155-1159, 2001), with the CH3 residues forming an interface between adjacent IgG:IgG molecules, thus forming hexamers that optimally present binding sites for the six globular head domains of the C1q subunit that initiate activation of the classical complement pathway.
[0033] Furthermore, many cellular molecules, including cell surface molecules, require substantial clustering by a ligand (which may be soluble or another cell surface molecule) to induce a signal that results in a cellular response, and therefore the dimerization typically achieved with antibodies may not be sufficient to induce a signal that leads to a meaningful cellular response. However, it is known that the strength of the signal can be increased by increasing the clustering of the target molecule, for example through an approach involving the addition of other entities that crosslink the ligand (Chenoweth AC et al., Immunol Cell Biol 98:287-304, 2020), and therefore, in the case of an antibody (such as a mAb) bound to its target molecule, such "super cross-clustering" or "hyper-clustering" of the target molecule can be achieved by the use of an additional anti-immunoglobulin antibody that crosslinks the mAb that is bound to the target molecule. Without wishing to be bound by theory, it is believed that proteins such as mutant antibodies comprising the H429F point mutation described above may similarly achieve "supercross-clustering or hyperclustering" of target molecules through self-association upon binding to the target molecule. Depending on the nature of the target molecule, such clustering may induce an enhanced signaling response that may lead to, for example, cell proliferation (e.g., when the target molecule is, for example, CD3 or CD28), stimulation of inhibitory pathways to inhibit or reduce cellular responses (e.g., immune checkpoints; reviewed in Chenoweth et al., supra, 2020), or stimulation of pathways that induce cell death, such as programmed cell death, including apoptosis (see, for example, Ashkenazi A., Nat Rev Drug Discov 7(12):1001-1012, 2008). Stimulation of cellular pathways by mAbs for the development of therapeutic molecules is an approach that has been used to treat a variety of diseases including cancer, inflammatory and autoimmune diseases, infectious diseases, cardiovascular diseases, and others (Ashkenazi, supra 2008).
[0034] Thus, in a first aspect, the present disclosure provides an immunotherapeutic protein comprising one or more immunoglobulin heavy chain polypeptides comprising an Fc region component comprising at least a CH3 domain (or at least a CH4 domain), wherein the one or more polypeptides comprise an amino acid substitution at a position corresponding to H429 (Eu numbering) in the amino acid sequence of a human IgG1 heavy chain.
[0035] In some embodiments, the immunotherapeutic protein of the first aspect comprises a dimeric immunotherapeutic protein comprising first and second immunoglobulin heavy chain polypeptides comprising an Fc region component comprising CH2 and CH3 domains (such that the first and second polypeptides are capable of forming (e.g., by dimerization) an Fc fragment or an Fc-like fragment), and wherein the Fc region component of at least one of the first and second polypeptides comprises an amino acid substitution at a position corresponding to H429 (Eu numbering) of the amino acid sequence of a human IgG1 heavy chain. Thus, the immunotherapeutic protein of such embodiments may be an immunoglobulin molecule, such as an antibody or antibody-like molecule, such as a dimeric polypeptide comprising a pair of single chain Fv polypeptides linked via an Fc fragment (i.e., scFv-Fc), or a minibody (i.e., a protein comprising a pair of scFv polypeptides linked via a CH3 domain (see, e.g., the discussion of multivalent scFv-Fc and minibodies in Olafsen T et al., Generation of Antibody Fragments and Their Derivatives, Antibody Engineering Second edition, pp 69-84, 2010)).
[0036] In other embodiments, the immunotherapeutic protein of the first aspect comprises a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a CH4 domain), wherein the Fc region component comprises an amino acid substitution at a position corresponding to H429 (Eu numbering) in the amino acid sequence of a human IgG1 heavy chain. Thus, the immunotherapeutic protein of such embodiments may be provided in the form of a fusion protein or protein conjugate. Those skilled in the art will appreciate that in a fusion protein, a partner polypeptide is covalently linked (i.e., "fused") to an Fc component (i.e., as a fusion partner) at the N-terminus or C-terminus (i.e., Fc component) of the fusion partner via a peptide bond or a linker sequence (e.g., a short peptide linker sequence such as an immunoglobulin hinge sequence or a well-known glycine-serine linker such as GGGGS), whereas in a protein conjugate, a partner polypeptide is covalently linked (i.e., "fused") to an Fc component (i.e., as a fusion partner) via a chemical linkage, e.g., a disulfide bond (e.g., through one or more cysteine (C) residues) or a crosslinker compound, e.g., a homobifunctional crosslinker, e.g., disuccinimidyl suberate (DSS) (e.g., bis(sulfosuccinimidyl) suberate (BS)). 3 ; Thermo Fisher Scientific, Waltham, MA, United States of America), or disuccimidyl tartrate (DST) for linking amine groups, or heterobifunctional crosslinkers, such as m-maleimidobenzoyl-N-hydroxysuccinimide ester (MDS) and N-(ε-maleimidocaproxy)succinimide ester (EMCS), or by other non-covalent bonds, such as hydrogen bonds, to the Fc component (i.e., as a conjugate partner). When the Fc component is the conjugate partner, the immunotherapeutic protein conjugate may be considered a crosslinked protein, and the Fc component may be conjugated to the partner polypeptide at the N-terminus or C-terminus, but may otherwise be conjugated at any other suitable site on the partner polypeptide. Alternatively, the Fc component (as a conjugate partner) can be conjugated to the partner polypeptide at the N-terminus or C-terminus of the Fc component, or at any other suitable site on the Fc component (e.g., within the CH1 or upper hinge sequence if these are included in the Fc region component).
[0037] The Fc region component (hereinafter also referred to as "Fc component") of an immunotherapeutic protein can be derived from one or more immunoglobulin types (e.g., IgG or IgA) and can, for example, be a heavy (H) chain polypeptide fragment corresponding to that produced by papain digestion (i.e., the polypeptide is cleaved within the upper hinge sequence to yield constant heavy domain 2 (CH2; amino acids A231 to K340 of a human IgG1 heavy chain polypeptide (Eu numbering)), constant heavy domain 3 (CH3; amino acids G341 to G446 or K447 of a human IgG1 heavy chain polypeptide (Eu numbering)), and the lower hinge sequence (also known as the hinge proximal sequence of CH2; amino acids P232 to P238 (Eu numbering)), and the core hinge sequence (amino acids C226 to C228 (Eu numbering)). Examples of suitable Fc region components may include full-length (i.e., "intact") Fc regions such as those described herein (e.g., 229), as well as similar heavy chain polypeptide fragments that may be prepared through digestion of immunoglobulin heavy chain polypeptides with plasmin and human neutrophil elastase (NHE). Further examples of suitable Fc region components may include fragments of heavy chain polypeptides that include all or a portion of the upper hinge sequence and constant heavy domain 1 (CH1), in addition to the CH2 and CH3 domains and lower and core hinge sequences, while other suitable Fc region components may include fragments of heavy chain polypeptides that include only the CH3 domain (e.g., amino acids G341 to G446 or K447 (Eu numbering) of a human IgG1 heavy chain polypeptide) or fragments thereof. Additionally, suitable Fc region components may include fragments of heavy chain polypeptides that include only the CH3 domain (e.g., amino acids G341 to G446 or K447 (Eu numbering) of a human IgG1 heavy chain polypeptide) or fragments thereof. They may include heterologous ("hybrid") CH3 domains, such as fragments derived from CH3 domains and strand-exchange engineered domain (SEED) forms of CH3 domains from other proteins, such as IgA (Davies et al., Prot Eng Des Sel 23(4):195-202, 2009).
[0038] In some embodiments, the Fc region component is derived from a human immunoglobulin heavy chain polypeptide (such as those shown in Figures 3 and 4).
[0039] In other embodiments, the Fc region component is derived from an IgG heavy chain polypeptide, preferably an IgG1 or IgG3 (eg, human IgG1 or IgG3) heavy chain polypeptide, and more preferably IgG1.
[0040] The Fc region component comprises an amino acid substitution at a position corresponding to H429 (Eu numbering) of the amino acid sequence of a human IgG1 heavy chain polypeptide. If the Fc region component is derived from another immunoglobulin type or isotype (or from an immunoglobulin from another species), it will be appreciated that one of skill in the art can readily determine the position corresponding to H429 of human IgG1 heavy chain polypeptide IgG1, for example, by routine sequence alignment (e.g., as shown in Figures 3 and 4).
[0041] Among the preferred mutations at position 429 are: H→X, where X is selected from tyrosine (H429Y), phenylalanine (H429F), tryptophan (H429W), glutamic acid (H429E), aspartic acid (H429D), glutamine (H429Q), serine (H429S), asparagine (H429N), and threonine (H429T).
[0042] Some preferred amino acid substitutions at the position corresponding to H429 of the amino acid sequence of a human IgG1 heavy chain polypeptide include an H→Y (eg, H429Y) substitution and an H→F (eg, H429F) substitution.
[0043] The amino acid substitution at the position corresponding to H429 of the amino acid sequence of a human IgG1 heavy chain polypeptide may be the only mutation in the Fc component, however, in some embodiments, the Fc component may include one or more additional mutations (e.g., amino acid substitutions). For example, the Fc component may contain one or more sequence mutations known to those of skill in the art (see, e.g., the examples listed in Table 1 of Wang X et al., Protein Cell 9(1):63-73, 2018, the entire disclosure of which is incorporated herein by reference), such as mutations that can modulate FcγR binding (e.g., S239D / I332E (Eu numbering) in IgG1, which increases FcγRIIIa binding); mutations to improve antibody-dependent cellular cytotoxicity (ADCC), such as S239D / I332E (Lazar GA et al., Proc Natl Acad Sci USA 103(11):4005-4010, 2006), opsonophagocytosis (e.g., G236A / S239D / I332E; Richards JO et al., Mol Cancer Ther 7:2517-2527, 2008), or complement activation (e.g., S267E / H268F / S324T; Moore GL et al., MAbs 2:181-189, 2010), or reduced effector function (e.g., IgG1: L234A / L235A; IgG4: F234A / L235A; Xu D et al., Cell Immunol 200(1):16-26, 2000); mutations that may increase inhibition via FcγRIIb co-engagement (S267E / L328F; Chu SY et al., Mol Immunol 45(15):3926-3933, 2008); and mutations that confer enhanced binding to the neonatal Fc receptor (FcRn), such as M252Y / S254T / T256E, to increase half-life in vivo and thereby improve pharmacokinetics (PK) (Dall'Acqua WF et al., J Immunol 169(9):5171-5180, 2002).
[0044] Other mutations that may be included in the Fc region component include mutations to enhance complement activation, for example, amino acid mutations at a position corresponding to K447 (Eu numbering) of the amino acid sequence of a human IgG1 heavy chain polypeptide, particularly including K447X, where X is selected from null (i.e., K447del; an amino acid deletion or truncation in the Fc component), and glutamic acid (i.e., K447E) (van der Bremer ETJ et al., mAbs 7(4):672-680, 2015). Additionally, the Fc region component may also include mutations that modulate glycosylation (e.g., a mutation at a position corresponding to Asn297 (Eu numbering) of the amino acid sequence of a human IgG1 heavy chain polypeptide, such as N297A, N297Q, or N297G to provide a site with modified glycosylation (e.g., lack of a glycan at position 297) to abolish FcγR and complement C1 binding and / or activation) (Wang et al., 2018 supra).
[0045] Alternatively, Fc region components can also be engineered to achieve modified glycosylation by producing the immunotherapeutic protein in the presence of kifunensine, a mannosidase inhibitor that prevents normal maturation of N-linked glycans, including core fucosylation of N-linked glycans; modifications that enhance activity specifically via FcγRIIIa. Furthermore, an Fc component lacking core fucosylation of the Asn297 glycan can also be achieved by culturing host cells expressing the immunotherapeutic protein with inhibitors of fucosylation (e.g., 2-fluoroperacetylated fucose, or the like), or by expression of enzymes that modify glycosylation pathways (e.g., GDP-6-deoxy-D-lyxo-4-hexulose reductase; Neha M et al., J Biotech 5:100015, 2020), or by modification of these pathways by gene suppression (e.g., siRNA silencing of the α-1,6-fucosyltransferase fucosyltransferase gene FUT8; Imai-Nishiya H et al., BMC Biotechnol 7:84, 2007), or knockout (Yamane-Ohnuki N et al., Biotechnol Bioeng 87:614-622, 2004).
[0046] The immunotherapeutic protein of the first aspect may be monomeric, dimeric, or oligomeric in solution (eg, in saline at neutral pH, such as physiological pH of about 7.4).
[0047] For example, in some embodiments, the immunotherapeutic protein comprises monomers in saline, each monomer containing one copy of the Fc region component, while in other embodiments, the immunotherapeutic protein comprises dimers in saline, the Fc region component self-associating (i.e., forming dimers) by non-covalent bonds such as hydrogen bonding, or through the formation of disulfide bonds through one or more cysteine (C) residues, particularly if located within the hinge sequence, particularly the core hinge sequence (if present) (Yoo EM et al., J Immunol 170:3134-3138, 2003). Thus, in some embodiments, the Fc region component comprises a core hinge sequence that allows the immunotherapeutic protein to self-associate (i.e., form a dimer) by forming an interchain disulfide bond between one or more cysteine (C) residues of the core hinge sequences of the two Fc region components, while in other embodiments, the Fc region component comprises a CH3 domain that allows CH3:CH3 self-association through non-covalent interactions, or the Fc region component comprises a CH3 domain and a CH2 domain that allow self-association through CH2:CH2 and CH3:CH3 non-covalent interactions. Note that in the following examples and figures, the dimeric forms of the immunotherapeutic proteins are considered to be single molecules (i.e., each contains two copies of the protein dimerized through the Fc region components) and are referred to as monomers / monomeric.
[0048] In other embodiments, the immunotherapeutic protein comprises an oligomer in saline (at neutral pH, such as a physiological pH of about 7.4), where the immunotherapeutic protein comprises an amino acid substitution at a position corresponding to H429 of the amino acid sequence of a human IgG1 heavy chain polypeptide, which allows the Fc or Fc-like fragment comprising the mutated Fc component to self-associate into a soluble oligomeric form in saline (e.g., an oligomeric form comprising, for example, 3 copies, 4 copies, 5 copies, 6 copies, or 12 copies assembled from a dimeric form of the immunotherapeutic protein, such that in some particular embodiments, the oligomeric form of the immunotherapeutic protein may comprise 6 dimeric proteins (i.e., a hexameric form) comprising a total of 12 copies of the immunotherapeutic protein). In such embodiments, the amino acid substitution at a position corresponding to H429 of the amino acid sequence of a human IgG1 heavy chain polypeptide comprises H429X 1 X 1 is selected from tyrosine (i.e., H429Y), methionine, isoleucine, leucine, tryptophan, and valine, Preferably, the immunotherapeutic protein comprises an H→Y (ie, H429Y) substitution.
[0049] In yet other embodiments, the immunotherapeutic protein may form oligomers upon binding to an associated target through "on-target" oligomerization. Such oligomerization may occur with the immunotherapeutic protein being a monomer or dimer in saline (at neutral pH, such as physiological pH of about 7.4) and containing an amino acid substitution at a position corresponding to H429 in the amino acid sequence of a human IgG1 heavy chain polypeptide that allows for on-target oligomerization into an oligomeric form (e.g., a form containing 3 copies, 4 copies, 5 copies, 6 copies, or 12 copies (e.g., a hexamer in a dimeric form) of the immunotherapeutic protein). In such an embodiment, the amino acid substitution at a position corresponding to H429 in the amino acid sequence of a human IgG1 heavy chain polypeptide is H429X 2 wherein X 2is selected from phenylalanine (i.e., H429F), glutamic acid, glutamine, and serine, Preferably, the immunotherapeutic protein comprises an H→F (ie, H429F) substitution.
[0050] Alternatively, oligomeric forms of the immunotherapeutic proteins of the first aspect may be produced by using other techniques known to those skilled in the art, such as, for example, the use of Fc multimeric forms (stradomers™) that comprise linked multimerization domain (MD) sequences from the hinge region of human IgG2 or isoleucine zipper (ILZ) to the N- or C-terminus of mouse IgG2a (Fitzpatrick EA et al., Front Immunol 11, article 496, 2020), as well as multimerization sequences from IgM (Melcheil et al., Sci Rep 1:124 doi:10.1038 / srep0012, 2011), or docking and dimerization sequences from unrelated proteins such as cyclic adenosine monophosphate-dependent protein kinase and A-kinase anchor protein (Rossi EA et al., Bioconjug Chem 23(3):309-323, 2012).
[0051] It has further been found that the immunotherapy protein of the first aspect may exhibit enhanced binding of neonatal Fc receptor (FcRn) due to an amino acid substitution at a position corresponding to H429 (Eu numbering) of the amino acid sequence of human IgG1 heavy chain. Since FcRn is known to "recycle" antibodies to control how long they last in the body, this is expected to mean that the immunotherapy protein will exhibit a greater half-life in vivo (i.e., compared to a comparable immunotherapy protein without a mutation at H429), thereby improving pharmacokinetics (PK) (Ward ES and RJ Orber, Trends Pharmacol Sci 39(10):892-904,2018).
[0052] Dimeric immunotherapeutic proteins (e.g., immunoglobulin molecules) The immunotherapeutic protein of the first embodiment may be a dimeric immunotherapeutic protein comprising an immunoglobulin molecule, the immunoglobulin molecule comprising a first and a second immunoglobulin heavy chain polypeptide, each comprising an Fc region component comprising at least a CH3 domain (or at least a CH4 domain). The Fc region components of the first and second immunoglobulin heavy chain polypeptides may self-associate (i.e., form dimers) by non-covalent bonds such as hydrogen bonds, or through the formation of disulfide bonds through one or more cysteine (C) residues, particularly if located within the hinge sequence, particularly the core hinge sequence (if present) (Yoo EM et al., J Immunol 170:3134-3138, 2003), or may otherwise be linked by a cross-linking compound, such as those described above (e.g., by cross-linking the CH3 domains of the Fc region components). As such, the immunotherapeutic protein may be, for example, an antibody or antibody derivative, e.g., an immunoglobulin molecule such as an scFv-Fc (a dimer of scFv polypeptides is formed through dimerization of Fc region components), a minibody (a dimer of scFv polypeptides is formed through linkage of CH3 domain / CH4 domains), or any other suitable Fc-containing antibody or derivative known to those of skill in the art (e.g., as summarized in the "Periodic Table of Antibodies" supra).
[0053] Thus, a dimeric immunotherapeutic protein comprises at least one antigen recognition structure, or in other words, an antigen binding region (e.g., a variable domain V such as a Fab fragment). L and V HThe antigen-binding region may further comprise an scFv or antigen-binding region comprising: The antigen-binding region may specifically bind to a therapeutically important antigen or epitope, for example, a cancer-associated antigen, such as a cancer antigen present on the surface of a cancerous cell (e.g., CD20, CD38, and CD52 antigens found on the surface of CLL cells, and cell surface antigens differentially expressed and / or present in cancer cells, such as mucins (e.g., MUC-1) or carbohydrates (e.g., Lewis X) that are overexpressed in some breast and pancreatic cancers), an autoantigen (e.g., an autoantigen associated with SLE or multiple sclerosis (MS)), an allergen (e.g., bee venom), an antigen associated with other inflammatory diseases such as immune complex vasculitis, an antigen from a transplanted tissue or organ, or an antigen of an infectious agent, such as an antigen of a bacterial, yeast, parasitic, or viral pathogen (e.g., an antigen of SARS-CoV-2 virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Respiratory Syncytial Virus (RSV), or Dengue virus).In other examples, the antigen binding region may specifically bind to a cell surface molecule known to induce cell proliferation (i.e., the cell surface molecule may be, for example, CD3 or CD28) and / or may specifically bind to a cell surface molecule known to stimulate an inhibitory pathway to inhibit or reduce a cellular response (i.e., the cell surface molecule may be, for example, an immune checkpoint molecule, e.g., 4-1BB (CD137), cluster of differentiation (CD40, CD154), OX40 receptor ( TNFRSF4, CD134), tumor necrosis factor receptor type II (TNFR2, CD120b), glucocorticoid-inducible TNFR-related protein (GITR, TNFRSF18, CD357), cluster of differentiation 27 (CD27), T-cell immunoglobulin and mucin domain-containing-3 (TIM-3), B and T lymphocyte attenuation factor (BTLA, CD272), lymphocyte activation gene-3 (LAG3, CD223), cytotoxic T lymphocyte-associated protein 4 (CTLA4, C D152), inducible T cell costimulatory (ICOS, CD278), cluster of differentiation 28 (CD28), TT cell immunoreceptor with Ig and ITIM domains (IGIT, Vstm3), programmed death ligand 1 (PDL-1, CD274), and programmed cell death protein 1 (PD-1, CD279), and oligomerization of the immunotherapeutic proteins can result in enhanced cross-linking (e.g., superclustering), which in turn can result in enhanced signaling that induces, for example, enhanced cell proliferation, or an inhibited / reduced cellular response (i.e., through enhanced stimulation of an inhibitory pathway). In yet another example, the antigen binding region can specifically bind to a cell surface molecule known to induce a cellular response selected from stimulation of an inhibitory pathway to inhibit or reduce the response. In yet another example, the antigen binding region can specifically bind to a cell surface molecule that induces cell death when engaged by another molecule, such as a ligand or agonist mAb.Such cell surface molecules include, for example, those of the TNF receptor superfamily (also known as TNFRSF), which includes tumor necrosis factor receptor 1 (TNFR1, TNFRSF1A, CD120a), Fas (CD95, APO-1), death receptor 3 (DR3, TNFRSF25), death receptor 4 (DR4, CD261, TNFRSF10A, TRAILR1), death receptor 5 (DR5, CD262, TNFRSF10B, TRAILR2), and death receptor 6 (CD358, TNFRSF21). For example, under physiological conditions, binding of TNF-related apoptosis-inducing ligand (TRAIL) to its receptor, DR5 (Carneiro BA et al., Nat Rev Clin Oncol 17(7):395-417, 2020), or FAS ligand to its receptor on the cell surface, FAS (CD95), induces oligomerization that initiates signaling leading to cell death (Leukocyte and Stromal Cell molecules: The CD Markers, by Zola H et al., page 195, John Wiley & Sons, 2007). For example, other molecules (not related to TNFRSF) that can induce apoptotic signals leading to cell death when crosslinked by mAbs or fragments thereof include CD38 (see Gambles MT et al., Molecules 26(15):4658, 2021), CD20 (see Shan D et al., Cancer Immunol Immunother 48:673-683, 2000, and Cardarelli PM et al., Cancer Immunol Immunother 51:15-24, 2002), and CD52 (see Rowan W et al., Immunology 95:427-436, 1998). These molecules can also be advantageously targeted by dimeric immunotherapeutic proteins, such that oligomerization can result in enhanced crosslinking and induction of apoptotic signals to result in cell death, as may be desired in the target cells.
[0054] In some embodiments, an immunoglobulin molecule in accordance with the present disclosure may comprise two antigen-binding regions, each of which specifically binds to a different antigen or epitope.
[0055] In some embodiments, immunoglobulin molecules according to the present disclosure that are antibodies can be, for example, of the IgD, IgE, or IgM isotype, but are preferably of the IgA or IgG isotype, such as antibodies of any of the human IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4 subtypes.
[0056] The first and second immunoglobulin heavy chain polypeptides of a dimeric immunotherapeutic protein comprising an immunoglobulin molecule can be the same (ie, a homodimer) or different (ie, a heterodimer).
[0057] In some embodiments, immunoglobulin molecules according to the present disclosure that are antibodies may be antibodies that form oligomers either through self-association of the antibody into oligomers (e.g., hexamers) either in solution (e.g., in saline at a neutral pH, such as a physiological pH of about 7.4), or upon binding to an associated target (e.g., an antigen against which the antibody variant is directed) through "on-target" oligomerization.
[0058] For example, without wishing to be bound by theory, it is believed that immunoglobulin molecules that are antibodies comprising an H429Y amino acid substitution in the Fc region component may form oligomers in solution (e.g., in saline at physiological pH), which may lead to an overall increase in the strength of binding (e.g., enhanced avidity) to a target binding partner (e.g., a cancer antigen, an antigen of a bacterial or viral pathogen, or other soluble target molecule or molecular complex). Thus, in the context of antibodies directed against cancer antigens present on the surface of cancerous cells, antibodies according to the present disclosure (in the form of oligomers in solution) may exhibit an enhanced ability to bind to cancerous cells leading to their destruction, for example, by CDC by complement or by phagocytosis by macrophages and / or ADCC, and in the context of antibodies directed against soluble target molecules or molecular complexes, antibodies according to the present disclosure (in the form of oligomers in solution) may exhibit an enhanced ability to bind to soluble target molecules or molecular complexes leading to their removal by phagocytosis by macrophages.
[0059] On the other hand, it is believed that immunoglobulin molecules that are antibodies comprising an H429F amino acid substitution in the Fc region component may form oligomers upon binding to the relevant target such that the assembled Fc component "on target" presents a stabilized and optimal platform for binding with enhanced avidity to, for example, the C1q complement protein complex, thereby leading to complement activation and then complement dependent cytotoxicity (CDC). Thus, in the context of antibodies directed against cancer antigens present on the surface of cancerous cells, antibodies according to the present disclosure may exhibit an enhanced ability to activate complement on the cancerous cells, leading to their destruction.
[0060] In some embodiments, an immunoglobulin molecule according to the present disclosure may be provided or used as a first immunoglobulin molecule having a first antigen-binding region directed to a first antigen in combination with a second immunoglobulin molecule (according to the present disclosure) having a second antigen-binding region directed to a second antigen. By way of example only, in such a combination, the first antigen may be a cancer antigen present on the surface of a cancerous cell (e.g., CD38 found on the surface of CLL cells) and the second antigen may be a death receptor (e.g., DR5). Oligomerization of the first and second immunoglobulin molecules may lead to the formation of hetero-oligomers, such as heterohexamers, in which different cell surface targets are assembled into clusters, which may lead to enhanced induction of apoptotic signals resulting in cell death (e.g., when a death receptor is targeted), due to target cell specificity achieved, for example, through binding of a cancer antigen present on a cancerous cell.
[0061] Fusion / Conjugated Immunotherapy Proteins The immunotherapeutic protein of the first aspect may comprise a fusion protein or protein conjugate comprising a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a CH4 domain).
[0062] The fusion protein or protein conjugate according to the present disclosure may be a monomer, dimer, or oligomer. For example, in some embodiments, the fusion protein or protein conjugate comprises a monomer, each monomer comprising one copy of the partner polypeptide (or a fragment thereof) and one copy of the Fc region component, while in other embodiments, the immunotherapeutic protein comprises a dimer, the Fc region component self-associating (i.e., forming a dimer) either by non-covalent bonds such as hydrogen bonds, or through the formation of disulfide bonds through one or more cysteine (C) residues, particularly if located within the hinge sequence, particularly the core hinge sequence (if present) (Yoo EM et al., J Immunol 170:3134-3138, 2003). In such dimers, the immunotherapeutic protein comprises two Fc region components (associated with each other to form, for example, an Fc fragment or an Fc-like fragment) and two fusion / conjugate partner polypeptides (or two fragments thereof), and as such may be considered bivalent with respect to the partner polypeptides (or fragments thereof). The two fusion / conjugate partner polypeptides (or two fragments thereof) of a dimeric fusion protein or protein conjugate may be the same (i.e., homodimers) or different (i.e., heterodimers). In some embodiments of such dimers, as depicted in Figure 53A, the fusion protein may be antibody-like (Ab-like), e.g., having an H2 format or an H2L2 format (a monomeric fusion protein may be produced with a light (L) chain, which may then be optionally fused / conjugated to a partner polypeptide, such as a target recognition structure). As can be readily appreciated, each target recognition structure of an Ab-like molecule having an H2 or H2L2 format can be the same or different, such as "X1 X1 X1 X1", "X1 X1 X1 X2", "X1 X1 X2 X2", "X1 X1 X2 X3", or "X1 X2 X3 X4", where X1, X2, X3, and X4 each represent a different target recognition structure. Also, one or more of the target recognition structures can be replaced with an alternative partner polypeptide type, such as an enzyme or reporter molecule.
[0063] The partner polypeptide may provide beneficial functions and / or characteristics to the immunotherapeutic protein.
[0064] In some embodiments, the partner polypeptide can be a cell surface receptor polypeptide (or a fragment thereof) or a co-receptor polypeptide (or a fragment thereof).
[0065] For example, the partner polypeptide may be a cell surface molecule, such as a cell surface receptor polypeptide (or fragment thereof) that can bind to a structural protein of the virus, such that the immunotherapeutic protein can act as a "decoy" to block viral interaction and cellular entry of the virus into the host cell. Thus, some examples of such cell surface receptor polypeptides (or fragments thereof) that may comprise the partner polypeptide include angiotensin-converting enzyme 2 (ACE2) ectodomain (ACE2 is a cell entry receptor for SARS-CoV-2), nucleolin (a cell entry receptor for RSV), dipeptidyl peptidase 4 (DPP4, CD26), Hsp70 (a cell entry receptor for Japanese encephalitis virus), hepatitis A virus cell receptor 1 (HAVCR1 / TIM-1; a cell entry receptor for hepatitis A virus and Ebola virus), cluster of differentiation 155 (CCL1), to name just a few. These include CD155 (a cell entry receptor for poliovirus), glucose transporter 1 (GLUT1 (a cell entry receptor for human T-cell leukemia virus 1), proto-oncogene tyrosine protein kinase MER (MERTK (a host factor promoting swine fever virus entry)), TYRO3 protein tyrosine kinase (TYRO3 (a cell surface protein associated with lymphocytic choriomeningitis (LMCV) infection), AXL (a cell surface protein associated with lymphocytic choriomeningitis (LMCV) infection), and cluster of differentiation 4 receptor (CD4 receptor (a cell entry receptor for human immunodeficiency virus (HIV)). In embodiments in which the partner polypeptide is a cell surface receptor polypeptide (or fragment thereof) capable of binding to a viral structural protein, a point mutation at a position in the Fc region component corresponding to H429 (Eu numbering) of the amino acid sequence of a human IgG1 heavy chain may, for example, provide the immunotherapeutic protein with an enhanced ability to provide an antiviral effect through CDC of infected cells (e.g., if the mutation is H429F) or confer enhanced virus neutralization on the immunotherapeutic protein (e.g., if the mutation is H429Y).In other examples, the partner polypeptide can be a ligand for a cell surface molecule known to induce cell proliferation (i.e., the cell surface molecule can be, for example, CD3 or CD28) and / or can be a ligand for a cell surface molecule known to stimulate an inhibitory pathway to inhibit or reduce a cellular response (i.e., the cell surface molecule can be, for example, an immune checkpoint molecule, such as 4-1BB, CD40, OX40, TNFR2, GITR, CD27, TIM-3, BTLA, LAG3, CTLA4, ICOS, CD28, TIGIT, PDL-1, and PD-1, which may be used to direct the expression of an immunotherapeutic protein. Glycomerization can result in enhanced cross-linking (e.g., supercross-clustering), which in turn can result in enhanced signaling inducing, for example, enhanced cell proliferation, or inhibited / reduced cell responses (i.e., through enhanced stimulation of inhibitory pathways). In yet another example, the partner polypeptide can be a ligand for a cell surface molecule that induces cell death when engaged by another molecule, such as a ligand or agonist mAb (e.g., the aforementioned cell surface molecules of the TNFRSF (e.g., TNFR1, Fas, DR3, DR4, DR5, and DR6), as well as other molecules, such as CD38, CD20 (Shan et al., supra, 2000, and Cardarelli et al., supra, 2002) and CD52 (Rowan et al., supra, 1998). Thus, in some embodiments, the immunotherapeutic protein of the first aspect may comprise a dimeric fusion protein or protein conjugate comprising, for example, TRAIL (i.e., a ligand for DR4 or DR5) as a partner polypeptide linked to an Fc region component comprising at least a CH3 domain containing an H429F amino acid substitution. Upon binding of the ligand to a cell surface molecule, oligomerization of the immunotherapeutic protein of these embodiments may result in enhanced cross-linking and induction of an apoptotic signal to effect cell death, as may be desired in the target cell.
[0066] When the partner polypeptide is a co-receptor polypeptide (or fragment thereof), the co-receptor polypeptide (or fragment thereof) can be, for example, CXC chemokine receptor type 4 (CXCR4), CC chemokine receptor type 5 (CCR5) (a co-receptor of the CD4 receptor that binds to the HIV viral glycoprotein gp120 and enables HIV to fuse with the host cell membrane), tetraspanins and occludin (which are co-receptors required to enable infection by Hepatitis C virus (HCV)), and Gas6 (which is a ligand for receptors (such as AXL and TYRO3) that together bind to phosphatidylserine shown on viruses including West Nile virus, Zika virus, and Ebola virus, and facilitates the entry of such viruses into host cells), among others.
[0067] In another example, the partner polypeptide can be a cell surface receptor polypeptide (or a fragment thereof) that can bind to a ligand for the cell surface receptor. Thus, some examples of such polypeptides (or fragments thereof) include cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (or a soluble extracellular fragment thereof). CTLA4 functions as an immune checkpoint and downregulates immune responses. Immunotherapeutic proteins, including fusion proteins or protein conjugates that include CTLA4 partner polypeptides (e.g., CTLA4-Fc component fusion proteins), can show enhanced binding to CTLA4 ligands by forming dimers or oligomers, thereby serving as decoys to provide various therapeutic effects for the potential treatment of tumors (e.g., melanoma and colorectal cancer) and various autoimmune diseases, such as SLE and rheumatoid arthritis (RA). Further examples of suitable cell surface receptor polypeptides (or fragments thereof, such as ectodomains) capable of binding to ligands for cell surface receptors include other immune checkpoints (e.g., PD1) and other cytokine receptors, such as interleukin-1 receptor (IL-1R), interleukin-6 receptor (IL-6R), tumor necrosis factor receptor-2 (TNFR2, also known as CD120b), or receptors for cytokines of the TGF-β superfamily (see review in Czajkowsky DM et al., Mol Med 4(10):1015-1028, 2012). Immunotherapeutic proteins, including fusion proteins or protein conjugates comprising IL-1R (or a fragment thereof), can potentially be used in anti-IL-1 therapy, for example, for the treatment of type 2 diabetes, and immunotherapeutic proteins, including fusion proteins or protein conjugates comprising IL-6R (or a fragment thereof), can potentially be used in anti-IL-6 therapy, for example, for the treatment of tumors and RA. Immunotherapeutic proteins, including fusion proteins or protein conjugates comprising TNF-R2 or its ectodomain, could potentially be used in the treatment of RA or other inflammatory diseases or conditions.
[0068] Without wishing to be bound by theory, it is believed that fusion proteins or protein conjugates according to the present disclosure (whether in monomeric or dimeric form) comprising an H429Y amino acid substitution in the Fc region component may form oligomers in solution (e.g., in saline at a neutral pH, such as a physiological pH of about 7.4), which may lead to an overall increase in the strength of binding (e.g., enhanced avidity) to target binding partners (e.g., ligands for viral structural proteins or cell surface receptors, or other soluble target molecules or molecular complexes). Thus, in the context of a fusion or conjugated protein comprising a cell surface receptor polypeptide or fragment thereof capable of binding to a viral structural protein, this results in enhanced avidity of binding to the virus, providing enhanced virus neutralization (possibly imparted by cross-linking and / or aggregating viral particles (virions)). However, it is believed that, at least in some embodiments, such soluble oligomers may be substantially unable to bind to Fc receptors, and thus may be capable of virus neutralization with little or no complement activation.
[0069] On the other hand, and again without wishing to be bound by theory, it is believed that fusion proteins or protein conjugates (whether in monomeric or dimeric form) comprising the H429F amino acid substitution in the Fc region component may form oligomers upon binding to the relevant target (e.g., a viral structural protein or a ligand for a cell surface receptor) such that the assembled Fc component "on target" presents a stabilized, optimal configuration for binding (e.g., with enhanced avidity) to the C1q complement protein complex, thereby leading to activation of complement and subsequently enhanced complement-based effector functions such as complement-dependent cytotoxicity (CDC).
[0070] Immunotherapeutic proteins according to the present disclosure may be produced according to any of the standard methodologies known to those of skill in the art. For example, one of skill in the art can readily prepare an immunotherapeutic fusion protein by generating a construct using standard molecular biology techniques that includes a polynucleotide sequence encoding the fusion protein, introducing the construct into a suitable host cell for expression of the fusion protein (e.g., human kidney (HEK) host cells or derivatives thereof, e.g., Expi293 cells (Thermo Fisher Scientific)), culturing the host cell according to a standard culture protocol, and recovering the expressed fusion protein from the culture supernatant using, for example, any of the known suitable methodologies for purification (e.g., affinity chromatography (e.g., protein A), ion exchange chromatography (IEX), size exclusion chromatography (SEC), and combinations thereof). Similar methodologies can be used to prepare immunotherapeutic proteins that are immunoglobulin molecules, such as antibodies or Ab-like molecules. That is, one of skill in the art can easily prepare the variable heavy (V) domain of a suitable antibody (e.g., one that includes an antigen-binding region that binds to an antigen of interest). H ) and light (V LMutant antibodies (i.e., antibodies containing an amino acid substitution at a position corresponding to H429 (Eu numbering) of the amino acid sequence of the human IgG1 heavy chain) can be readily prepared by generating a construct comprising a polynucleotide sequence encoding a constant heavy (CH) region sequence and, for example, a constant heavy (CH) region from an IgG1 antibody, and incorporating the substitution into the polynucleotide sequence encoding the CH3 region by standard molecular biology techniques such as site-directed mutagenesis, altering the polynucleotide sequence to encode mutations at H429 (e.g., H429F and H429Y). As with the preparation of immunotherapeutic fusion proteins, the constructs are introduced into suitable host cells (e.g., human kidney (HEK) host cells or derivatives thereof) cultured according to standard culture protocols and expressed. The mutant antibodies can be purified from the culture supernatant using any of the known suitable methodologies for purification, such as, for example, affinity chromatography. Furthermore, when affinity chromatography (e.g., protein A) is used for purification, particularly when the immunotherapeutic protein is in the form of an Ab-like molecule, the use of mild elution conditions, such as the use of an elution buffer that contains a low concentration of arginine (e.g., less than 130 mM) and is at pH 5 or less, has been found to be advantageous to suppress the formation of aggregates. This can be achieved, for example, by a standard liquid chromatography system that can deliver a buffer gradient to the column, in this case, for example, a linear gradient of up to 35% of 130 mM arginine (pH 4.0).
[0071] In some preferred embodiments, recovery of the expressed immunotherapeutic protein according to the present disclosure is as follows. (i) preferably carried out under conditions of mildly acidic pH (e.g., a pH below neutral pH, such as pH 6.5, preferably pH 5.5, and more preferably pH 5.0) when it is desired that the immunotherapeutic protein is provided in monomeric form; or (ii) when it is desired that the immunotherapeutic protein is provided in an oligomeric form (e.g., a hexamer), preferably carried out under conditions of substantially neutral pH (e.g., a pH in the range of 7.0 to 8.5, preferably 7.5 to 8.0, or more preferably, a physiological pH of about 7.4); or (iii) Especially when it is desired that the immunotherapeutic protein is provided as an antibody-like molecule, this is preferably carried out using a method comprising affinity chromatography using an elution buffer containing a low concentration of arginine (e.g., less than 130 mM) and a pH of 5.0 or less (preferably about pH 4.0).
[0072] In some specific embodiments, recovery of the expressed immunotherapeutic protein according to the present disclosure comprises recovery by size-exclusion chromatography (SEC), for example under mildly acidic pH conditions for production of monomeric forms of the immunotherapeutic protein, or substantially neutral pH conditions for production of the immunotherapeutic protein in oligomeric form. SEC may optionally be followed by a recovery step comprising ion exchange chromatography (IEX).
[0073] In a second aspect, the disclosure provides the use of an immunotherapeutic protein as defined in the first aspect for treating or preventing a disease or condition in a subject, the disease or condition may for example be selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases, and proliferative diseases.
[0074] In a third aspect, the disclosure provides the use of an immunotherapeutic protein as defined in the first aspect in the manufacture of a medicament for treating or preventing a disease or condition, wherein the disease or condition is selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases, and proliferative diseases.
[0075] In a fourth aspect, the disclosure provides a method for treating or preventing a disease or condition comprising administering to a subject an effective amount of an immunotherapeutic protein as defined in the first aspect, wherein the disease or condition is selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases, and proliferative diseases.
[0076] Among the diseases and conditions that may be treated or prevented by the method of the fourth aspect are autoimmune diseases and conditions such as SLE and MS, other inflammatory diseases (e.g. immune complex vasculitis), infectious diseases and proliferative diseases (particularly solid tumors such as breast cancer), blood cancers such as lymphoproliferative disorders (LPDs) including leukemias (e.g. acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL)), adenocarcinomas and lymphomas, as well as multiple myeloma (MM) and X-linked proliferative disorders.
[0077] The method of the fourth aspect of the present disclosure is typically applied to the treatment of disease or condition in human subjects.However, the subject may also be selected from, for example, livestock animals (e.g., cows, horses, pigs, sheep, and goats), companion animals (e.g., dogs and cats), and exotic animals (e.g., non-human primates, tigers, elephants, etc.).
[0078] In some embodiments, the immunotherapeutic protein comprises a fusion protein comprising a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a constant heavy domain 4 (CH4) domain), where the partner polypeptide is a cell surface receptor polypeptide (or fragment thereof) capable of binding to a viral structural protein such that the immunotherapeutic protein can act as a "decoy" to block viral interaction and viral cellular entry into a host cell, and the method of the fourth aspect may further comprise administering an antibody directed against the virus (i.e., the target virus). For example, where the immunotherapeutic protein comprises an ACE2 polypeptide (or a fragment thereof) that binds to the RBD of the CoV-2 spike protein, the antibody can be selected from, for example, an antibody that is a broadly neutralizing coronavirus mAb (i.e., a bNmAb that can neutralize multiple coronavirus types or strains), a broadly reactive coronavirus mAb (i.e., a mAb that cannot neutralize but can bind to multiple coronavirus types or strains), a broadly neutralizing SARS-CoV-2 mAb (i.e., a bNmAb that can neutralize multiple SARS-CoV-2 strains), and a broadly reactive SARS-CoV-2 mAb, a broadly neutralizing coronavirus spike stem-specific mAb, a broadly reactive coronavirus spike stem-specific mAb, a broadly neutralizing SARS-CoV-2 spike stem-specific mAb, and a broadly reactive SARS-CoV-2 spike stem-specific mAb. In some specific embodiments, the antibody may be targeted to an epitope of a SARS-CoV-2 structural protein other than the spike protein (S), such as the envelope protein (E), membrane protein (M), or nucleocapsid protein (N). In some other specific embodiments, the antibody may be targeted to an epitope on the spike protein (S), for example, but at a site distinct from the RBD.More generally, when the immunotherapeutic protein comprises a cell surface receptor polypeptide other than an ACE2 polypeptide or a co-receptor polypeptide or fragment thereof, the antibody directed against the target virus can be selected from, for example, broadly neutralizing antibodies against a class / family of viruses (e.g., human immunodeficiency virus (HIV)) or antibodies that are broadly reactive against a class / family of viruses, broadly neutralizing antibodies against strains of a particular virus type (e.g., bNmAb that can neutralize multiple HIV-1 strains), and mAbs that are broadly reactive against a particular virus type. As shown below, it has been found that the immunotherapeutic protein of the present disclosure and antibodies directed against the target virus can work synergistically together to enhance CDC killing of cells (e.g., virus-infected cells).
[0079] Similarly, where the immunotherapeutic protein comprises a fusion protein comprising a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a constant heavy domain 4 (CH4) domain), and the partner polypeptide is directed, for example, to a therapeutically important target (e.g., the partner polypeptide is a cell surface receptor polypeptide (or fragment thereof) capable of binding to CTLA4, which functions as an immune checkpoint and downregulates the immune response), the method of the fourth aspect may further comprise administering an antibody directed against that target (e.g., an antibody that binds to CTLA4) to provide an enhanced response, such as, for example, enhanced CDC killing of cells (e.g., cancer cells).
[0080] Where the method of the fourth aspect involves administering an antibody in addition to the fusion protein (i.e. as described in the previous two paragraphs), preferably the antibody is, for example, H429X 2 and an Fc region component comprising an amino acid substitution at a position corresponding to H429 (EU numbering) of the amino acid sequence of a human IgG1 heavy chain polypeptide, such as an amino acid substitution, wherein X 2is selected from phenylalanine (H429F), glutamic acid (H429E), glutamine (H429Q), and serine (H429S).
[0081] In a fifth aspect, the present disclosure provides a pharmaceutical composition or medicament comprising an immunotherapeutic protein as defined in the first aspect, and a pharma- ceutically acceptable carrier, diluent, and / or excipient.
[0082] Immunotherapeutic proteins may be administered in combination with one or more additional agents for the treatment of the particular disease or condition being treated. For example, in the context of treating a proliferative disease, immunotherapeutic proteins may be used in combination with other agents for treating cancer (e.g., anti-neoplastic agents, such as cisplatin, gemcitabine, cytosine arabinoside, doxorubicin, epirubicin, taxoids including taxol, topoisomerase inhibitors, such as etoposide, cytostatic agents, such as tamoxifen, aromatase inhibitors (e.g., anastrozole), and inhibitors of growth factor function (e.g., antibodies such as the anti-erbB2 antibody trastuzumab (Herceptin™)). In some embodiments, immunotherapeutic proteins may be administered with one or more additional agents, which may also be immunotherapeutic proteins according to the present disclosure. For example, a first immunotherapeutic protein according to the present disclosure may be administered in combination with other agents for the treatment of cancer (e.g., anti-neoplastic agents, such as cisplatin, gemcitabine, cytosine arabinoside, doxorubicin, epirubicin, taxoids including taxol, topoisomerase inhibitors, such as etoposide, cytostatic agents, such as tamoxifen, aromatase inhibitors (e.g., anastrozole), and inhibitors of growth factor function (e.g., antibodies such as the anti-erbB2 antibody trastuzumab (Herceptin™)). In some embodiments, immunotherapeutic proteins may be administered with one or more additional agents, which may also be immunotherapeutic proteins according to the present disclosure. When the immunotherapeutic protein comprises an ACE2 polypeptide (or a fragment thereof) that binds to the RBD of the CoV-2 spike protein, the second immunotherapeutic protein of the present disclosure can be an antibody directed against the target CoV-2 virus, in particular an antibody targeted to an epitope of a different structural protein (e.g., the envelope protein (E), the membrane protein (M), or the nucleocapsid protein (N)), or an antibody targeted to an epitope on the same structural protein (i.e., the spike protein (S)), but at a site different from the RBD. As shown below, it has been found that such combinations of immunotherapeutic proteins can work together synergistically to enhance CDC killing of cells (e.g., virus-infected cells).
[0083] When used in combination with other agents, the immunotherapeutic protein can be administered in the same pharmaceutical composition or in separate pharmaceutical compositions. If administered in separate pharmaceutical compositions, the immunotherapeutic protein and the other agent can be administered simultaneously or sequentially in any order (e.g., within seconds or minutes or even hours (e.g., 2-48 hours)).
[0084] The immunotherapeutic protein may be formulated into a pharmaceutical composition with a pharma- ceutically acceptable carrier, diluent, and / or excipient. Examples of suitable carriers and diluents are well known to those skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 1995. Examples of suitable excipients for the various different forms of pharmaceutical compositions described herein can be found in Handbook of Pharmaceutical Excipients, 2001, edited by A Wade and PJ Weller. nd Edition, (1994). Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, and the like. Examples of suitable diluents include ethanol, glycerol, and water. The selection of carriers, diluents, and / or excipients can be made with regard to the intended route of administration and standard pharmaceutical practice.
[0085] The pharmaceutical composition comprising the immunotherapeutic protein defined in the first aspect may further comprise any suitable binder, lubricant, suspending agent, coating agent, and solubilizing agent. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flowing lactose, beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Preservatives, stabilizers, and even dyes may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may also be used.
[0086] The pharmaceutical composition comprising the immunotherapeutic protein defined in the first aspect is typically adapted for intravenous or subcutaneous administration.Accordingly, the pharmaceutical composition can comprise a solution or emulsion that can be injected into a subject and is prepared from a sterile or sterilizable solution.The pharmaceutical composition can be formulated in unit dosage form (i.e., in the form of a unit dose, or a separate portion that comprises a multiple or subunit of a unit dose).
[0087] The immunotherapeutic proteins, uses, and pharmaceutical compositions of the disclosure are further described below with reference to the following non-limiting examples. EXAMPLES
[0088] Example 1 ACE-2-Fc fusion proteins containing the H429 mutation and activity analysis Methods and Materials Constructs and fusion proteins The amino acid sequence of the human ACE2 polypeptide is available from the European Nucleotide Archive (ENA, European Molecular Biology Laboratory) under the accession number BAB40370. The ectodomain of the protein (amino acids 19-740; shown as SEQ ID NO:1 in Table 1) contains the catalytic domain and the collectrin domain. In this example, different forms of the ACE2 ectodomain were produced and studied; in particular, a truncated (tr) ACE2 ectodomain containing amino acids 19-615 of the mature ACE2 polypeptide (referred to as trACE2, shown as SEQ ID NO:2 in Table 1) and excluding the collectrin domain, a full-length (fl) ACE2 ectodomain to (flACE2; containing amino acids 19-740 of the mature ACE2 polypeptide; SEQ ID NO:1 in Table 1), and an enhanced flACE2 ectodomain (EflACE2) containing a triple mutation within the ACE2 polypeptide that has been reported to improve its binding affinity to the S protein (Chan et al., 2020 supra). These proteins were produced as fusion proteins with an Fc region component derived from human IgG1 to generate trACE2-Fc, flACE2-Fc, and EflACE2-Fc according to standard techniques (see Table 2).
[0089] For example, a construct encoding the trACE2 ectodomain in pcDNA3.4 (Thermo Fisher Scientific) was prepared by joining a polynucleotide sequence encoding the trACE2 ectodomain to a synthetic sequence encoding a linker and a sequence encoding a human IgG1 Fc (specifically, an IgG1 Fc having the amino acid sequence of accession number AXN93652.1 (immunoglobulin gamma 1 constant region, partial [Homo sapiens]; National Center for Biotechnology Information (NCBI) database). For the generation of the flACE2-Fc expression construct, KpnI digestion of the trACE2 construct was performed, followed by insertion of a codon-optimized polynucleotide sequence encoding the ACE2 collectrin domain (GeneArt, Thermo Fisher Scientific). For the generation of the eflACE2-Fc expression construct, a polynucleotide sequence equivalent to that encoding flACE2-Fc but with three mutations (i.e., T27Y, L79T, and N330Y; Chan et al. A synthetic polynucleotide sequence having the ACE2.v2.4 (described by et al., 2020 supra) was used. In addition, variants of the fusion protein were produced that incorporated the H429F and H429Y mutations in the Fc component, which were introduced using cleavage at a unique AfeI site within the IgG Fc coding sequence and subsequent insertion of the appropriate mutagenic oligonucleotide using NEBuilder (New England Biolabs, Ipswich, MA, United States of America) according to the manufacturer's instructions.
[0090] The H429 residue occupies a "buried" site in the IgG1 Fc structure (see Figure 1), occupied by a histidine (His / H) residue that is also found in the corresponding position of the Fc fragments of all other human immunoglobulin classes (Figures 3, 4), and thus in, for example, human IgG1, IgG2, IgG3, and IgG4, as well as primate IgG subclasses and some mouse IgG subclasses. For example, the 1981 published structure of human IgG1-Fc (PDB: 1Fc1; Deisenhofer, 1981 supra) shows that H429 is not a surface-accessible residue (Figure 1), and in a space-filled representation of the Fc, H429 is only "visible" when the overlying residues are rendered in a non-space-filled manner, as shown in Figure 1C. Also, analysis of the residues adjacent to H429 indicates that H429 is beneath the side chains of these residues, and calculations of accessible surface area (ASA) for Fc residues indicate that H429 is solvent inaccessible (0% ASA (Å 2 ) Figure 1C). H429 is also not a surface-accessible residue in other Fc structures, including the Fc in the structure of an anti-HIV mAb (PDB: 1HZH; Saphire et al., supra), which forms a hexameric ring structure, but H429 does not form part of the interface. Similarly, analysis of the Fc structure of an anti-Lewis Y mAb (Ramsland et al., J Immunol 187(6):3208-3217, 2011) showed that H429 is also buried in this antibody. [Table 1-1] [Table 1-2]
[0091] Expression of fusion proteins was carried out using transient transfection of Expi293 cells (Thermo Fisher Scientific). All expressed fusion proteins were first purified from culture supernatants by ion exchange chromatography (IEX), followed by additional purification by size exclusion chromatography (SEC). In particular, the supernatants of Expi293 cells transiently transfected for expression of each ACE2-Fc fusion protein (the Fc region was that of wild-type (WT) hIgG1 Fc as described in the previous paragraph) were extensively dialyzed against 10 mM Tris-HCl pH 8.0 and applied to a High-Q column (BioRad Laboratories, Hercules, CA, United States of America). Bound proteins were eluted with a linear gradient into buffer A containing 0.4 M NaCl. Fractions were examined by SDS-PAGE, and those fractions containing the flACE2-Fc WT fusion protein were pooled, concentrated using a 30 kDa cutoff filtration device (Pall Corporation, Port Washington, NY, United States of America), and separated by size-exclusion chromatography (SEC) using a Superose 6 column (GE Life Sciences, Chicago, IL, United States of America).
[0092] The SARS-CoV-2 RBD-Ig and RBD AviTag were previously described. The RBD AviTag was biotinylated in situ using Expi293BirA cells (Wines BD et al., J Immunol 197(4):1507-1516, 2016).
[0093] Lamelli native PAGE (N-PAGE), 150V, 2.5 hours, 4°C, according to Wines BD et al., J Immunol 162(4):2146-2153, 1999).
[0094] Virus neutralization assay Antiviral titers were determined using SARS-CoV-2 (CoV / Australia / VIC01 / 2020) in a microneutralization assay as previously described (Juno JA et al., Nat Med 26(9):1428-1434, 2020).
[0095] Biolayer Interferometry Measurement of the affinity of ACE2-Fc fusion protein for CoV-2S RBD was performed on an Octet RED96e (ForteBio, Fremont, CA, United States of America). All assays were performed at 25 °C using an anti-human IgG Fc capture (AHC) biosensor chip (ForteBio) in kinetic buffer (phosphate-buffered saline (PBS) pH 7.4 supplemented with 0.1% (w / v) bovine serum albumin (BSA) and 0.05% (v / v) TWEEN-20). After a 60-second (60 s) biosensor baseline step, the fusion protein (20 mg / mL) was loaded onto the anti-human IgG Fc capture (AHC) biosensor by soaking the sensor chip for 200 s and then washing in kinetic buffer for 60 s. For most of the fusion proteins, association measurements were performed by immersion in a two-fold dilution series of SARS-CoV-2 RBD from 16 to 250 or 500 nM for 180 seconds, then measuring dissociation in kinetics buffer for 180 seconds. For EflACE2-Fc WT, a two-fold dilution series from 2 to 31 or 63 nM was used. The biosensor chip was regenerated five times using a cycle of 5 seconds in 10 mM glycine pH 1.5 and 5 seconds in kinetics buffer, and baseline drift was corrected by subtracting the mean shift of the fusion protein-loaded sensor not incubated with SARS-CoV-2 RBD and the unloaded sensor incubated with SARS-CoV-2 RBD. K DCurve fitting analysis was performed using Octet Data Analysis 10.0 software using a global fit 1:1 model to determine Δp and kinetic parameters. Curves that could not be fitted were excluded from the analysis. Kinetic constants reported are representative of two independent experiments.
[0096] ACE2-Fc fusion protein and recombinant dimeric rsFcγR binding by flow cytometry ACE2-Fc fusion protein or rituximab (a chimeric mAb targeted against CD20) at 5 μg / ml or the indicated concentrations were incubated with transfected spike protein-expressing Ramos cells (Ramos-S cells; Lee WS et al., medRxiv doi:10.1101 / 2020.12.13.20248143, 2020) at 5 × 10 ng / mL in 25 μl of PBS containing 0.5% (w / v) BSA and 1 mM glucose (PBS / BSA / G). 6 Cells / ml were incubated on ice for 30 min, then washed twice with PBS / BSA / G and incubated with PE- or FITC-conjugated anti-human IgG-Fc for 30 min on ice, then washed again and resuspended in 25 μl PBS / BSA / G.
[0097] Assessment of dimeric recombinant soluble FcγR (rsFcγR) binding was performed as previously described (Wines et al., 2016 supra). ACE2-Fc-opsonized Ramos-S cells or rituximab-opsonized cells were resuspended in 0.5 μg / ml biotinylated dimeric rsFcγRIIa (H131 allelic form) or dimeric rsFcγRIIIa (V158 allelic form), or BSA / PBS / G, incubated on ice for 30 min, followed by 1 / 500 streptavidin-APC (or anti-hIgG-Fc FITC for confirmation of ACE2-Fc opsonization) for 20 min on ice. Cells were washed, resuspended in PBS / BSA / G, and analyzed on a Canto™ II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, United States of America).
[0098] Complement-dependent cytotoxicity (CDC) assay CDC was measured using Ramos-S cells opsonized with ACE2-Fc functional protein or a control mAb, rituximab, followed by incubation with human serum as a source of complement. Thus, Ramos-S cells were first incubated with the fusion proteins as described above or rituximab (5 × 10 in 25 μl PBS / BSA / G for 30 min on ice). 6 Cells were washed and then resuspended in 1 / 3 diluted normal human serum for 30 min at 37° C. Cells were washed twice with PBS and then enumerated for dead cells by staining with 1 / 500 Zombie Green (from Zombie Green Fixable Viability kit, BioLegend, San Diego, CA, United States of America according to the manufacturer's instructions) before being fixed with 2% paraformaldehyde in PBS and analyzed on a Canto™ II flow cytometer (Becton Dickinson).
[0099] Complement fixation immunoassay for ACE2-Fc fusion protein 96-well flat-bottom MaxiSorp Nunc plates (Thermo Fisher Scientific) were coated overnight with 5 μg / ml avidin in PBS, blocked, and then incubated for 1 h at room temperature with either serial 2-fold dilutions or a single concentration (2.5 μg / ml) of biotinylated RBD in 0.1% casein (Hartley et al., Science Immunology 5(54)doi:10.1126 / sciimmunol.abf8891, 2020). ACE2-Fc fusion protein was then added over the indicated concentration range. To measure C1q fixation, plates were incubated with 10 μg / ml purified human C1q (Merck Millipore, Burlington, MA, United States of America) for 30 min at room temperature, followed by incubation with a 1 / 2000 dilution of rabbit anti-C1q IgG (Kurtovic L et al., BMC Med 17:45 2019) for 1 h at room temperature. In experiments to measure C5b-C9 fixation, plates were incubated with 10% fresh human serum for 30 min at room temperature, followed by incubation with a 1 / 2000 dilution of rabbit anti-C5b-C9 (Merck Millipore) for 1 h at room temperature, washed, and then incubated with goat anti-rabbit IgG conjugated to HRP (Merck Millipore) at a 1 / 2000 dilution for 1 h at room temperature, followed by incubation with TMB substrate (Life Technologies Corporation, Carlsbad, CA, United States of America) for 15–20 min at room temperature. Reactivity was stopped using 1 M sulfuric acid and absorbance was measured at OD450nm. Test samples and reagents were prepared in PBS supplemented with 0.1% (w / v) casein, and plates were washed three times between each step with PBS containing 0.05% (v / v) TWEEN-20. Samples were tested in duplicate and background reactivity was corrected using negative control wells in which ACE2-Fc protein was omitted. Means and SEM from independent experiments are shown.
[0100] RBD variant multiplex assay Custom multiplex arrays were produced using SARS-1 S1 subunit (ACROBiosystems, Newark, DE, United States of America), SARS-Cov-2 S1, and HCoV NL63 S1 and S2 subunits (Sino Biological Inc., Beijing, China), NL63 S trimer (BPS Bioscience, San Diego, CA, United States of America), and hexahistidine-tagged RBD WT protein (amino acids 19-613) and 21 variants identified from the GISAID RBD surveillance repository expressed from pcDNA3 in Expi293 cells and purified by affinity chromatography. Bead coupling, washing steps, and data acquisition on a FlexMap3D™ analyzer (Luminex Corporation, Austin, TX, United States of America) were as previously described (Lee et al., 2020 supra). In summary, direct binding of ACE2-Fc fusion proteins trACE2-Fc, flACE2-Fc, and EflACE2-Fc at 0.5–250 nM was detected using 25 μl of 1.3 μg / ml anti-human IgG R-phycoerythrin conjugate (SouthernBiotech, Birmingham, AL, United States of America). 50 The data are plotted against a three-parameter agonist versus response curve (r 2>0.85). For competition assays, RBD or S1 coupled beads were incubated with 20 μl of 25 μg / ml biotinylated Avi-tagged ACE2 in the presence of various non-biotinylated ACE2-Fc fusion protein "competitors" at 1-280 nM for 2 h at room temperature. Binding of biotinylated ACE2 (aa19-615) was performed first using streptavidin, R-phycoerythrin conjugate (SAPE) (Thermo Fisher Scientific) at 4 μg / ml (1 h) followed by R-phycoerythrin, biotin-XX conjugate (Thermo Fisher Scientific) at 10 μg / ml (1 h).
[0101] FcγRIIIa-NF-κB-RE nanoluciferase reporter assay FcγRIIIa-NF-κB-RE nanoluciferase reporter assays were performed using IIA1.6 / FcR-γ / FcγRIIIa V158 cells expressing NF-κB response element-driven nanoluciferase (NanoLuc, pNL3.2.NF-κB-RE [NlucP / NF-κB-RE / Hygro], Promega Corporation, Madison, WI, United States of America) and were essentially performed as previously described (Lee et al., 2020 supra). In summary, Ramos cells expressing spike-IRES-Orange2 were used as target cells and incubated with agonist and FcγRIIIa / NF-κB-RE reporter cells for 5 hours, followed by measurement of induced nanoluciferase with Nano-Glo substrate (Promega Corporation).
[0102] Results and Discussion Construction and production of ACE2-Fc fusion protein A series of ACE2-Fc fusion proteins (Table 2) were produced and analyzed for their ability to neutralize SARS-CoV-2 infection and mediate Fc-dependent effector functions typically attributed to the mechanism of action of antibodies. [Table 2-1] [Table 2-2]
[0103] In an attempt to increase the avidity of binding to the SARS-CoV-2 spike protein or to confer and improve Fc-dependent effector functions, three versions of the ACE2 ectodomain were fused to the Fc region of IgG1 that was either unmodified or altered by mutation (i.e., replacement of histidine 429 with phenylalanine (H429F) or tyrosine (H429Y)) or modified glycosylation (i.e., lacking core fucose; trACE2-Fc-kif).
[0104] ACE2-Fc fusion protein purification Proteins were produced in Expi293 cells and purified by ion exchange (IEX) and then size exclusion chromatography (SEC) at pH 7.4 (Figure 5). All of the fusion proteins showed an IEX purification profile similar to that of flACE2-Fc-WT (Figure 5A), which contained a major elution peak (peak*, Figure 5A), and SDS-PAGE analysis of collected fractions showed a single major species of approximately 270 kDa (Figure 5B). With the exception of those fusion proteins containing the H429Y mutation, SEC analysis and purification confirmed the presence of a major monomeric species (Figure 5C) (note: the monomeric species is believed to be a single molecule (i.e., a monomeric molecule) containing two (dimerized) copies of the respective ACE2-Fc fusion protein, which was collected for further analysis), for example, for flACE2-Fc-WT, only trace amounts of higher molecular weight oligomers and other impurities were evident (Figure 5). Indeed, the presence of similar monomeric species was also evident after IEX purification of all fusion proteins using unmodified Fc-WT or Fc region components containing the H429F modification (not shown). For fusion proteins containing the H429Y mutation, SEC analysis (FIG. 5D) (i.e., the major IEX peak from the flACE2-Fc H429Y mutant, not shown), as well as the major IEX peak from the trACE2-Fc H429Y and EflACE2-Fc H429Y proteins (not shown)) revealed significant amounts of oligomers (Y oli ) and monomer (Y mn ) species, which were then separately assessed for functional activity.
[0105] Binding of SARS-CoV-2S ACE2-Fc fusion protein RBD by ELISA Binding of trACE2-Fc WT, flACE2-Fc WT, and EflACE2-Fc WT fusion proteins to the SARS-CoV-2 receptor binding domain (RBD) (Figure 6A-C) was similar overall (i.e., EC 50The enhanced intrinsic affinity of EflACE2-Fc was less evident in binding to this bivalent form of RBD presented in fusion with mouse IgG1 Fc (RBD-Ig), whereas the binding activity of various fusion proteins with mutated Fc components was also of slightly lower affinity, as was the case for monomeric flACE2-Fc-H429Y (EC 50 0.48 nM) (FIG. 6D) and was comparable with the exception of the other H429Y Fc variants, which also tended to have lower affinity levels (FIG. 6).
[0106] Oligomerization of ACE2-Fc H429Y fusion protein is pH dependent The oligomerization of fusion proteins containing the mutated H429Y Fc moiety was investigated by SEC separation at pH 5.0 of flACE2-Fc-H429Y prepared by IEX. In contrast to SEC at pH 7.4 (Figures 5D and 7A), SEC at pH 5.0 (Figure 7B) showed that N-PAGE showed the formation of monomeric Y. mn It was revealed that a greater proportion of the purified monomeric flACE2-Fc-H429Y was purified to homogeneity (see FIG. 7C: lane 1 vs lane 2). mn (pH 5.0) was reanalyzed by dialysis at pH 7.4 followed by both N-PAGE (FIG. 7C) and SEC at pH 7.4 (FIG. 7D). Re-exposure to pH 7.4 resulted in the formation of oligomer Y oli and monomer Y mn This resulted in a mixture of species (see FIG. 7C; lane 2 pH 5.0, lane 5 pH 7.4), indicating that some equilibrium between these forms occurs at neutral pH. mn showed comparable binding to RBD-Ig as other flACE2-Fc WT fusion proteins and Fc variants (Figure 7E), and the abundance of oligomers was apparently related to the substitution of histidine 429 with tyrosine, as it was not observed in fusion proteins with the phenylalanine-substituted H429F Fc region moiety.
[0107] Assessment of virus neutralization efficacy The antiviral activity of the ACE2-Fc fusion protein was determined in a microneutralization assay of SARS-CoV-2 infection of Vero cells (Figure 8) and EC 50 The endpoint corresponds to approximately 99% neutralization of inoculum virions (Khoury DS et al., Nat Rev Immunol 20(12):727-738, 2020).
[0108] The SARS-CoV-2 neutralization endpoint of the truncated ectodomain, trACE2 (2.70 μM), was improved by approximately 10-fold by fusion to the wild-type Fc region of IgG1 (trACE2-Fc WT, 283 nM) (Figure 8). The improved potency was consistent with improved avidity of binding to the SARS-CoV-2 spike RBD due to ACE2-Fc bivalency resulting from fusion of the ACE2 ectodomain to the IgG Fc region, and was similar to that of flACE2-Fc WT. EflACE2-Fc-WT showed an additional approximately 20-fold (11 nM) improvement over the flACE2-Fc WT and trACE2-Fc WT fusion proteins, and an approximately 200-fold improvement over unfused trACE2.
[0109] Analysis of the Fc modifications revealed some interesting differences. First, the H429Y mutation in trACE2-Fc and flACE2-Fc improved their virus neutralization potency (Figure 8), which was surprising since the neutralization function of the ACE2-Fc fusion protein occurs well away from the modification at the H429 position (i.e., in the fusion protein, the ACE2 polypeptide is predicted to neutralize the virus, but the H429 residue is distal to ACE2, residing in the CH3 domain of the Fc component). Second, the oligomeric form of trACE2-Fc-H429Y isolated by SEC at pH 7.4 improved their virus neutralization potency (Figure 8). oli The neutralizing activity of flACE2-Fc-H429Y (21.9 nM) was found to be 13-fold enhanced over trACE2-Fc WT. oli , and the monomer Y mnBoth morphologies (Fig. 5B) (endpoints of 10.0 and 20.9 nM, respectively; Fig. 8) demonstrated greater potency than the flACE2-Fc WT (124 nM) fusion protein and were similar to the virus neutralization achieved with EflACE2-Fc WT (10.6 nM), whereas EflACE2-Fc-H429Y oli was seemingly more potent (4 nM), displaying neutralizing activity of EflACE2-Fc WT (10.6 nM) that was more than 200-fold greater than that of the unfused trACE2, or in the case of EflACE2-Fc-H429Y (4 nM), more than 600-fold greater (Figure 8). Thus, the Fc-H429Y mutation increased neutralization of SARS-CoV-2 in the trACE2-Fc and flACE2-Fc fusion protein formats, and also trended toward greater levels of potency when combined with the ACE2 triple mutation in the inherently higher affinity EflACE2-Fc.
[0110] Substitution of histidine 429 (H429F) in the ACE2-Fc fusion protein with phenylalanine did not enhance neutralization.
[0111] Interaction of ACE2-Fc fusion protein with FcγR The interaction of FcγRIIa and FcγRIIIa with ACE2-Fc fusion proteins was assessed by flow cytometry using ACE2-Fc opsonized Ramos-S cells and dimeric recombinant soluble FcγR (Wines et al., 2016 supra). trACE2-Fc, flACE2-Fc, and EflACE2-Fc fusion proteins all bound FcγRIIa and FcγRIIIa (Figures 9A, 9B), whereas variant proteins containing the mutated H429Y Fc component largely abolished binding to both of these Fc receptor types.
[0112] FcγRIIIa activation by ACE2-Fc fusion protein Antibody-dependent cellular cytotoxicity (ADCC) and Fc-dependent clearance of the virus are important antiviral effector mechanisms that may play a protective role during SARS-CoV-2 infection (Li D et al., bioRxiv doi:10.1101 / 2020.12.31.424729, 2021, and Shafer A et al., J Exp Med 218(3):e20201993, 2021). Therefore, in this experiment, we evaluated the ability of trACE2-Fc, flACE2-Fc, and EflACE2-Fc fusion proteins, as well as variant proteins, to activate FcγRIIIa. We found that Ramos-S cells opsonized with ACE2-Fc fusion proteins containing the wild-type (WT) Fc region all initiated FcγRIIIa activation (Figure 10). However, it was surprising that the flACE2-Fc fusion protein induced a greater level of activation than trACE2-Fc, indicating that the inclusion of a collectrin domain in the ACE2 component of the fusion protein substantially and surprisingly improves the potency of FcγRIIIa activation by the ACE2-Fc fusion protein. Furthermore, it was found that the increased affinity that the EflACE2-Fc fusion protein has for the SARS-CoV-2 spike protein did not alter the level of FcγRIIIa activation, which was comparable to that of flACE2-Fc (Figure 10D).
[0113] Production of a trACE2-Fc fusion protein in the presence of kifunensine, trACE2-Fc-kif (van Berkel PHC et al., Biotechnol Bioeng 105(20:350-357, 2010), also improved the modest level of FcγRIIIa activation exhibited by trACE2-Fc to levels comparable to those of the flACE2-Fc and EflACE2-Fc fusion proteins (Figure 10D), and upregulated CD20 +The levels of the therapeutic anti-CD20 mAb, rituximab, on Ramos-S cells approached those of the therapeutic anti-CD20 mAb, rituximab (Figures 10A, 10D). The mannosidase inhibitor kifunensine prevents normal N-linked glycosylation, including core fucosylation, and in immunoglobulins, the lack of fucose on the heavy chain glycan at Asn297 is known to improve FcγRIIIa binding and activation (Ferrara C et al., Proc Natl Acad Sci USA 108(31):12669-12674, 2011). It was therefore hypothesized that similar processing of the flACE2-Fc and EflACE2-Fc fusion proteins, or amino acid residue substitutions to increase affinity for FcγRIIIa (Wang et al., 2018 supra), would likely further improve their FcγRIII activation potency.
[0114] Modification of trACE2-Fc, flACE2-Fc, and EflACE2-Fc fusion proteins by including the H429F Fc component mutation did not affect FcγRIII activation by opsonized Ramos-S cells (Figure 10). In contrast, including the mutated H429Y Fc component in all ACE2-Fc fusion proteins eliminated cellular FcγRIIIa activation, consistent with the aforementioned failure to bind to Fc receptors, particularly FcγRIIIa (Figure 9B). Thus, while enhancing virus neutralization, the H429Y modified Fc components in trACE2-Fc, flACE2-Fc, and EflACE2-Fc fusion proteins were inactive in FcγR binding (Figure 9) and in cellular activation through FcγRIIIa (Figure 10). The hierarchy of FcγRIIIa activation by fusion proteins was flACE2-Fc WT = EflACE2-Fc > trACE2-Fc, highlighting that the presence of the collectrin domain is a critical component in optimal activation of FcγRIIIa by ACE2-Fc fusion proteins.
[0115] Complement fixation, activation, and lysis of SARS-CoV-2 spike cells by the ACE2 Fc protein ACE2-Fc fusion proteins containing mutated Fc region components were investigated for their ability to fix complement components C1q and C5-C9 in an ELISA-based assay using avidin-immobilized RBD-biotin (Figure 11A-F) and, importantly, their ability to mediate complement-dependent killing of cells expressing the SARS-CoV-2 spike protein (Figure 11G). When the RBD was restricted (Figures 11A, 11B), the activity of fusion proteins containing mutated H429F Fc components was surprisingly enhanced over their counterparts containing wild-type Fc regions. Additionally, binding of C5b-9 (Figures 11E, 11F), which forms the membrane attack complex on cells, was comparable for fusion proteins containing mutated H429F Fc region components. Moreover, despite their oligomerization (Figures 6 and 7), a feature associated with superior CoV-2 neutralizing activity (Figure 8), both trACE2-Fc-H429Y and flACE2-Fc-H429Y fusion proteins showed little difference in C1q or C5-9 fixation relative to their counterparts containing wild-type Fc regions (Figures 11A-F). Moreover, it was evident that the trACE2-Fc fusion protein was more potent in fixing complement C1q than flACE2-Fc (see Figures 11C, 11E as well as Figures 11D, 11F). This is likely because the presence of the collectrin dimerization domain in flACE2-Fc reduces the segmental flexibility of the fusion protein, thereby negatively affecting complement C1q binding. However, this difference was significantly reduced by inclusion of the H429F Fc mutation in the trACE2-Fc-H429F and flACE2-Fc-H429F fusion proteins, particularly evident in the immobilization of the C5b-C9 complex (Figures 11E, 11F).
[0116] Surprisingly, the fusion protein containing the mutated H429F Fc region component was the only highly active ACE2-Fc fusion protein in serum complement-dependent cytotoxicity (CDC) of Ramos-S cells (Figure 11G). Despite the ability of trACE2-Fc WT, as well as trACE2-Fc-kif fusion protein and flACE2-Fc WT to fix C1q and C5b-9 in ELISA assays (Figures 11A, 11C, 11E), they were unable to induce complement-mediated cell death, as was EflACE2-Fc WT, despite its higher affinity for the SARS-CoV-2 spike protein. trACE2-Fc-H429Y mn The fusion protein was also active, albeit weakly, in complement-mediated killing.
[0117] Since it is well known that activation of the complement cascade can also lead to phagocytosis of cells, microorganisms, or particles opsonized with C1q (or other complement fragments such as C3b or C3bi; Ricklin D et al., Immunol Rev 274(1):33-58, 2016) that bind to specific cell surface receptors, such as CR1 or CR3 on phagocytic cells (Vandendriessche S et al., Front Cell Dev Biol 9:624025, 2021), the observed enhancement of Fc-dependent complement lysis by ACE2-Fc fusion proteins containing the H429Y mutation is likely to be reflected in a similar enhancement in complement-dependent phagocytosis of ACE2-Fc coated targets (e.g., virions) through complement receptors.
[0118] conclusion Immunotherapeutic proteins in the form of fusion proteins comprising angiotensin-converting enzyme 2 (ACE2) polypeptides (or fragments thereof) fused to Fc region components comprising the H429 mutation have been found to offer considerable potential for the treatment or prevention of coronavirus infections. For example, the selection of full-length or truncated (i.e., fragments) ACE2, as well as various modifications of the Fc component, may also allow for considerable "tuning" of antiviral agents to modify the action by which the antiviral effect is achieved. For example, by including an Fc component in an immunotherapeutic protein comprising an H429Y substitution, oligomeric immunotherapeutic proteins may be produced that exhibit increased virus neutralization as well as abrogation of FcγR binding and activation. On the other hand, by including an Fc component in an immunotherapeutic protein comprising an H429F substitution, antiviral effects including complement-dependent cytotoxicity (CDC) of spike protein-expressing cells (e.g., infected cells) may be achieved. These unique Fc mutations thus allow for complementary approaches to tune the function of the Fc region component, which may aid in the development of therapeutically important ACE2-Fc fusion proteins and other fusion proteins by allowing the selection of the desired functional profile.
[0119] Example 2 Chimeric anti-TNP IgG1 antibodies containing the H429 mutation and activity analysis Methods and Materials Generation of anti-TNP human IgG and mutant anti-TNP human IgG plasmid constructs. Variable-weight (V) plasmid constructs of the murine anti-trinitrophenyl (anti-TNP) antibody TIB142. H ) and light (V LChimeric anti-TNP human IgG antibody constructs consisting of Fc region sequences and sequences from constant heavy (CH) regions from human IgG subclasses have been described in detail previously - hIgG1 (Patel D et al., J Immunol 184(11):6283-6292, 2010), hIgG2 and hIgG4 (Wines et al., 2016 supra). All chimeric antibody sequences were subcloned into pCR3 vector. Using standard molecular biology techniques, mutations for H429F, H429Q, H429E, H429S, H433A and H435A substitutions were made in the cDNA sequence encoding the Fc region components.
[0120] Expression and production of IgG antibodies by Expi293 cells IgG antibodies were produced in Expi293 human embryonic kidney cells as previously described (Wines et al., 2016 supra). Briefly, Expi293 cells were maintained in Expi293 Expression Medium (Gibco, Waltham, MA, United States of America) for both cell growth and protein production. Cells were co-transfected with IgG heavy chain plasmid (15ug) and light chain plasmid (15μg) diluted in Opti-MEM I Reduced-Serum Medium (Gibco) using the Expifectamine transfection kit (Life Technologies) and then cultured for 4 days. Culture supernatants were clarified by centrifugation and filtered through a 0.2 μm filter, after which IgG was purified by affinity chromatography using a Hi-Trap HP Protein A column (GE Healthcare Life Sciences, Marlborough, MA, United States of America) and eluted with 0.1 M citric acid, pH 3.5, followed by neutralization with 1 M Tris-HCl, pH 9.0, and dialyzed against PBS pH 7.5. Aggregates were removed by subsequent gel filtration on a Superose 6 10 / 300GL column (GE Healthcare Life Sciences), and monomeric IgG peak fractions were collected. Antigen-binding activity of all antibody preparations was tested on BSA-TNP by ELISA as described (Wines et al., 2016 supra).
[0121] Evaluation of antigen-binding activity by monoclonal anti-TNP mAb Anti-TNP mAbs were assessed by ELISA for antigen binding activity by binding to TNP-haptenylated BSA (TNP-BSA) as previously described in Wines et al., 2016 supra.
[0122] ELISA immunoassay for detection of complement fixation by mAbs 96-well flat-bottom MaxiSorp Nunc plates (Thermo Fisher Scientific) were coated overnight at 4°C with 20 μg / ml TNP-BSA in PBS. The next morning, plates were blocked with 0.1% (w / v) casein in PBS for 2 h at 37°C and then incubated with anti-TNP mAb (concentrations of 4–0.125 μg / ml) for 2 h at room temperature. To measure C1q fixation, TNP:anti-TNP plates were incubated with 10 μg / ml purified human C1q (Merck Millipore) for 30 min at room temperature, followed by incubation with a 1 / 2000 dilution of rabbit anti-C1q IgG (Kurtovic L et al., BMC Med 17:45 2019) for 1 h at room temperature. In experiments to measure C5b-C9 fixation, TNP:anti-TNP plates were incubated with 10% fresh human serum for 30 min at room temperature, followed by incubation with a 1 / 2000 dilution of rabbit anti-C5b-C9 (Merck Millipore) for 1 h at room temperature, followed by washing and then incubation with goat anti-rabbit IgG conjugated to HRP (Merck Millipore) at a 1 / 2000 dilution for 1 h at room temperature, followed by incubation with TMB substrate (Life Technologies) for 15-20 min at room temperature. Reactivity was stopped using 1 M sulfuric acid and absorbance was measured at OD450 nm. Test samples and reagents were prepared in 0.1% (w / v) casein in PBS, and plates were washed three times between each step using 0.05% (v / v) Tween 20 in PBS. Samples were tested in duplicate and background reactivity was corrected using negative control wells in which the antibody was omitted.
[0123] Results and Discussion Anti-TNP antibody construct The TNP-WT mAb used in this example comprises either of two human heavy chain isotypes, first, the TNP-specific V domain of mouse monoclonal antibody TIB142 fused to the CH1-hinge-CH2-CH3 domain of human IgG1, encoded by cDNA (SEQ ID NO:33), in N- to C-terminal order. Hand secondly, a TNP-specific V domain of mouse monoclonal antibody TIB142 fused to the CH1-hinge-CH2-CH3 domain of human IgG2, encoded by a codon-optimized cDNA having the sequence shown in SEQ ID NO: 35, in the order from N-terminus to C-terminus. H The TNP-specific light chain polypeptide (SEQ ID NO:36) was an IgG2 isotype polypeptide comprising the TNP-specific V domain of mAb TIB142 fused to a human kappa chain constant domain, encoded by codon-optimized DNA having the sequence shown as SEQ ID NO:37. L domain included.
[0124] Modification of IgG enhances complement fixation When antibodies such as mAbs are bound to their target antigens, the classical pathway of complement is activated, which can lead to physiological effects including target cell destruction by complement-dependent lysis (CDC) or complement-mediated antibody-dependent phagocytosis (C'ADCP) by specialized phagocytic cells through specific receptors for complement proteins and fragments. Activation of this major amplifier effector system of innate immunity critically depends on and is initiated by the binding of the hexameric complement protein C1q, which is part of the C1 complex. This binding of C1q by antibodies bound to their target antigens ultimately leads to the formation of the membrane attack complex (MAC), which contains other complement components (C5b, C6, C7, C8, C9).
[0125] Because the H429F Fc region component mutation conferred potent CDC to the ACE2-Fc fusion protein (see Example 1), the effects of these (Figure 12) and several other mutations (Figure 13) were evaluated in human IgG1 under various conditions of antigen density or input mAb concentration. The Fc component mutations were investigated in ELISA for complement fixation in the context of an intact (chimeric) IgG1 antibody with a mouse V domain recognizing the TNP hapten and the human IgG1 constant domain. Surprisingly, the substitution of histidine at position 429 in the TNP-IgG1-H429F mAb resulted in enhanced C1q binding compared to that of the unmodified TNP-IgG1-WT mAb (Figure 12). Next, the TNP-specific mAb was evaluated for the generation of membrane attack complex proteins (Figure 12). Again, TNP-IgG1-H429F mAb exhibits enhanced complement activation, as seen by increased formation of MAC proteins (C5b, C6, C7, C9), and importantly, this is entirely consistent with its observed enhanced ability to bind C1q conferred by the H429F mutation. Thus, modifications at position 429 can unexpectedly alter the properties of an antibody. This enhanced function is surprising, since amino acid 429 is buried within the CH3 domain of IgG1, away from the complement C1q binding surface in the CH2 of the H chain and away from the binding site for leukocyte Fc receptors (Hogarth PM and Pietersz GA. Nature Reviews Drug Discovery 11:311-331, 2012; Chenoweth et al., 2020 supra).
[0126] The H429F mutation in the IgG1 antibody enhanced both C1q (Figure 12A) and C5b-C9 fixation (Figure 12B). The complement enhancing activity of mutant IgG1 antibodies containing the H429F mutation, especially in fixation of C1q, was most evident when the lower density TNP:BSA antigen was opsonized by the mutated IgG (Figure 12). Thus, in the context of both the ACE2-Fc fusion protein and the intact IgG1 antibody, the H429F Fc component mutation enhances complement activation.
[0127] The antigen-binding activity of the anti-TNP mAbs, TNP-IgG1-WT, TNP-IgG2-WT, and the modified (mutant) mAb, TNP-IgG1-H429F, was assessed by ELISA for binding to TNP-haptenylated BSA (TNP-BSA) as described (Wines et al., 2016 supra). All of the mAbs showed virtually equivalent binding activity to TNP-BSA (Figure 12C), indicating that the enhanced complement activation by the Fc-modified anti-TNP antibodies was due to the Fc mutations and not differences in antigen-binding activity.
[0128] conclusion The data obtained in this example showed that the IgG-H429F mutant is capable of enhanced C1q and C5b-C9 fixation to allow increased complement activation and can therefore be expected to be capable of inducing useful complement-based effector functions.
[0129] Example 3: Production and Analysis of Modified Forms of Therapeutic Antibodies Containing the H429 Mutation In this example, the effect of modification of position H429 (i.e., by amino acid substitution) on the properties of the antibody was evaluated using a number of unrelated chimeric mAbs containing different antigen-binding variable domains that bind to unrelated epitopes within different target molecules on different cell types. These antibodies were "based" on various commercially used and in some cases clinically important mAbs. In particular, the experiments were aimed at determining the possible functional effects of amino acid substitutions at position 429 in antibodies with the V domains of the anti-HER2 mAbs Trastuzumab and Pertuzumab, anti-CD20 mAbs with the V domains of Rituximab or 11B8, and the V domain of the anti-CD38 mAb Daratumumab.
[0130] Methods and Materials Antibodies and antibody constructs DNA sequences obtained by RT-PCR or synthetic DNA corresponding to immunoglobulin variable and constant sequences were assembled by standard molecular biology techniques including ligation and Gibson assembly (NEBuilder, New England Biolabs) or as fully synthetic DNA to encode entire immunoglobulin heavy and light chains. These sequences were utilized in expression vectors such as pcDNA3.1, pcDNA3.4 (Thermo Fisher Scientific), and pCIneo (Promega Corporation).
[0131] The unmodified mAbs used in this example were formatted in human IgG heavy chains and produced with human kappa light chains. The unmodified mAbs were generated using the specific V H and V L domain and is referred to as the wild-type (WT) form; for example, the "WT" trastuzumab antibody used in this example is the wild-type (WT) HER2-specific V domain of trastuzumab, as previously described. H and V L Including the domain (https: / / go.drugbank.com / drugs / DB00072).
[0132] More specifically, the trastuzumab-WT mAb used in this example is composed of, from the N-terminus to the C-terminus, the HER2-specific V domain of trastuzumab fused to the CH1-hinge-CH2-CH3 domain of human IgG1. H The polypeptide of the anti-HER2 mAb Trastuzumab light chain was as described in https: / / go.drugbank.com / drugs / DB00072 (the amino acid sequence of which is provided as SEQ ID NO: 12) and contained the HER2-specific V domain of Trastuzumab fused to a human kappa constant domain and encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 13. Similarly, the polypeptide of the anti-HER2 mAb Trastuzumab light chain was as described in https: / / go.drugbank.com / drugs / DB00072 (SEQ ID NO: 14) and contained the HER2-specific V domain of Trastuzumab fused to a human kappa constant domain. Ldomain and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO:15.
[0133] The 11B8-WT mAb used in this example comprises, from N-terminus to C-terminus, the CD20-specific V domain of 11B8 fused to the CH1-hinge-CH2-CH3 domain of human IgG1. H The polypeptide of the anti-CD20 mAb 11B8 light chain is as previously described (SEQ ID NO: 18) and comprises the CD20-specific heavy chain polypeptide of 11B8 fused to the human kappa constant domain, as previously described (U.S. Patent No. 8,529,902) (SEQ ID NO: 16), which comprises the CD20-specific V domain of 11B8 fused to the human kappa constant domain, as previously described (SEQ ID NO: 17). L domain and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO:19.
[0134] The daratumumab-WT mAb used in this example is the CD38-specific V-domain of daratumumab mAb fused to the CH1-hinge-CH2-CH3 domain of human IgG1, in the order of N-terminus to C-terminus. H The polypeptide of the anti-CD38 mAb Daratumumab light chain comprises the CD38-specific V domain of the anti-CD38 mAb Daratumumab mAb fused to a human kappa constant domain, as previously described (https: / / go.drugbank.com / drugs / DB09331) (SEQ ID NO: 20), and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 21. Similarly, the polypeptide of the anti-CD38 mAb Daratumumab light chain comprises the CD38-specific V domain of the anti-CD38 mAb Daratumumab mAb fused to a human kappa constant domain, as previously described (https: / / go.drugbank.com / drugs / DB09331) (SEQ ID NO: 20), and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 21. L domain, as previously described at https: / / go.drugbank.com / drugs / DB09331 (SEQ ID NO: 22) and encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 23.
[0135] The Pertuzumab-WT mAb used in this example comprises, from the N-terminus to the C-terminus, a HER2-specific V-domain fused to the CH1-hinge-CH2-CH3 domains of human IgG1. HThe polypeptide of the anti-HER2 mAb Trastuzumab light chain comprises a HER2-specific heavy chain polypeptide as previously described at https: / / go.drugbank.com / drugs / DB06366 (SEQ ID NO: 24) containing the HER2-specific V domain of Pertuzumab mAB fused to a human kappa constant domain and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 25. Similarly, the polypeptide of the anti-HER2 mAb Trastuzumab light chain comprises a HER2-specific V domain of Pertuzumab mAB fused to a human kappa constant domain. L domain, as previously described at https: / / go.drugbank.com / drugs / DB06366 (SEQ ID NO: 26) and encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 27.
[0136] The Rituximab-WT mAb used in this example is the CD20-specific V-domain of Rituximab fused, from N-terminus to C-terminus, to the CH1-hinge-CH2-CH3 domains of human IgG1. H The CD20-specific heavy chain polypeptide (described at https: / / go.drugbank.com / drugs / DB00073) (SEQ ID NO: 28) includes a CD20-specific V domain of rituximab fused to a human kappa constant domain and encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 29. L The polypeptide of the anti-CD20 mAb Rituximab light chain as previously described at https: / / go.drugbank.com / drugs / DB000723 (SEQ ID NO: 30), including the domains, and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 31.
[0137] Synthesis of unmodified and mutated heavy chains Antibody expression vectors were generated by standard methods known to those skilled in the art. In summary, the antibody expression vectors consisted of synthetic polynucleotide sequences encoding antibody heavy or light chains appropriately arranged in plasmids such as, for example, pcDNA3 and pcDNA3.4 (Thermo Fisher Scientific). Expression vectors for antibodies of different specificities were generated by using existing variable domains (V HOr V L ) at the borders of the vector. The new synthetic DNA encoding the new V domain and flanked by sequences (e.g., 25 nucleotides) that were homologous to the cut vector was then assembled by reaction with NEBuilder (New England Biolabs) according to the manufacturer's instructions.
[0138] Fc variants were produced by synthesis of a synthetic polynucleotide sequence encoding the variant or by cleaving the Fc coding sequence of an antibody expression plasmid with the appropriate restriction enzyme and incorporating the new mutagenized synthetic DNA in a reaction using NEBuilder (New England Biolabs) according to the manufacturer's instructions.
[0139] Expression of antibody constructs Expression of antibodies was performed using transient transfection of Expi293F cells (Thermo Fisher Scientific). Expi293F cells were cultured in EXPI expression medium (Life Technologies) and 24 h prior to transfection cells were incubated with 2 × 10 6 On the day of transfection, the cells were divided into 7.5 x 10 viable cells / ml. 7 Live log-phase cells were centrifuged and resuspended in 25 ml pre-warmed antibiotic-free Expi293 expression medium and maintained at 37° C. until transfection. Cells were then transfected at room temperature using the Life Technologies Expifectamine Transfection Kit as follows. Eighty microliters of ExpiFectamine 293 reagent was diluted in 1.5 ml of Opti-MEM-I reduced serum medium (Gibco) and incubated at room temperature for 5 minutes. Thirty micrograms of DNA (15 μg of heavy chain DNA and 15 μg of light chain DNA) was diluted in 1.5 ml of Opti-MEM-I reduced serum medium, then added to the diluted ExpiFectamine reagent, incubated at room temperature for 20-30 minutes, then added dropwise to the Expi293F cell suspension, which was then cultured at 37°C for 16-18 hours, at which point 150 μL of the manufacturer's Enhancer 1 and 1.5 ml of Enhancer 2 were added, and the cells were cultured at 37°C for an additional 4 days.
[0140] Cell cultures were harvested and centrifuged at 2500 rpm for 20-30 min, and the supernatants were filtered through 0.2 μm high-flow filters (Sartorius AG, Göttingen, Germany) prior to purification. The presence of the expected antibodies in the supernatants was confirmed by SDS-PAGE.
[0141] Protein A affinity purification of mAbs mAb was purified from the supernatant of transfected Expi293F cells by protein A affinity chromatography. Briefly, a Hi-trap™ protein A high performance column (GE Healthcare Life Sciences) was washed and equilibrated in binding buffer (20 mM NaH2PO4 pH 7.0), cell culture supernatant was loaded, the column was washed with binding buffer to baseline OD280nm, bound antibody was eluted with 0.1M sodium citrate tribasic dihydrate (pH 3.5), 1 ml fractions were collected and immediately neutralized with 1M Tris-HCl pH 9.0, and antibody-containing fractions were pooled.
[0142] Size Exclusion Chromatography (SEC) of mAbs After Protein A affinity purification, antibodies were further purified and characterized using size exclusion chromatography (SEC). Protein A purified antibodies were concentrated to an OD280nm of 6-8 using a 30 kDa molecular weight cutoff centrifugal concentrator device (Merck-Millipore). A Superose 6 10 / 300GL column (GE Healthcare Life Sciences) was equilibrated in PBS pH 7.2, then the concentrated Protein A affinity purified antibodies were loaded and separated at a flow rate of 0.5 ml / min in PBS, collecting 0.5 ml fractions. For some mAbs, SEC was performed at pH 5.0, so the concentrated Protein A purified mAbs were dialyzed overnight against buffer (100 mM sodium citrate, 100 mM NaCl, pH 5.0) and then applied to a Superose 6 10 / 300 column pre-equilibrated in the same buffer. The dialyzed antibody was applied to a Superose column SEC at a flow rate of 0.5 ml / min and 0.5 ml fractions were collected from the column.
[0143] Assessment of antigen binding by monoclonal antibodies Purified antibodies were tested for antigen binding prior to functional analysis. mAbs recognizing cell surface antigens were tested for antigen recognition by flow cytometry as previously described in Trist et al., J Immunol 192(2):792-803,2014. Anti-CD20 mAbs based on rituximab or 11B8 and anti-CD38 mAbs based on daratumumab were tested for binding to Ramos lymphoma cells expressing CD20 and CD38. Anti-HER2 mAbs based on trastuzumab and pertuzumab mAbs were tested on the HER2-expressing ovarian cancer cell line SK-OV-3. Briefly, mAbs were titrated by serial 2-fold dilutions in 25 μl of FACS buffer (PBS with 0.5% (w / v) BSA). Then, 5×10 6Twenty-five microliters of target cells at a concentration of 1000 μl / ml were added to the titrated mAb and incubated on ice for 30 minutes. The cells were then washed twice in FACS buffer, resuspended with 50 μl of anti-human IgG(Fab')2-Alexa 647 conjugate, incubated on ice for 30 minutes, washed twice in cold FACS buffer, and then resuspended in 200 μl of FACS buffer. The cells were analyzed by flow cytometry using a BD FACSCanto™ II flow cytometer.
[0144] Flow cytometric detection of C1q binding to cells opsonized with monoclonal antibodies. C1q binding to antibody-opsonized cells was assessed by flow cytometry. Ramos lymphoma cells or SK-OV-3 adenocarcinoma cells (5 × 10 in FACS buffer) were cultured at 4 °C for 1 h. 6 100 μL / ml) were incubated with serial dilutions of anti-CD20 rituximab-based antibody or anti-HER2 trastuzumab-based antibody, respectively, for 30 min on ice. Cells were washed twice in FACS buffer, resuspended in normal human serum diluted 1 / 3 in FACS buffer, and incubated for an additional 30 min on ice. Cells were then washed twice in cold FACS buffer, and bound C1q was detected by resuspending cells in rabbit antiserum detecting human C1q (1:500 dilution) and incubated for an additional 30 min on ice. Cells were then washed twice in cold FACS buffer, resuspended in phycoerythrin-conjugated donkey antiserum detecting rabbit antibodies for 30 min, washed twice more, and resuspended in 200 μL ice-cold FACS buffer before analysis on a BD FACSCanto™ II flow cytometer (Becton Dickinson).
[0145] Complement-dependent lysis of cells CDC was measured by flow cytometry using the Zombie Green Fixable Viability kit (BioLegend) after opsonization of target cells with mAbs. The mAbs of interest were serially diluted 2-fold in 25 μl of PBS / BSA / G (PBS containing 0.5% (w / v) BSA and 1 mM glucose) or Lebowitz-15 (L-15) medium (containing 0.5% (w / v) BSA and lacking phenol red) starting at the initial concentration indicated in the figures. Thus, for each WT or modified mAb (i.e., H429 mutant mAb), or combinations thereof, 5 × 10 mAbs in 25 μl of PBS / BSA / G were diluted 2-fold. 6 25 μl of target cells at a concentration of 1 / ml were then added to the titrated mAb and incubated on ice for 30 min. The cells were then washed twice in buffer, resuspended in 50 μl of complement (normal human serum (NHS) thawed just before use and diluted 1:3 in buffer) and incubated at 37° C. for 30 min. After incubation, the cells were washed twice in cold buffer without BSA, then resuspended in 50 μl of Zombie Green (prepared in DMSO according to the manufacturer's instructions; BioLegend), diluted 1 / 500 in PBS, and incubated on ice for a further 30 min, protected from light. The cells were then washed once in buffer, resuspended in 50 μl of 2% paraformaldehyde / BSA / PBS / G, incubated on ice for 30 min, then washed once in PBS / BSA and resuspended in 200 μl of PBS / BSA / G. Cells were analyzed by flow cytometry using a BD FACSCanto™ II flow cytometer (Becton Dickinson).
[0146] MAb collaboration to enhance C1q binding and CDC 5 x 10 in 25 μl PBS / BSA / G 5Ramos cells at cells / ml were incubated with 2-fold diluted Rituximab-WT in the presence of 0.025 μg / ml Daratumumab-WT, or Rituximab-H429F with 2-fold diluted Rituximab-H429F in the presence of 0.025 μg / ml Daratumumab-H429F variant or 0.5 μg / ml 11B8-H429F variant in the presence of 1 / 3 dilution of normal human serum for 30 min at 37° C., washed twice with PBS, incubated with 1 / 500 Zombie Green on ice for 30 min, washed again with PBS / BSA / G, and fixed with 2% paraformaldehyde. Cells were washed, resuspended in PBS / BSA / G, and analyzed on a BD FACSCanto™ II flow cytometer (Becton Dickinson).
[0147] Results and Discussion Antigen binding by monoclonal antibodies The antigen-binding capacity of the purified antibodies used in this example was tested and confirmed prior to functional analysis.
[0148] Purified mAbs detecting cell surface antigens were then applied to antigen-positive Ramos cells (CD20 + CD38 + ) or SK-OV-3 cells (HER2 +), all of the mAbs showed readily detectable levels of antigen binding (Figure 14). Furthermore, within each group, the modified mAbs carrying mutations in the IgG heavy chain showed binding activity similar to that of the unmodified (WT) forms (e.g., anti-CD20 mAb Rituximab-WT and Rituximab-H429F and Rituximab-H429Y mutants showed comparable homogenous binding to CD20-expressing Ramos cells). Similarly, the anti-CD38 Daratumumab-WT mAb and its CH3-modified mutants, Daratumumab-H429F, and anti-CD20 11B8-WT and its CH3-modified mutants all gave binding profiles comparable to their respective wild-type forms (Figure 14). Additionally, the anti-HER2 mAb trastuzumab-WT and its modified CH3 mutant forms, trastuzumab-H429F and trastuzumab-H429Y, showed readily detectable and comparable binding to SK-OV-3 adenocarcinoma cells, as did pertuzumab-WT and its modified CH3 mutants (Figure 14).
[0149] Using mAbs that bind to cell surface molecules, the effect of modifications at position 429 on antibody properties was further investigated. In particular, substitution of H429 was found to alter the physical characteristics of the antibody and selectively promote antibody oligomerization. For example, using variants of the Rituximab antibody that are structurally similar in terms of the introduced tyrosine and phenylalanine amino acids, i.e., Rituximab-H429F mAb and Rituximab-H429Y mAb, it was found that while both Rituximab-H429F mAb and Rituximab-H429Y mAb eluted from a Protein A affinity column as a single homogenous peak with elution characteristics like unmodified Rituximab-WT IgG (Figure 15A), purification by size exclusion chromatography (SEC) at pH 7.2 (Figure 16A) showed that Rituximab-H429Y mAb IgG exhibited a surprisingly different SEC profile (i.e., compared to the profiles for Rituximab-WT and Rituximab-H429F antibodies). That is, the Rituximab-H429Y mAb SEC profile showed two distinct peaks, Rituximab-WT and Rituximab-H429F. It revealed one IgG peak (to the right of the vertical line in FIG. 16A) that was consistent with a single IgG peak in the SEC of the mAb, as well as a second peak (see FIG. 16A, to the left of the vertical line) that likely contained preformed oligomers (IgG(oli)) of Rituximab-H429Y, indicating an equilibrium between the formation of oligomeric and non-oligomeric forms. The presence of both oligomeric and non-oligomeric IgG in Rituximab-H429Y mAb was surprising and different from Rituximab-WT IgG, but even more surprising that this was different from that observed with Rituximab-H429F mAb. Thus, the different biophysical properties of Rituximab-H429Y and Rituximab-H429F mAbs are determined solely by the presence of a hydroxyl in the tyrosine at position 429 of Rituximab-H429Y mAb.
[0150] Using SDS-PAGE, oligomers observed in the SEC IgG of Rituximab-H429Y mAb (IgGoli ) and non-oligomeric (IgG) forms were found to behave similarly to each other and to rituximab-WT IgG and rituximab-H429F mAb IgG. That is, despite its oligomeric nature, rituximab-H429Y IgG oli Rituximab-H429Y migrated under non-reducing conditions as a single ∼150 kDa IgG species identical to its non-oligomeric Rituximab-H429Y IgG (H2L2) form, importantly indicating that the oligomerization of the mAb promoted by the H429Y mutation was non-covalent in nature (Figure 17A). Furthermore, this indicates that Rituximab-H429Y does not form preformed oligomers of IgG (IgG, H2L2) and IgG resulting from non-covalent association between IgG heavy chains carrying the H429Y mutation (IgG oli ) at pH 7.2. Further analysis under reducing conditions by reduction in dithiotheitol (DTT) showed that these non-covalent oligomers of rituximab-H429Y and non-oligomeric rituximab-H429Y IgG were resolved into the expected ∼50 kDa heavy (H) chain and light ∼25 kDa (L) chain species identical to the SDS-PAGE characteristics of rituximab-WT and rituximab-H429F variants.
[0151] Thus, the H429Y modification confers a new feature to Rituximab; in solution at pH 7.2, the mAb exists as a preformed non-covalent oligomer of IgG that exists in equilibrium with a single IgG molecule. In contrast, Rituximab-H429F and Rituximab-WT mAbs exist in solution only as a single IgG species. Thus, the choice of amino acid at position H429 has unpredictable effects on the physical properties of Rituximab IgG.
[0152] These effects of mutations at position H429 were also found to be independent of the V domain: a comparable evaluation of the H429 substitution in trastuzumab, a mAb that detects a cell surface molecule (i.e., HER2) that is unrelated to rituximab and structurally distinct from CD20, achieved similar results (see Figures 15B, 16B, and 17B). Notably, elution of trastuzumab-WT IgG from a protein A affinity matrix with citrate buffer, pH 3.0, resulted in a homogenous single peak (Figure 15B), as did the elution of trastuzumab-H429F and trastuzumab-H429Y mutant mAbs (the single IgG peak is consistent with the peak obtained for the unmodified trastuzumab-WT IgG mAb). Size-exclusion chromatography (SEC) at pH 7.2 (FIG. 16B) then revealed that unmodified trastuzumab-WT and trastuzumab-H429F mAbs each contained the expected single major IgG species, whereas trastuzumab-H429Y mAb, in contrast, exhibited two distinct peaks (FIG. 16B). The first trastuzumab-H429Y IgG peak coincided with the single IgG peak observed for trastuzumab-WT and trastuzumab-H429F mAbs (FIG. 16B, to the right of the vertical line), and the second trastuzumab-H429Y IgG peak was consistent with oligomeric IgG (IgG oli ) (Figure 16B, left of vertical line). In addition, SDS-PAGE (Figure 17B) showed that under non-reducing conditions (i.e., without disulfide bond reduction), the IgG peaks of trastuzumab-WT and trastuzumab-H429F mAbs each migrated with the expected mass of 150 kDa. And, in the case of trastuzumab-H429Y mAb, SDS-PAGE (Figure 17B) showed that under non-reducing conditions, ...H429Y (IgG oli(IgG H2L2) and non-oligomeric (IgG H2L2) species migrated similarly as a single 150 kDa species, clearly demonstrating that trastuzumab-H429Y can exist at pH 7.2 as both a single IgG and preformed oligomers of IgG resulting from non-covalent association between IgG heavy chains carrying the H429Y mutation.
[0153] Thus, the amino acid substitution at position 429 in the trastuzumab heavy chain confers the same properties as those observed for the equivalent substitution in rituximab-based mAbs, and therefore the effect on the physical characteristics of the mutated mAb (particularly oligomerization) promoted by the H249Y mutation may have a significant impact on antibody specificity, molecular target, epitope, as well as V. H and V L It is independent of the domain.
[0154] Preformed oligomeric and non-oligomeric H429Y IgG antibodies exhibit enhanced CDC. Without wishing to be bound by theory, it is believed that oligomerization, and in particular hexamerization, of mAbs provides an optimal basis for C1q binding and activation of the complement cascade leading to complement-dependent effector responses (e.g., phagocytosis or killing of target cells by complement-dependent cytotoxicity (CDC)). Such oligomers / hexamers can be formed either in solution or on the target (i.e., "on-target" oligomerization or assembly).
[0155] The impact on antibody effector function resulting from the H429Y modification of the CH3 domain of the IgG heavy chain was evaluated by complement-dependent cytotoxicity assay (CDC) (see FIG. 18). As an example, the impact of the H429 mutation on CDC potency was determined for oligomeric and non-oligomeric forms of Rituximab-H429Y using CD20-positive Ramos lymphoma cells as target cells. Thus, both oligomeric Rituximab-H429Y (IgG(oli)) and non-oligomeric IgG (H2L2) forms (FIG. 18A), separated by SEC at pH 7.2, were evaluated for CDC potency and compared to CDC of unmodified Rituximab-WT IgG. Ramos cells were incubated in the presence of serial dilutions of Rituximab-WT IgG or non-oligomeric Rituximab-H429Y IgG (H2L2) (p1 fraction in FIG. 18A) or oligomeric Rituximab-H429Y IgG H2L2 species (p2 fraction in FIG. 18A). Normal human serum (diluted 1 / 3) was then added as a source of complement, and the percentage of Ramos cells killed by CDC at each mAb concentration was determined by flow cytometry (FIG. 18B). Non-oligomeric Rituximab-H429Y IgG (H2L2) (p1 fraction) showed a surprising enhancement in CDC potency compared to unmodified Rituximab-WT. The non-covalent oligomeric IgG form of Rituximab-H429Y (IgG oli ) (p2 fraction) also showed enhanced CDC compared to rituximab-WT. Interestingly, both the oligomeric p2 and non-oligomeric p1 forms exhibited similarly enhanced CDC potency consistent with H429Y oligomers forming hexamers in solution at pH 7.2 prior to binding to target cells, or, in the case of the non-oligomeric form, IgG(H2L2) forming hexamers on the target cell surface following antigen binding, thereby providing an optimal Fc configuration for C1q binding and thus enhanced complement activation as observed with the mAb-H429Y form of IgG.
[0156] Thus, substitution of H429 with tyrosine not only alters the physical characteristics of the mAb to allow oligomerization in solution, but also enhances complement-dependent killing of target cells, regardless of whether the IgG is oligomerized in solution or on the target.
[0157] Oligomerization of mAbs containing H429Y mutations is controlled by changing pH. The nature of non-covalent oligomerization of mAbs containing H429Y modifications in the CH3 domain was further investigated by changing the pH of the buffer (environment) (Figure 18C). In particular, trastuzumab-H429Y mutant mAbs (purified by protein A affinity chromatography) were either dialyzed into a buffer at pH 7.2 and then also subjected to SEC at pH 7.2, or dialyzed into a citrate buffer at pH 5.0 and then subjected to SEC at pH 5.0. At pH 7.2, both oligomeric and non-oligomeric IgG were present, but lowering the pH of the buffer completely reversed the formation of IgG hexameric oligomers, and only IgG(H2L2) species were evident (Figure 18C). Thus, the H429Y modification of the CH3 domain promotes pH-sensitive, non-covalent oligomerization of the mAb, thereby promoting oligomerization / hexamerization in solution or on target that enhances complement effector potency. Furthermore, the ability to control oligomerization by changes in pH may be useful in the production of immunoglobulins bearing this modification.
[0158] The H429F mutation enhances activation of the serum complement cascade The extent to which modification of the CH3 domain at H-chain position 429 affected C1q binding was examined by flow cytometry on cells treated with irrelevant mAbs that recognize CD20 or HER2 and carry the H429F mutation in CH3 of their heavy chains. The results are shown in Figure 19A-D. C1q binding was assessed on CD20 Ramos cells treated with either Rituximab-WT or Rituximab-H429F mAb (Figure 19A,B). Similarly, C1q binding was also measured on HER2-positive SK-OV-3 cells treated with Trastuzumab-WT or Trastuzumab-H429F mAb (Figure 19C,D). C1q bound detectably above background controls to Ramos cells treated with Rituximab-WT mAb (Figure 19A) and to SK-OV-3 cells treated with Trastuzumab-WT (Figure 19C). Importantly, C1q binding to both rituximab-H429F-treated Ramos cells (Figure 19B) and trastuzumab-H429F-treated SK-OV-3 cells (Figure 19D) was enhanced compared to rituximab-WT and trastuzumab-WT. Thus, substitution of H429 in the CH3 domain of the heavy chain enhanced C1q binding in these unrelated anti-CD20 and anti-HER2 mAbs. Thus, it is also clear that this functional enhancement by H429 modification is independent of the antibody variable region and the molecular target and epitope detected. Furthermore, enhanced C1q binding is consistent with enhanced antibody-dependent activation of complement in the classical complement pathway, which leads to the generation of MAC, which leads to cell lysis via CDC.
[0159] Therefore, because binding of the C1q component of the C1 complex initiates the classical complement cascade that leads to cell lysis, the impact of enhanced C1q binding on CDC killing potency was also determined using rituximab-H429F mAb and compared to that of unmodified rituximab-WT (Figure 19E). In particular, the percentage of Ramos cells killed by CDC was assessed by flow cytometry at each of the indicated mAb concentrations (Figure 19E). As well as the surprising enhancement of C1q binding conferred by the H429F modification of the CH3 domain in rituximab-H429F mAb (Figure 19A compared to Figure 19B), the CDC killing potency (EC 50 ) was also dramatically improved (>10-fold) compared to CDC by unmodified rituximab-WT (Figure 19E). This surprising improvement in C1q binding and CDC killing potency by the H429F mutation is consistent with oligomerization (particularly hexamerization) of the antibodies on the target surface, which appears to provide an optimal configuration of the mAb Fc for binding of C1q that is itself a hexamer, as exemplified by analysis of the rituximab-H429F mAb.
[0160] Enhanced complement activation of mAbs carrying the H429 mutation is epitope independent As discussed above, the H429 substitution in the anti-CD20 rituximab mAb was found to strongly increase its CDC activity, and to assess whether the enhancement of antibody function could be applied to a different epitope within a single molecular target, complement activation was examined using a second anti-CD20 mAb. The results are shown in Figures 20-22.
[0161] The type II anti-CD20 mAb, 11B8, inherently exhibits poor CDC activity but, importantly, also detects a distinct epitope from the type I anti-CD20 mAb rituximab (Meyer S et al., Br J Haematol 180(6):808-820, 2018). 11B8-WT mAb and its variants containing the H429F substitution were produced as described above and purified separately by protein A affinity chromatography (Figure 20). A single homogenous IgG peak was obtained for 11B8-WT and 11B8-H429F mAb (Figure 20), indicating that the modification did not alter the purification characteristics of the modified mAb compared to the unmodified 11B8-WT mAb. Size exclusion chromatography also demonstrated that, similar to 11B8-H429F mAb, 11B8-WT mAb contained a single non-oligomeric IgG (H2L2) species (Figure 21A). This was confirmed by SDS-PAGE analysis (Figure 21B), which revealed the expected 150 kDa IgG species before reduction of disulfide bonds for wild-type and mutant mAbs (Figure 21B), which resolved into approximately 50 kDa heavy chain and 25 KD light chain species after reduction in DTT.
[0162] The CDC potency of 11B8 WT was also compared with that of the H429-modified antibody 11B8-H429F (Figure 22). 11B8-WT and 11B8-H429F were titrated in the presence of normal human serum as a source of complement, and the percent killing of Ramos cells was assessed for each mAb concentration. It was found that the 11B8-WT mAb was unable to induce appreciable CDC, whereas, in contrast, the Fc-modified 11B8-H429F mAb mediated potent CDC (Figure 22). Thus, CDC potency was enhanced in two separate unrelated mAbs, Rituximab-H429F and 11B8-H429F (compare Figure 19E and Figure 22), indicating that improved CDC by modification at the H429 position can be achieved in different mAbs targeting distinct epitopes within the same target molecule. This also indicates that the enhanced CDC achieved by CH3 modifications is also independent of the variable domain of the modified antibody.
[0163] The enhancing effect of H429F is independent of antibody, molecular target, and cell type. The enhanced complement activation potency conferred by the H429 substitution to other mAbs was evaluated in the antibody daratumumab, recognizing a fourth unrelated molecular target, namely CD38, a cell surface molecule structurally unrelated to CD20 or HER2 (de Weers M et al., J Immunol 2011;186:1840-1848,2011; Overdijk mB et al., MAbs 7:311-321,2015). Daratumumab-WT mAb was formatted as a human IgG1 and kappa light chain mAb as described above. A variant of this antibody was engineered to replace the H429 residue with phenylalanine to generate daratumumab-H429F mAb. In each case, the daratumumab-based IgG mAb showed comparable characteristics and eluted from a protein A affinity column as a single homogenous peak (Figure 23). Further purification by SEC resulted in a single IgG (H2L2) peak for the daratumumab-WT mAb and a comparable peak for the daratumumab-H429F mutant mAb (Figure 24A). Furthermore, SDS-PAGE confirmed that the SEC-purified mAbs contained the expected 150 kDa IgG species (before disulfide bond reduction) and approximately 50 kDa heavy chain and 25 kDa light chain species after reduction in DTT (Figure 24B).
[0164] The CDC potency of daratumumab-H429F mAb was compared to that of daratumumab-WT mAb (Figure 25). Each mAb was individually titrated by serial 2-fold dilutions in the presence of normal human serum as a source of complement. The percentage killing of CD38-expressing Ramos cells was evaluated for each mAb concentration and is shown in Figure 25. Both daratumumab-WT and daratumumab-H429F mAb achieved approximately 80% killing of Ramos lymphoma cells, but daratumumab-H429F mAb exhibited greater CDC potency, approximately 15-fold higher EC50. The improved CDC potency of daratumumab-H429F mAb was then examined using CD38-positive cells KMS-12-PE myeloma cells, which are resistant to CDC (Figure 26A). Daratumumab-WT mAb, even at a concentration (5 μg / ml) 5-fold greater than that required for maximal killing of Ramos lymphoma cells (1 μg / ml), showed barely detectable CDC of KMS-12-PE cells (about 80% lysis; see FIG. 25) over background control lysis (about 20%) in the presence of complement (no mAb C' only). In contrast, potent CDC of KMS-12-PE cells was mediated by daratumumab-H429F mAb (FIG. 26A). In further experiments, CDC efficacy was evaluated on CD38-expressing SUP-15 acute lymphoblastic leukemia (ALL) cells. As can be seen from FIG. 26B, SUP-15 cells also resisted CDC killing by daratumumab-WT mAb but were easily killed by daratumumab-H429F mutant mAb. Thus, substitutions at position 429 in the CH3 domain not only enhance CDC against certain targets, but can also rescue potent CDC against lysis-resistant targets. Furthermore, the enhanced CDC potency against the CD38 target (structurally distinct from CD20 detected by rituximab and 11B8, and HER2 detected by trastuzumab) also indicates that the improved efficacy is independent of the target and epitope detected, and therefore also independent of the V domain.
[0165] H429 substitution promotes functional synergy between mAbs directed against different epitopes Functional synergy between the mAbs and mediated by the H429 modification was investigated by determining the extent of C1q binding in a mixture of mAbs (trastuzumab and pertuzumab) targeting distinct epitopes on HER2.
[0166] The purification profile of Pertuzumab-WT mAb and a mutant in which H429 was replaced with phenylalanine (i.e., Pertuzumab-H429F mAb) is shown in (Figures 27 and 28A). For each mAb, a single comparable IgG peak was obtained from Protein A affinity chromatography (Figure 27), and when further purified by size-exclusion chromatography, a single homogenous non-oligomeric IgG species was observed (Figure 28A, right of vertical line). SDS-PAGE analysis (Figure 28B) confirmed that these peaks contained a 150 kDa IgG (H2L2) species that was resolved into a ∼50 kDa heavy chain and a ∼25 kDa light chain after reduction (Figure 28B).
[0167] Cooperation between irrelevant anti-HER2 mAbs detecting different epitopes on HER2, Trastuzumab-WT, and Pertuzumab-WT was determined by assessing the degree of C1q binding in the mixture of mAbs quantified by flow cytometry (Figure 29A). Ovarian cancer cells SK-OV-3 treated with equal concentrations of the mixture of HER2 mAbs, Trastuzumab-H429F or Pertuzumab-H429F containing the H429F modification, showed enhanced C1q binding (MFI=10,877) over Pertuzumab-H429F (MFI=798) or Trastuzumab-H429F (MFI=1739) observed when the mAbs were used individually at the same concentrations (Figure 29A).
[0168] Cooperative enhancement of C1q binding was further evaluated by titrating individual anti-HER2 mAbs or paired mixtures of mAbs with 2-fold serial dilutions from a starting concentration of 5 μg / ml, either for each mAb alone or in a mixture of mAbs in a 1:1 ratio starting at 2.5 μg / ml:2.5 μg / ml of each mAb in the mixture (FIG. 29B). Trastuzumab-H429F and pertuzumab-H429F acted synergistically to further enhance complement activation, especially at limiting mAb concentrations (e.g., at 1.25 μg / ml; FIG. 29B, indicated by arrows). C1q binding by a mixture of trastuzumab-H429F at 1.25 μg / ml and pertuzumab-H429F at 1.25 μg / ml (MFI=6327) was greater than C1q binding by the individual mAbs used alone at the same or twice the concentration (i.e., trastuzumab-H429F MFI=603 at 1.25 μg / ml, or 1101 at 2.5 μg / ml, and pertuzumab-H429F MFI=457 at 1.25 μg / ml, or 658 at 2.5 μg / ml) and greater than the mixture of WT mAbs at the same 1:1 concentration (e.g., trastuzumab-WT at 1.25 μg / ml and pertuzumab-WT at 1.25 μg / ml). MFI=522) and was greater than the wild-type mAb used alone (i.e., trastuzumab-WT MFI=258 at 1.25 μg / ml, or 405 at 2.5 μg / ml and pertuzumab-WT MFI=424 at 1.25 μg / ml, or MFI=483 at 2.5 μg / ml). This improved complement activation potency further indicates that greater functional potency can be achieved by cooperative synergy in mixtures of CH3 domain-modified mAbs recognizing different epitopes.
[0169] Modifications of the CH3 domain allow mAbs of different specificities to act synergistically in CDC independent of the target. The cooperative synergy of mAbs leading to greater functional potency as reflected by enhanced C1q binding (Figure 29) was investigated for enhanced CDC lysis of targets using a mixture of mAbs detecting either two different molecular structures (i.e., CD20 and CD38) or two different epitopes within the same molecular structure, CD20. The results are shown in Figure 30.
[0170] Cooperation in CDC between antibodies detecting different molecular structures and different epitopes was determined using a mixture of Rituximab-WT or Rituximab-H429F mAbs targeting CD20 in pairwise combination with Daratumumab-WT or Daratumumab-H429F mAbs targeting an unrelated surface molecule, CD38. When Rituximab-WT mAb was titrated in the presence of 0.25 μg / ml Daratumumab-WT mAb (FIG. 30A), cooperation in CDC was not evident; i.e., CDC observed with any concentration of Rituximab-WT was greater than baseline CDC observed in the presence of 0.25 μg / ml Daratumumab-WT alone (0 μg / ml Rituximab, FIG. 30A) or with any concentration of Rituximab-WT alone (i.e., titrated in the absence of Daratumumab-WT). However, in contrast to the unmodified wild-type mAb, Rituximab-H429F and Daratumumab-H429F mAbs acted to enhance CDC cell killing (Figure 30B). Notably, cooperation between the mAbs in mediating CDC was readily observed in the Rituximab-H429F concentration range of 0.5 μg / ml to 0.125 μg / ml when used with Daratumumab-H429F mAb at 0.025 μg / ml (note, enhancement is indicated by the up arrow in Figure 30B). CDC mediated by Rituximab-H429F mAb with Daratumumab-H429F mAb was significantly greater than either H429F mAb alone (Rituximab-H429F or Daratumumab at 0.025 μg / ml; enhancement is indicated by the up arrow in Figure 30B).
[0171] Functional cooperation between mAbs detecting different epitopes but within the same target molecule was investigated in a mixture of different CD20 mAbs. The results are shown in Figure 30C. Titration of Rituximab-H429F mAb in the presence (0.5 μg / ml) or absence of 11B8-H429F mAb revealed that the mAbs act synergistically. Cooperation between the mAbs was easily detected at limiting concentrations of both mAbs (0.25 μg / ml to 0.031 μg / ml of Rituximab-H429F and 0.05 μg / ml of 11B8-H429F), with CDC being greater than either of the mAbs alone (enhancement indicated by the up arrow in Figure 30C).
[0172] Thus, mAb cooperation and synergy by modification of the antibody heavy chain at position 429, particularly H429F, is broad in its effect, promoting greater functional potency through cooperation and functional synergy in mixtures of mAbs, regardless of the epitopes detected by the individual mAbs (i.e., whether the epitopes reside on the same or different molecular targets).
[0173] Example 4 Killing of B Lymphocytes by Anti-CD20 Therapeutic Antibodies with the H429 Mutation Monoclonal antibodies are used to treat inflammatory diseases, such as autoimmune diseases, by targeting normal (i.e., non-malignant) cells. For example, the anti-CD20 mAb rituximab is used to treat inflammatory diseases by targeting normal B lymphocytes known to express CD20 (Lee DSW et al., Nat Rev Drug Discov 20:179-199, 2021).
[0174] Methods and Materials Isolation of leukocytes from human peripheral blood Peripheral blood mononuclear cells (PBMCs) were isolated from anticoagulated venous blood (Vacutainer ACD-A Becton Dickinson) by centrifugation on a Ficoll gradient. Purified cells from the plasma / Ficoll interface were washed in flow cytometry buffer (L-15 medium lacking phenol red and containing 0.5% BSA (L15-BSA)) and cultured at 5 × 10 6 The pellet was resuspended in L15-BSA to a concentration of 1 ml / ml.
[0175] Complement-dependent lysis of cells CDC killing of normal peripheral blood B lymphocytes in PBMCs mediated by WT and mutated anti-CD20 mAbs was measured by flow cytometry as described above using the Zombie Green Fixable Viability kit (BioLegend) after opsonization of the cells with mAbs.
[0176] CDC was performed in 96-well plates. Cells (25 μl, 5 × 10 6IgG-opsonized cells were then resuspended in 50 μl of human serum diluted 1 / 3 in L15-BSA as a source of complement and incubated at 37°C for 30 min. The treated cells were then washed once in L15-BSA and resuspended in 50 μl of anti-CD19-APC antibody (BioLegend) in L15-BSA and further incubated for 30 min. After washing twice in L-15 lacking BSA, the cells were resuspended in 50 μl of Zombie Green (diluted 1 / 500 in protein-free L-15 medium or PBS according to the manufacturer's instructions) and incubated on ice for 30 min. Cells were washed once in L15-BSA and fixed on ice by resuspending the cells in 2% paraformaldehyde in buffer for 30 min, washed once at the end, and then resuspended in 200 μl of L15-BSA for flow cytometry analysis. B lymphocytes were identified by staining for CD19, and the percentage of dead B lymphocytes specifically killed by CDC was calculated using the CD19 staining in PBMC samples treated with the negative control mAb Trastuzumab-WT or Trastuzumab-H429F antibodies. + Zombie Green + CD19 compared to cell background control + Zombie Green + Listed as a percentage of cells.
[0177] Results and Discussion CDC killing of normal B lymphocytes by rituximab-H429F was examined by flow cytometry and compared to that of unmodified rituximab-WT (Figure 31). Rituximab-H429F showed greater potency, killing more than 85% of B cells (Figure 31B), compared to the much lower killing by unmodified rituximab-WT, which killed only 30% of peripheral blood B lymphocytes (Figure 31A). There was no CDC of B lymphocytes by the negative control anti-HER2 mAb, trastuzumab-WT, or trastuzumab-H429F, since HER2 is not expressed on B lymphocytes (Figures 31C,D).
[0178] Example 5 The H429F modification improves the function of other types of immunoglobulins Histidine 429 is conserved in the equivalent position in all human Ig classes and subclasses (Figures 3 and 4), i.e. in all IgG and IgA subclasses (Figure 3), IgD (Figure 4), and also in the CH3 domain of IgE and IgM, the CH4 domain being equivalent to that of IgG (Figure 4). The effect of modification of H429 on the function of other immunoglobulins was evaluated using human IgG3 and human IgG4 as examples.
[0179] Methods and Materials Antibodies and antibody constructs The mAbs used in this example contained heavy chains of IgG3 or IgG4 subclasses. The IgG3 heavy chain used herein contains three amino acid substitutions, N392K, M397V, and R435H, introduced to avoid aggregation of the purified antibody (Saito S et al., Prot Sci 28(5):doi:10.1002 / pro,2019).
[0180] The Rituximab-IgG3 CD20-specific heavy chain polypeptide (SEQ ID NO: 38) comprises, from N-terminus to C-terminus, the CD20-specific VH domain of Rituximab fused to the CH1-hinge-CH2-CH3 domain of aggregation-resistant human IgG3 (https: / / go.drugbank.com / drugs / DB00073) and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 39. Similarly, the polypeptide of the anti-CD20 mAb Rituximab light chain as previously described (SEQ ID NO: 30) comprises the CD20-specific VL domain of Rituximab fused to the human kappa constant domain (https: / / go.drugbank.com / drugs / DB00073) and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 31.
[0181] The Rituximab-IgG4-WT formatted CD20-specific heavy chain polypeptide (SEQ ID NO: 40) comprises, from N-terminus to C-terminus, the CD20-specific VH domain of Rituximab fused to the CH1-hinge-CH2-CH3 domain of human IgG4, and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 41. Similarly, the polypeptide of the anti-CD20 mAb Rituximab light chain as previously described by reference (SEQ ID NO: 30) comprises the CD20-specific VL domain of Rituximab fused to the human kappa constant domain, and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 31.
[0182] Modifications to the mAb heavy chain were produced by synthesis of the entire antibody chain codon-optimized polynucleotide sequence containing specific modifications to encode, for example, H429F (GeneArt; Thermo Fisher Scientific), and antibody expression vectors were generated by standard methods known to those of skill in the art. Briefly, the antibody expression vectors consisted of synthetic polynucleotide sequences encoding unmodified antibody heavy chains or carrying modifications / mutations or light chains appropriately positioned within an expression plasmid, such as, for example, pcDNA3.4 (Thermo Fisher Scientific).
[0183] Expression of antibody constructs Expression of antibodies was performed using transient transfection of Expi293F cells (Thermo Fisher Scientific) under the same conditions as described for rituximab and the therapeutic mAbs described elsewhere herein. For all mAbs, cell cultures were harvested after transfection, centrifuged at 2500 rpm for 20-30 min, and the supernatants were filtered through a 0.2 μm high-flow filter (Sartorius AG) before purification. The presence of the expected antibodies in the supernatants was confirmed by SDS-PAGE electrophoresis by the method of Laemmli.
[0184] Protein A affinity purification of MAbs mAbs were purified from the supernatants of transfected Expi293F cells by protein A affinity chromatography as described herein.
[0185] Size Exclusion Chromatography (SEC) Purification of mAbs Following Protein A affinity purification, size exclusion chromatography (SEC) was used to further purify and characterize the antibodies described herein.
[0186] Assessment of antigen binding by monoclonal antibodies (mAbs) Purified antibodies were tested for antigen binding to CD20 positive Ramos lymphoma cells by flow cytometry prior to functional analysis.
[0187] Complement-dependent lysis of cells mAb-mediated CDC was measured after opsonization of Ramos cells with mAbs by flow cytometry as described herein using the Zombie Green Fixable Viability kit (BioLegend).
[0188] Results and Discussion The anti-CD20 mAb rituximab was formatted with an unmodified aggregation-resistant IgG3 heavy chain (rituximab-IgG3), an aggregation-resistant IgG3 heavy chain containing the H429F mutation (rituximab-IgG3-H429F), a wild-type IgG4 heavy chain (rituximab-IgG4-WT), or an IgG4 heavy chain containing the H429F modification (rituximab-IgG4-H429F).
[0189] Rituximab-IgG3 mAb was formatted as an aggregation-resistant human IgG3 and kappa light chain mAb, and a mutant of this antibody was engineered to replace the H429 residue with phenylalanine to generate Rituximab-IgG3(KVH)-H429F mAb. Rituximab-IgG4-WT mAb was also produced and formatted as a human IgG4 and kappa light chain mAb. In each case, the Rituximab IgG3 and IgG4 mAbs showed comparable characteristics and eluted from the Protein A affinity column as a single homogenous peak. Further purification by SEC resulted in a single IgG(H2L2) peak for each of the mAbs. Furthermore, SDS-PAGE confirmed that the SEC-purified mAbs contained the expected intact IgG species (before disulfide bond reduction) as well as the approximately 50 kDa heavy chain and 25 kDa light chain species after reduction in dithiothreitol.
[0190] The CDC potency of Rituximab-IgG3-H429F was evaluated on Ramos cells by flow cytometry and compared to that of Rituximab-IgG3-WT (Figure 32A). Each mAb was titrated by serial two-fold dilutions in the presence of normal human serum as a source of complement. The percentage killing of CD20-expressing Ramos cells was evaluated at each mAb concentration shown in Figure 32A. Rituximab-IgG3-H429F mAb showed greater CDC potency than Rituximab-IgG3 mAb, especially when the concentration of mAb was limiting. The results are important because they demonstrate that the effect of the H429 modification can be successfully incorporated into antibodies containing mutations located elsewhere in the heavy chain (e.g., N392K, M397V, and R435H mutations that overcome IgG aggregation). Furthermore, the R435H mutation is known to enhance the in vivo half-life of IgG3, therefore the enhanced CDC with the H429F mutation (Figure 32A) demonstrates that the H429 modification can be successfully incorporated into antibodies bearing other mutations that affect their in vivo half-life.
[0191] The CDC potency of Rituximab-IgG4-H429F was also assessed on Ramos cells and compared to that of Rituximab-IgG4-WT (Figure 32B). Unmodified Rituximab-IgG4-WT was unable to kill Ramos cells, but surprisingly, the H429-modified Rituximab-IgG4-H429F mAb mediated readily detectable CDC.
[0192] Clearly, the functional effects resulting from the H429F modification are not limited to human IgG1 but may be more broadly applicable to other immunoglobulin types, which is important because histidine 429 is conserved at the equivalent position in all human immunoglobulins (IgG, IgA, IgD, IgE, and IgM; see Figures 3 and 4) and in immunoglobulins of other mammals (e.g., primates).
[0193] Example 6 CDC killing by antibodies with the H429 mutation is also complement dependent CDC by mutated antibodies is dependent on both antibodies and complement Ramos cells were opsonized with mAbs targeting different molecular targets, CD20 and CD38, or with mAbs targeting epitopes within the same molecular target (CD20). CDC of Ramos cells using daratumumab-H429F or 11B8-H429F was assessed in the presence of complement (mAb and human complement), in the presence of mAb but in the absence of complement (mAb only), or in the absence of mAb but in the presence of complement (complement only or C' only) (Figure 33). CDC lysis of Ramos cells was evident only in the presence of both mAb and complement. Cells opsonized only with mAb (i.e., in the absence of complement) showed little lysis under the conditions of the CDC assay. Similarly, non-opsonized cells showed little lysis when incubated with complement only. Thus, lysis of opsonized cells in the CDC assay was dependent on both antibody and complement.
[0194] Example 7 H429 modification confers enhanced CDC to monoclonal antibodies Isatuximab is a monoclonal antibody that recognizes the human CD38 cell surface molecule and exhibits functional properties distinct from those of several other anti-CD38 mAbs, such as daratumumab (Deckert J et al., Clin Cancer Res 20:4574-4583, 2014). Isatuximab inhibits the ADP-ribosyl cyclase activity of the CD38 molecule, detecting a distinct epitope from daratumumab, which poorly inhibits the enzymatic activity (Deckert J et al., 2014 supra). We assessed the effect of H429 modification on the CDC activity of the functionally distinct isatuximab against cells resistant to CDC killing.
[0195] Methods and Materials Antibodies and antibody constructs The Isatuximab-WT mAb used in this example comprises, in N-terminal to C-terminal order, a CD38-specific heavy chain polypeptide having the amino acid sequence shown as SEQ ID NO: 42, which comprises the CD38-specific VH domain of Isatuximab mAb fused to the CH1-hinge-CH2-CH3 domain of human IgG1, and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 43. The polypeptide of the anti-CD38 mAb Isatuximab light chain comprises the amino acid sequence shown as SEQ ID NO: 44 (which comprises the CD38-specific VL domain of Isatuximab mAb fused to a human kappa constant domain), and is encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 45.
[0196] Synthesis of unmodified and mutated heavy chains Antibody expression vectors were generated by standard methods known to those skilled in the art. In summary, the antibody expression vectors consisted of synthetic polynucleotide sequences encoding antibody heavy or light chains appropriately arranged in plasmids such as, for example, pcDNA3 and pcDNA3.4 (Thermo Fisher Scientific). Expression vectors for antibodies of different specificities were generated by substituting existing variable domains (V H Or V L ) at the borders of the vector. The new synthetic DNA encoding the new V domain and flanked by sequences (e.g., 25 nucleotides) that were homologous to the cut vector was then assembled by reaction with NEBuilder (New England Biolabs) according to the manufacturer's instructions.
[0197] Fc variants were produced by synthesis of a synthetic polynucleotide sequence encoding the variant or by cleaving the Fc coding sequence of an antibody expression plasmid with the appropriate restriction enzyme and incorporating the new mutagenized synthetic DNA in a reaction using NEBuilder (New England Biolabs) according to the manufacturer's instructions.
[0198] Expression of antibody constructs Expression of antibodies was carried out using transient transfection of Expi293F cells (Thermo Fisher Scientific) under the same conditions described above for the therapeutic mAbs described elsewhere herein. For all mAbs, cell cultures were harvested after transfection, centrifuged at 2500 rpm for 20-30 min, and the supernatants were filtered through a 0.2 μm high-flow filter (Sartorius AG) prior to purification. The presence of the expected antibodies in the supernatants was confirmed by SDS-PAGE.
[0199] Purification of mAbs and evaluation of antigen binding The mAb was purified from the supernatant of transfected Expi293F cells by Protein A affinity chromatography as described herein. After Protein A affinity purification, the antibodies described herein were further purified and characterized using size exclusion chromatography (SEC). The purified antibodies were then tested for antigen binding to CD38 positive SUP-15 acute lymphoblastic leukemia (ALL) cells by flow cytometry prior to functional analysis.
[0200] Complement-dependent lysis of cells mAb-mediated CDC was measured after opsonization of SUP-15 acute lymphoblastic leukemia (ALL) cells with mAbs by flow cytometry as described herein using the Zombie Green Fixable Viability kit (BioLegend).
[0201] Results and Discussion Isatuximab-WT mAb was formatted as a human IgG1 and kappa light chain mAb as described above. A mutant of this antibody was engineered to replace the H429 residue with phenylalanine to generate isatuximab-H429F mAb. In each case, the isatuximab-based mAbs showed comparable characteristics and eluted from the Protein A affinity column as a single homogenous peak. Further purification by SEC also resulted in a single IgG (H2L2) peak for each of the mAbs. Furthermore, SDS-PAGE confirmed that the SEC-purified mAbs contained the expected intact IgG species (before disulfide bond reduction) as well as the approximately 50 kDa heavy chain and 25 kDa light chain species after reduction in dithiothreitol.
[0202] The CDC potency of Isatuximab-H429F mAb was compared to Isatuximab-WT mAb (Figure 34). Each mAb was individually titrated by serial two-fold dilutions in the presence of normal human serum as a source of complement. CDC potency percentage (% killing) was assessed on CD38-expressing SUP-15 acute lymphoblastic leukemia (ALL) cells. As can be seen from Figure 34, SUP-15 cells resisted CDC killing by Isatuximab-WT mAb, but were easily killed by Isatuximab-H429F mutant mAb. Thus, substitutions at position 429 of the CH3 domain can not only enhance CDC against certain cellular targets, but can also confer potent CDC against targets that are resistant to lysis. Importantly, the results demonstrate that lysis of resistant targets can be achieved by H429 modification of unrelated mAbs that also detect distinct epitopes - isatuximab-H429F (Figure 34) and daratumumab-H429F (Figure 26). Additionally, the results also demonstrate that improved CDC efficacy can be conferred to mAbs with other functional attributes, such as the ability to inhibit target molecule function, in this example, isatuximab's ability to inhibit the ADP-ribosyl cyclase action of CD38.
[0203] Example 8. Generation of anti-death receptor antibodies with the H429 mutation Methods and Materials The mAbs used in this example are listed below in Table 3. The mAbs detect two different epitopes of the human death receptor 5, designated BDR5 and TDR5 (DR5; Overdijk MB et al., Mol Cancer Ther 19:2126-2138, 2020), and were produced in the H2L2 format with heavy chains of human IgG1, IgG2, or IgA2 subclasses and their appropriate light chains of the human kappa class. [Table 3]
[0204] Generation of DR5-specific antibody constructs with IgG heavy chains Immunoglobulin variable and constant region sequences were assembled by standard molecular biology techniques as complete synthetic DNA molecules to encode the entire immunoglobulin heavy and light chains, and these molecules were utilized in the expression vector pcDNA3.4 (Thermo Fisher Scientific).
[0205] The unmodified wild-type mAbs used in this example are based on the sequences of two different mAbs that specifically bind to the human DR5 molecule (see DR5-specific mAbs described in U.S. Pat. No. 10,882,913, the entire disclosure of which is incorporated herein by reference). The mAbs were produced as monoclonal IgG antibodies in the H2L2 format.
[0206] The unmodified DR5-specific mAbs generated comprised the specific VH and VL domains of the mAbs shown in Table 3 and are referred to as wild-type (WT) forms, for example the "wild-type" BDR5-1WT mAb antibody used in this example comprised DR5-specific heavy and light chains, the DR5-specific heavy chain of IgG1 subclass comprising the previously described HC-hDR5-01-G56T sequence but lacking the C-terminal lysine (see SEQ ID NO: 36 in US Pat. No. 10,882,913). The DR5-specific kappa light chain comprised the previously described LC-hDR5-01 polypeptide sequence (see SEQ ID NO: 39 in US Pat. No. 10,882,913). In other cases, unmodified antibodies were generated by fusing the VH domain of a DR5-specific antibody to a wild-type heavy (H) chain constant domain of a particular immunoglobulin subclass or class, for example, the unmodified H chain of BDR5-2WT mAb comprised the previously described DR5-specific VH domain polypeptide sequence of the HC-hDR5-01-G56T sequence (i.e., the VH domain from SEQ ID NO: 36 of US Pat. No. 10,882,913) fused to the constant domain of a wild-type IgG2 H chain lacking the C-terminal lysine. The DR5-specific kappa light chain of BDR5-2WT mAb comprised the previously described LC-hDR5-01 polypeptide sequence (i.e., the LC from SEQ ID NO: 39 of US Pat. No. 10,882,913). More specifically, the BDR5-1WT antibody of IgG1 subclass used in this example comprises the previously described DR5-specific heavy chain polypeptide sequence of HC-hDR5-01-G56T (i.e., from SEQ ID NO: 36 of US Pat. No. 10,882,913), but lacks a lysine residue at the C-terminus of the H chain, the polypeptide sequence of which is provided herein as SEQ ID NO: 46 and encoded by a codon-optimized DNA sequence (SEQ ID NO: 47). The DR5-specific kappa light chain of the BDR5-1WT mAb was previously described as LC-hDR5-01 in SEQ ID NO: 39 of US Pat. No. 10,882,913, the polypeptide sequence of which is provided herein as SEQ ID NO: 48 and encoded by a codon-optimized DNA having the nucleotide sequence shown as SEQ ID NO: 49.
[0207] Separately, the DR5-specific BDR5-2WT antibody was formatted as a human IgG2 antibody subclass comprising, in order from N-terminus to C-terminus, a DR5-specific VH domain from the previously described HC-hDR5-01-G56T sequence (i.e., from SEQ ID NO: 36 of US Pat. No. 10,882,913) fused to the CH1-hinge-CH2-CH3 domain (from the polypeptide sequence provided herein as SEQ ID NO: 50) of a human IgG2 subclass H chain lacking a lysine residue at the C-terminus of the H chain, and encoded by a codon-optimized DNA sequence (SEQ ID NO: 51). The polypeptide of the DR5-specific kappa light chain of mAb BDR5-2WT is as previously described as LC-hDR5-01 (i.e., SEQ ID NO: 39 of US Pat. No. 10,882,913), comprises the polypeptide sequence provided herein as SEQ ID NO: 48, and is encoded by the codon-optimized DNA sequence of SEQ ID NO: 49). Additionally, a DR5-specific antibody, designated TDR5, detecting an epitope distinct from that of the BDR5 mAb, in particular a TDR5 mAb based on the VH domain of the DR5-specific VH domain of the previously described HC-hDR5-05 polypeptide sequence (see SEQ ID NO: 40 of US Pat. No. 10,882,913), was also generated and produced with a DR5-specific kappa light chain having the previously described polypeptide sequence (see SEQ ID NO: 43 of US Pat. No. 10,882,913) as LC-hDR5-05. More specifically, the TDR5-1WT antibody of IgG1 subclass used in this example comprises the previously described DR5-specific heavy chain polypeptide sequence of HC-hDR5-05 (i.e., from SEQ ID NO: 40 of US Pat. No. 10,882,913), but lacks a lysine residue at the C-terminus of the H chain, the polypeptide sequence of which is provided herein as SEQ ID NO: 52 and was encoded by codon-optimized DNA having the sequence provided as SEQ ID NO: 53. The polypeptide sequence of the DR5-specific kappa light chain of the TDR5-1WT antibody is as previously described as LC-hDR5-05 in (i.e., SEQ ID NO: 43 of U.S. Pat. No. 10,882,913), is provided as SEQ ID NO: 54, and is encoded by a codon-optimized DNA sequence (SEQ ID NO: 55).
[0208] Separately, the TDR5-2WT antibody was formatted as a human IgG2 antibody comprising, in order from N-terminus to C-terminus, the DR5-specific VH domain from the previously described HC-hDR5-05 sequence (i.e., from SEQ ID NO: 40 of US Pat. No. 10,882,913) fused to the CH1-hinge-CH2-CH3 domain of the human IgG2 subclass lacking a lysine residue at the C-terminus of the H chain (see the polypeptide sequence provided as SEQ ID NO: 56), and encoded by a codon-optimized DNA sequence (SEQ ID NO: 57). The polypeptide of the DR5-specific kappa light chain of mAb TDR5-2WT is as previously described as LC-hDR5-05 in (i.e., SEQ ID NO: 43 of US Pat. No. 10,882,913), comprises the DR5-specific kappa light chain of the TDR5-1WT antibody (SEQ ID NO: 54), and is encoded by a codon-optimized DNA sequence (SEQ ID NO: 55).
[0209] Generation of DR5-specific antibody constructs bearing IgA H chains DNA sequences corresponding to the immunoglobulin variable and constant region sequences of the DR5 mAb were assembled by standard methodologies well known to those skilled in the art as complete synthetic nucleotide sequences to encode the entire immunoglobulin heavy and light chains. These sequences were utilized in expression vectors such as pcDNA3.4 (Thermo Fisher Scientific).
[0210] The unmodified mAb used in this example was based on the VH and VL chain domains of the DR5-specific mAb described in US Pat. No. 10,882,913, formatted in human IgA heavy chain and human kappa light chain (Table 3).
[0211] Unmodified IgA mAbs comprise the specific VH and VL domains of the mAbs shown (Table 3) and are referred to as wild-type (WT) forms; for example, the "wild-type" BDR5-A2WT mAb used in this example comprised a DR5-specific VH domain polypeptide sequence from within the previously described HC-hDR5-01-G56T sequence (SEQ ID NO: 36 of U.S. Pat. No. 10,882,913), and a DR5-specific kappa light chain comprising the polypeptide sequence of the previously described LC-hDR5-01 sequence (i.e., SEQ ID NO: 39 of U.S. Pat. No. 10,882,913). More specifically, the BDR5-A2WT mAb used in this example comprises a DR5-specific heavy chain polypeptide (whose amino acid sequence is provided as SEQ ID NO:58) that comprises, in order from N-terminus to C-terminus, the DR5-specific VH domain of the previously described HC-hDR5-01-G56T sequence (i.e., the VH portion of SEQ ID NO:36 of US Pat. No. 10,882,913) fused to the CH1-hinge-CH2-CH3 domain of the human IgA2 subclass, and was encoded by a codon-optimized DNA sequence (SEQ ID NO:59). The polypeptide of the DR5-specific kappa light chain of the BDR5-A2WT mAb is as previously described as LC-hDR5-01 (i.e., SEQ ID NO:39 of US Pat. No. 10,882,913), and comprises the DR5-specific VL domain of LC-hDR5-01 fused to the human kappa constant domain light chain polypeptide sequence (SEQ ID NO:48), and was encoded by a codon-optimized DNA sequence (SEQ ID NO:49). Additional DR5-specific antibodies formatted as IgA mAbs were generated. In particular, an IgA WT mAb, TDR5-A2WT, was generated based on the VH and VL domains of the DR5-specific HC-hDR5-05 sequence described in U.S. Pat. No. 10,882,913.More specifically, the TDR5-A2WT antibody used in this example comprises a DR5-specific heavy chain polypeptide (SEQ ID NO:60) comprising a DR5-specific VH domain within the previously described polypeptide sequence of HC-hDR5-05 (SEQ ID NO:40 in US Pat. No. 10,882,913) fused to the CH1-hinge-CH2-CH3 domain of human IgGA2 subclass, in N-terminal to C-terminal order, and encoded by a codon-optimized DNA sequence (SEQ ID NO:61). The DR5-specific light chain polypeptide of the DR5-specific mAb TDR5-A2WT mAb comprises the previously described polypeptide sequence of LC-hDR5-05 (SEQ ID NO:43 in US Pat. No. 10,882,913), comprising the polypeptide sequence provided herein as SEQ ID NO:54, and encoded by a codon-optimized DNA sequence (SEQ ID NO:55).
[0212] Generation of DR5-specific antibody constructs encoding mutated IgG and IgA heavy chains To generate the BDR5-1HF mAb, for example, a mAb comprising an H chain carrying a modification in the sequence at position 429, where histidine 429 was replaced with phenylalanine 429 (H429F) in the Fc portion of IgG1, was produced from a synthetic nucleotide sequence encoding the variant by standard methodologies known to those of skill in the art, and the mutation was verified by DNA sequence analysis. For human IgA H chain, H436 as defined by the Bur numbering convention is equivalent to the H429 position in human IgG1 (EU numbering) and is referred to herein as H429 as defined by the sequence alignment shown in Figures 3 and 4. The antibodies generated were as follows: (i) BDR5-1HF comprises a heavy chain of the IgG1 subclass bearing the H429F modification and comprises the polypeptide sequence shown as SEQ ID NO:62 encoded by a codon-optimized DNA sequence (SEQ ID NO:63). (ii) BDR5-2HF contained a heavy chain of the IgG2 subclass bearing the H429F modification and contained the polypeptide sequence shown in SEQ ID NO: 64 encoded by a codon-optimized DNA sequence (SEQ ID NO: 65). (iii) TDR5-1HF contained a heavy chain of the IgG1 subclass bearing the H429F modification and contained the polypeptide sequence shown in SEQ ID NO: 66 encoded by a codon-optimized DNA sequence (SEQ ID NO: 67). (iv) TDR5-2HF contained a heavy chain of the IgG2 subclass bearing the H429F modification and contained the polypeptide sequence shown in SEQ ID NO: 68 encoded by a codon-optimized DNA sequence (SEQ ID NO: 69). (v) BDR5-A2HF contained a heavy chain of the IgA2 subclass bearing the H429F modification and contained the polypeptide sequence shown in SEQ ID NO: 70 encoded by a codon-optimized DNA sequence (SEQ ID NO: 71). (vi) TDR5-A2HF contained a heavy chain of the IgA2 subclass carrying the H429F modification and contained the polypeptide sequence shown in SEQ ID NO: 72 encoded by a codon-optimized DNA sequence (SEQ ID NO: 73).
[0213] All H chain Fc variants were produced with their appropriate matched human kappa L chain as follows: BDR5 H chain variants were produced with human kappa L chains comprising the polypeptide sequence of LC-hDR5-01 previously described in (i.e., SEQ ID NO: 39 of U.S. Pat. No. 10,882,913), comprising the polypeptide sequence provided as SEQ ID NO: 48, and are encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 49. TDR5 H chain variants were produced with human kappa L chains comprising the polypeptide sequence of LC-hDR5-05 previously described in (i.e., SEQ ID NO: 43 of U.S. Pat. No. 10,882,913), comprising the polypeptide sequence of SEQ ID NO: 54, and are encoded by codon-optimized DNA having the sequence shown as SEQ ID NO: 55.
[0214] Antibody expression was performed using transient transfection of Expi293F cells (Thermo Fisher Scientific). Expi293F cells were cultured in Expi293 expression medium (Life Technologies) and 24 h prior to transfection cells were incubated with 2 × 106 On the day of transfection, the cells were divided into 7.5 x 10 viable cells / ml. 7 Live log-phase cells were centrifuged and resuspended in 25 ml of pre-warmed antibiotic-free Expi293 expression medium and maintained at 37° C. until transfection. Cells were then transfected at room temperature using the Expifectamine Transfection Kit (Life Technologies) as follows: 80 microliters of ExpiFectamine 293 reagent was diluted in 1.5 ml of Opti-MEM-I reduced serum medium (Gibco) and incubated at room temperature for 5 minutes. 30 μg of DNA (15 μg of H-strand DNA and 15 μg of L-strand DNA) was diluted in 1.5 ml of Opti-MEM-I reduced serum medium, then added to the diluted ExpiFectamine reagent and incubated at room temperature for 20-30 minutes, then added dropwise to the Expi293F cell suspension, which was then cultured at 37°C for 16-18 hours, at which point 150 μL of manufacturer's Enhancer 1 and 1.5 ml of Enhancer 2 were added and the cells were cultured at 34°C or 37°C for an additional 4 days.
[0215] Cell cultures were harvested and centrifuged at 2500 rpm for 20-30 min, and the supernatant was filtered through a 0.2 μm high-flow filter (Sartorius AG) prior to purification. The presence of the expected antibodies in the supernatant was confirmed by SDS-PAGE.
[0216] Protein A affinity purification of IgG mAb mAbs were purified from the supernatant of transfected Expi293F cells by protein A affinity chromatography. Briefly, a Hi-trap™ protein A high performance column (GE Healthcare Life Sciences) was washed and equilibrated in binding buffer (20 mM NaH2PO4, pH 7.0). Cell culture supernatant was loaded, the column was washed with binding buffer to baseline OD280nm, and bound antibodies were eluted with 0.1M sodium citrate tribasic dihydrate (pH 3.5), 1 ml fractions were collected and immediately neutralized with 1M Tris-HCl pH 9.0. Fractions containing antibodies were pooled.
[0217] Size Exclusion Chromatography (SEC) of IgG mAb After Protein A affinity purification, antibodies were further purified and characterized using size exclusion chromatography (SEC). Protein A purified antibodies were concentrated to an OD280nm of 6-8 using a 30 kDa molecular weight cutoff centrifugal concentrator device (Merck Millipore). A Superose 6 10 / 300GL column (GE Healthcare Life Sciences) was equilibrated in PBS, pH 7.2, then the concentrated Protein A affinity purified antibodies were loaded and separated at a flow rate of 0.5 ml per minute in PBS, collecting 0.5 ml fractions. For some mAbs, SEC was performed at pH 5.0, so the concentrated Protein A purified mAbs were dialyzed overnight against buffer (100 mM sodium citrate, 100 mM NaCl, pH 5.0) and then applied to a Superose 6 10 / 300 column pre-equilibrated in the same buffer. The dialyzed antibody was applied to a Superose column SEC at a flow rate of 0.5 ml per minute and 0.5 ml fractions were collected from the column.
[0218] Assessment of antigen binding by IgG or IgA mAb Purified antibodies were tested for DR5 antigen recognition prior to functional analysis by flow cytometry as previously described in Trist et al., J Immunol 192(2):792-803,2014 using a BD Biosciences Canto™ II flow cytometer (Becton Dickinson). DR5-specific mAbs were tested for binding to Colo205 colorectal cells, Ramos lymphoma cells, and KMS-12-PE cells. Briefly, purified mAbs or culture supernatants from mAb-producing Expi293 cells were titrated by serial two-fold dilutions in 25 μl of FACS buffer (phosphate-buffered saline with 0.5% (w / v) bovine serum albumin). Note that in the case of binding to KMS-12-PE cells, mAbs were used at a single concentration. Then, 5×10 6 Twenty-five microliters of target cells at a concentration of 1000 μg / ml were added to the mAb and incubated on ice for 30 min. The cells were then washed twice in FACS buffer and resuspended in 50 μl of anti-human IgG (Fc)-FITC conjugate (1 / 500 dilution; Chemicon Merck, Burlington, MA, United States of America) for detection of bound IgG mAb. After incubation on ice for 30 min, they were washed and resuspended in 200 μl of FACS buffer for analysis. IgA mAbs were detected with 50 μl of biotin-conjugated anti-human IgA (0.5 μg / ml) (BD Pharmingen, San Diego, CA, United States of America), incubated on ice for 30 min, washed, resuspended in APC-conjugated streptavidin (1 / 500 dilution), washed twice in cold FACS buffer, and then resuspended in 200 μl FACS buffer for analysis.
[0219] Viability assay The ability of the antibodies to induce cell death was evaluated in a viability assay. Antibodies were tested individually, either as single agents or as a mixture of two antibodies. Viability assays were performed using cell lines routinely cultured in culture medium consisting of RPMI 1640 medium supplemented with 10% (v / v) fetal calf serum + 4 mM glutamine and 100 U / ml penicillin and 0.1 mg / ml streptomycin.
[0220] Cells were harvested from cell culture, washed in culture medium by centrifugation at 200×g, and resuspended in culture medium. Cells were washed again and diluted to 1.2×10 6The cells were resuspended in culture medium to a concentration of 100 μg / ml. One hundred microliters (100 μL) of the cell suspension (10,000 cells) were added to wells of a 96-well flat-bottom sterile plate. Purified mAbs, either as individual mAbs or mAb mixtures, were added in 100 μL of medium at a single concentration or, alternatively, serially diluted two-fold in culture medium across a range of concentrations (10 μg / ml to 0.075 μg / ml) and 100 μL of each dilution was added to the 96-well plate previously seeded with cells along with an additional 75 μL of culture medium, for a total final volume of 200 μL in each well. For mAb mixtures, the total concentration of mAb was the same as in equivalent wells treated with single antibodies. Plates were then incubated at 37 °C in 5% CO2 for 48–72 h, and in some experiments, maximum cell death was determined by adding 10 μl of 1% SDS at the last hour of incubation (i.e., at the end of the incubation period). After the incubation period, cell viability was determined using a colorimetric assay using the Cell Counting Kit 8 (CCK-8; Abcam, Cambridge, United Kingdom). This assay indicates cell viability that is directly proportional to the number of live cells by the production of a formazan dye upon bio-reduction of the tetrazolium salt WST-8 by live cells. The WST-8 solution was diluted 1:2 with culture medium and 40 μl was added to each well of the 96-well plate. Plates were incubated at 37 °C for 2–5 h. Color development was determined by measuring absorbance at 450 nm (absorbance 450) on a Fluorostar OPTIMA (BMG LABTECH, Ortenberg, Germany).
[0221] Viability assay analysis of IgA-formatted DR5 mAbs was performed similarly to IgG, except that cell culture supernatant from mAb-producing Expi293 cells was used as the source of mAb and serially diluted as for IgG mAbs. Maximum viability control values were determined from cells cultured in 200 μL of culture medium in the absence of antibody. For maximum mortality, controls were determined from wells seeded only with cell suspension in 200 μL of culture medium, but treated with 10 μl of 1% SDS at the end of the 1-h incubation period at 37° C. (i.e., the last hour of the incubation period). After the incubation period, cell viability was determined using a colorimetric assay using the Cell Counting Kit 8 (CCK-8; Abcam). This assay indicates cell viability, which is directly proportional to the number of live cells, by the production of a formazan dye upon bioreduction of the tetrazolium salt WST-8 by live cells. WST-8 solution was diluted 1:2 with culture medium and 40 μl was added to each well of a 96-well plate. Plates were incubated at 37 °C for 2-5 h. Color development was determined by measuring the absorbance at 450 nm (absorbance 450) on a Fluorostar OPTIMA (BMG).
[0222] result Induction of apoptotic cell death by mAbs The effect of antibody Fc modification on the agonist activity of monoclonal antibodies was evaluated using the induction of apoptosis by DR5-specific antibodies as an example. MAbs (Table 3) that recognize different epitopes on the human death receptor 5 (DR5, TRAILR2) cell surface molecule were generated and examined for their ability to induce cell death as determined by cell viability assays. The mAbs, BDR5 and TDR5, were directed against two different epitopes on human DR5 and were formatted as H2L2 antibodies, containing a DR5-specific antibody light chain and a DR5-specific H chain that lacked a C-terminal lysine but was otherwise of wild-type human IgG1 or human IgG2 or human IgA subclass (Table 3), or else containing Fc-modified DR5-specific human IgG1, IgG2, and IgA H chains, in which the histidine at position 429 in the CH3 domain of the H chain was replaced with a phenylalanine (H429F).
[0223] Quantification of cell binding by IgG-formatted DR5-specific mAb Purified mAbs detecting DR5 were tested by flow cytometry for binding to DR5-positive Colo205 colorectal cells (Figure 35) or Ramos lymphoma cells (Figure 36). All mAbs showed readily detectable levels of target antigen binding. Furthermore, Fc-modified mAbs carrying mutations in the IgG heavy chain showed identical binding activity to that of the wild-type (WT) form. For example, IgG1 formatted BDR5-1HF containing the H429F modification showed identical binding to Colo205 cells as unmodified wild-type IgG1 BDR5-1WT (Figure 35A). DR5-specific mAbs BDR5-2HF and BDR5-2WT formatted as IgG2 scaffolds (Figure 35B) also showed identical binding activity to each other, thereby clearly demonstrating that Fc modifications do not affect the interaction of the mAbs with their target DR5 epitope. The observation that Fc modification at position 429 does not affect antigen binding by the modified mAb was confirmed by analysis of a TDR5 mAb that detects a second epitope distinct from that detected by the BDR5 mAb. Binding by TDR5-1WT and TDR5-1HF (Figure 35C) was identical to that by the IgG2 formatted forms TDR5-2WT and TDR5-2HF (Figure 35D). Further analysis of mAb binding to DR5 expressed on Ramos lymphoma cells showed that the binding profile of the mAb was not affected by the Fc mutations. IgG1 formatted mAbs BDR5-1WT and BDR5-1HF (Figure 36A) and IgG2 formatted BDR5-2WT and BDR5-2HF (Figure 36B) showed identical binding to Ramos lymphoma cells. TDR5-1WT, TDR5-1HF as IgG1 WT or H429F H chains, respectively (Figure 36C), and TDR5-2WT, TDR5-2HF as IgG2 WT and H429F H chains, respectively (Figure 36D) also bound comparably. Thus, binding to DR5 was not affected by the H429F mutation. This was further confirmed by binding to KMS-12-PE myeloma cells, where binding of wild type or H429F mAbs was identical for each mAb (e.g., BDR5-1WT and BDR5-1HF bound similarly as did IgG2 mAbs BDR5-2WT and BDR5-2HF; Figure 37).This again confirms that binding to the target antigen was not affected by the H429F mutation and that WT and mutant mAbs bound similarly to colorectal, B lymphoma, or myeloma cells.
[0224] Evaluation of cell killing efficacy of DR5-specific mAbs containing IgG H chains The ability of DR5 mAbs to induce death of cells of different lineages was determined in a colorimetric assay that measured the survival of cells cultured in the presence of DR5-specific antibodies (Figure 38, Figure 39). The relative potency of mAbs containing heavy chains bearing the H429F modification or containing the wild-type H chain was determined.
[0225] H429F enhances DR5 mAb-induced killing of colorectal cells Colo205 colorectal cells were incubated in the presence of 20 μg / ml of DR5 mAb. TDR5-1HF mAb, which contained an IgG1 H chain containing the H429F modification, was a potent inducer of death of Colo205 cells with an absorbance of 450 nm = 1.37 compared to cell survival in the absence of antibody with an absorbance of 450 nm = 2.24 (Figure 38, no antibody), and was substantially more potent than its wild-type counterpart TDR5-1WT, which contained a wild-type IgG1 heavy chain and showed little ability to induce cell death with an absorbance of 450 nm = 1.99 (Figure 38).
[0226] The effect of the H429F modification on DR5 mAb containing an IgG2 heavy chain was also determined. TDR5-2HF mAb (20 μg / ml) containing an IgG2 heavy chain containing the H429F modification was a more potent inducer of death of Colo205 cells with an absorbance of 450 nm = 1.32 (Figure 38) compared to cell survival in the absence of antibody with an absorbance of 450 nm = 2.24 (Figure 38, no antibody), and was substantially more potent than its wild-type counterpart TDR5-2WT, which contained a wild-type IgG2 heavy chain and showed little ability to induce cell death with an absorbance of 450 nm = 1.91 (Figure 38).
[0227] Thus, the H429F modification of the IgG Fc improves the ability of anti-death receptor mAbs to induce cell death and result in reduced cell survival. This improved potency due to the H429F modification is independent of the human IgG subclass, as TDR5-1HF and TDR5-2HF mAbs, which contain heavy chains of different IgG subclasses, show comparable improved potency compared to their wild-type counterparts (Figure 38).
[0228] TDR5 and BDR5 mAbs detect different epitopes on DR5. Therefore, to further determine the effect of the H429F modification on the action of anti-death receptor mAbs, Colo205 cells were incubated in a 1:1 mixture of TDR5-2HF (10 μg / ml of each mAb for a total mAb concentration of 20 μg / ml) mixed with BDR5-2HF mAb containing an IgG2 subclass H chain carrying the H429F modification (Figure 38). While TDR5-2HF mAb used individually showed a clear improvement in killing efficacy (absorbance 450 nm = 1.32) compared to its wild-type counterpart (absorbance 450 nm = 1.91), the mixture of BDR5-2HF and TDR5-2HF showed an even greater improvement in killing, in fact exhibiting almost complete killing of cells with an absorbance 450 nm = 0.1 (Figure 38).
[0229] H429F enhances DR5 mAb-induced killing of lymphoma cells The killing potency of the DR5 mAb against colorectal Colo205 cells was established and then the killing potency of the mAb against cells of a different lineage of Ramos lymphoma cells was examined (FIG. 39).
[0230] Both the TDR5-1HF mAb, which contains an IgG1 H chain containing the H429F modification, and the TDR5-2HF mAb, which contains an IgG2 H chain containing the H429F modification, were potent inducers of death of Ramos cells, TDR5-1HF Absorbance 450 nm = 0.39, TDR5-2HF Absorbance 450 nm = 0.42, compared to cell survival in the absence of antibody (no mAb), Absorbance 450 nm = 0.65, and were substantially more potent than their wild-type counterparts, which contain wild-type IgG1 or IgG2 H chains and showed little ability to induce cell death, TDR5-1WT Absorbance 450 nm = 0.59, TDR5-2WT Absorbance 450 nm = 0.51 (Figure 39). Thus, as observed in the killing of colorectal cells (Figure 38), H429F modification of IgG Fc improves the ability of anti-death receptor mAbs to induce cell death in lymphoma cells, resulting in reduced cell survival, indicating that the enhanced killing efficacy is not cell type dependent. Furthermore, the improved killing of lymphoma cells due to H429F modification is independent of human IgG subclass, as TDR5-1HF and TDR5-2HF mAbs containing H chains of different IgG subclasses (i.e., IgG1 or IgG2) show nearly equivalent improved potency compared to their IgG1 or IgG2 wild-type counterparts (Figure 39).
[0231] Because dual epitope targeting with a mixture of mAbs that contained H chains bearing the H429F modification showed maximal killing of Colo205 colorectal cells compared to killing by individual mAbs or wild-type mAbs (Figure 38), the same mixtures were tested for their ability to kill lymphoma cells (Figure 39). Thus, Ramos cells were incubated in a 1:1 mixture of TDR5-2HF (10 μg / ml of each mAb for a total mAb concentration of 20 μg / ml) mixed with BDR5-2HF mAb, which contains an IgG2 subclass H chain bearing the H429F modification (Figure 39). While the TDR5-2HF mAb used individually showed a clear improvement in killing efficacy (absorbance 450 nm = 0.42) compared to its wild-type counterpart (absorbance 450 nm = 0.51), the mixture of BDR5-2HF and TDR5-2HF showed an even greater improvement in killing, in fact exhibiting near complete killing of cells with an absorbance 450 nm = 0.03 (Figure 39).
[0232] Efficacy of dual epitope targeting: Killing by a mixture of IgG subclass-matched DR5 mAbs The effect of H429 modification on the killing potency of mixtures of mAbs directed against different epitopes was investigated using pairwise combinations of mAbs incubated with Colo205 cells (Figure 40). In each pairwise mixture, BDR5 and TDR5 mAbs were present in a 1:1 ratio, both mAbs contained the same IgG heavy chain subclass with H429F modification (BDR5-1HF with TDR5-1HF, both IgG1, or BDR5-2HF with TDR5-2HF, both IgG2), and their killing potency was compared to their equivalent paired mAbs with wild type H chains (BDR5-1WT with TDR5-1WT, both IgG1, or BDR5-2WT with TDR5-2WT, both IgG2). The mixture was titrated two-fold in series from 1 μg / ml of total mAb (BDR5 mAb 0.5 μg / ml + TDR5 mAb 0.5 μg / ml) and the effect on Colo205 cell survival was determined after 48 hours. The mixture of BDR5-1WT with TDR5-1WT containing IgG1 wild type chains was not able to induce significant killing of Colo205 cells. In fact, cell survival in this mixture, even at the highest concentration of 1 μg / ml, was comparable to that in the absence of antibody (no antibody, FIG. 40). Replacing the IgG subclass did not improve efficacy, since a mixture of IgG2 BDR5-2WT with TDR5-2WT also lacked killing potency, even at 1 μg / ml. Thus, the lack of potency of the WT mAb mixture was not affected by the IgG subclass, since both IgG1 and IgG2 mixtures were equally poor. However, mixtures containing mAbs with heavy chains containing the H429F modification were highly potent inducers of killing. Mixtures of BDR5-1HF with TDR5-1HF containing IgG1 H chains with the H429F modification achieved killing levels that were comparable to controls for maximum cell death as determined by cell survival in the presence of SDS detergent (SDS, FIG. 40). Furthermore, mAb mixtures BDR5-2HF with TDR5-2HF, in which the mAbs contained IgG2 H chains with the H429F modification, were as potent as their IgG1-based counterpart mAb mixtures, BDR5-1HF with TDR5-1HF.Thus, the improved potency is dependent on the H429F modification, but is independent of the IgG subclass, as they showed roughly equivalent killing improvements regardless of whether they were formatted as human IgG1 or human IgG2 subclass heavy chains.
[0233] Efficacy of dual epitope targeting: Killing by a mixture of DR5 mAbs of different specificities and IgG subclasses A pairwise comparison of mAbs detecting different epitopes of DR5 and containing IgG heavy chains of different IgG subclasses was performed to determine whether the superior killing potency of the mAb mixture was determined by the nature of the individual mAbs of the IgG subclasses and / or epitopes combined in the mixture. In particular, a paired mixture of 1:1 ratios of mAbs was created by mixing two mAbs at equal concentrations (0.5 μg / ml+0.5 μg / ml) to obtain a total anti-DR5 mAb concentration of 1 μg / ml in the mixture (Figure 41). The potency of the mixture of DR5 mAbs was then determined by culturing Colo205 cells with serial 2-fold titration mAb mixtures, where the DR5 mAbs in each mixture contained different human IgG heavy chain subclasses (Figure 41).
[0234] A mixture of BDR5-1WT mAb containing wild-type IgG1 heavy chain with TDR5-2WT mAb containing wild-type IgG2 heavy chain (BDR5-1WT+TDR5-2WT) showed only limited killing of Colo205 cells, and only at the highest concentration (0.5 μg / ml of each mAb, i.e., 1 μg / ml of total mAb). In contrast, the combination of BDR5-1HF mAb containing IgG1 heavy chain containing H429F modification mixed with TDR5-2HF containing IgG2 heavy chain containing H429F modification (BDR5-1HF+TDR5-2HF) mediated maximal killing equivalent to the level of SDS killing control (FIG. 41) and, importantly, showed a killing efficacy greater than the mixture of their wild-type mAb counterparts (BDR5-1WT+TDR5-2WT). Furthermore, the killing potency of the mixture of H429F modified mAbs was also more than 10-fold more effective by titration than their WT counterparts.
[0235] A reciprocal pairing mixture (BDR5-2HF+TDR5-1HF) in which BDR5-2HF contained an IgG2 heavy chain containing the H429F modification and was paired with TDR5-1HF, which contained an IgG1 heavy chain containing the H429F modification, also showed similar maximum killing levels and potencies as the BDR5-1HF+TDR5-2HF mixture. A comparable mixture of mAbs containing wild-type H chains (BDR5-2WT+TDR5-1WT) failed to show significant killing of Colo205 cells. It is also noteworthy that the killing levels achieved by IgGs containing H chains carrying the H429F modification were comparable to the killing by a "homogeneous" mixture (BDR5-2HF with TDR5-2HF) of mAbs of the same H chain subclass carrying the H429F modification, e.g., IgG2 (Figure 40, Figure 41).
[0236] Notably, mixtures of DR5 mAbs with wild-type H chains in any combination of pairs showed little efficacy, whereas inclusion of H429F in the mAb greatly increased cell killing.
[0237] Effect on killing of varying ratios of mAbs in the mixture Although the individual mAbs containing H429F showed improved potency over their wild-type counterparts when used individually (see Figures 38, 39, 42, and 43), the greatest potency was achieved with a mixture of mAbs containing H chains carrying the H429F modification (Figures 40, 41). However, the mixtures used in the above experiments (Figures 38-41) contained mAbs at the same concentration (i.e., 1:1 ratio). Thus, the effect of varying the ratio of individual mAbs in the mixture on cell viability was determined.
[0238] Cell viability was determined by culturing Colo205 cells (Figure 42) or Ramos cells (Figure 43) with a mixture of BDR5-1HF mAb and TDR5-1HF mAb at a final concentration of 1 μg / ml of total DR5-specific mAb as follows: 100% BDR5-1HF with 0% TDR5-1HF, 90% BDR5-1HF with 10% TDR5-1HF, 75% BDR5-1HF with 25% TDR5-1HF, 50% BDR5-1HF with 50% TDR5-1HF, 25% BDR5-1HF with 75% TDR5-1HF, 10% BDR5-1HF with 90% TDR5-1HF, and 0% BDR5-1HF with 100% TDR5-1HF. In the presence of individual mAbs containing wild-type H chains, survival of Colo205 cells was not affected, or in the case of Ramos cells, was barely affected. In fact, for Colo205 cells, treatment with individual mAbs was equivalent to survival in the absence of mAb (no antibody control, Figure 42, Figure 43). Survival in the presence of individual BDR5-1HF mAbs alone and individual TDR5-1HF mAbs alone, both of which contained H429F-modified IgG1 H chains, was slightly reduced compared to wild type. Surprisingly, however, all mixtures showed close to maximum killing of Colo205 and Ramos cells equivalent to the SDS maximum killing control. Also surprising, this potent killing was evident even when one mAb was present in the mixture at only 10%, e.g., BDR5-1HF 90:10 TDR5-1HF (Figure 42, Figure 43). Furthermore, the relative abundance of mAbs of one epitope specificity in the mixture did not affect potency (i.e., BDR5-1HF:TDR5-1HF mixtures were equipotent at all ratios, e.g., BDR5-1HF 90:10 TDR5-1HF was as potent as BDR5-1HF 10:90 TDR5-1HF; Figure 42, Figure 43).
[0239] Evaluation of mAbs containing IgA H chains bearing the H429 modification The DR5-specific mAbs used in the IgG experiments above were also produced containing either wild-type IgA H chains or IgA chains containing the H429F modification and assessed for their ability to induce cell death.
[0240] The DR5-specific mAbs, BDR5 and TDR5, directed against two different epitopes on human DR5, were produced as antibodies comprising the H chain of human IgA, and specifically human IgA2 subclass, as an example (Table 3), according to the method described above. Thus, BDR5-A2WT mAb and TDR5-A2WT mAb comprise a wild-type IgA2 subclass H chain, and BDR5-A2HF mAb and TDR5-A2HF mAb comprise an IgA2 subclass H chain carrying the equivalent of the H429F modification of IgG1 (Figure 3, Table 3), and in all cases the H chain was paired with a specific BDR5 or TDR5 human kappa light chain. Antibodies comprising those L chains and IgA H chains were produced in Expi293 cells, and the supernatants from these cultures were used as the source of DR5 mAbs.
[0241] Binding of IgA-formatted DR5-specific antibodies to target cells was assessed using indirect immunofluorescence and quantified by flow cytometry (Figure 44). All mAbs detected DR5 on Colo205 cells with binding levels significantly above background control levels of non-specific binding of fluorescent conjugates to cells in the absence of antibody (no antibody) or background levels of cell fluorescence (cells) (Figure 44). Turning to the ability of DR5-specific mAbs (containing IgA H chain) to induce cell death, this was assessed by culturing Colo205 cells in the presence of serial dilutions of mAbs (Figure 45). Titration curves revealed that inclusion of H429F in the IgA heavy chain conferred potent cell death, as mAbs that included IgA heavy chains containing the H429F modification were many times more potent inducers of cell death than comparable mAbs containing wild-type IgA heavy chains. Thus, for example, BDR5-A2HF (EC50 >1 / 256 dilution) and TDR5-A2HF (EC50 >1 / 512) were potent inducers of killing compared to IgA BDR5-A2WT (which showed little killing at any dilution) and TDR5-A2WT (which showed killing only at high concentrations (low dilutions) (EC50 approx. 1 / 6 dilution)).
[0242] Notably, the conversion of killing potency upon inclusion of the H429F modification in the immunoglobulin heavy chain is evident in both IgA and IgG heavy chains.
[0243] Cell specificity and killing efficacy by a mixture of H429F-modified mAbs detecting different molecular targets As described above, mixtures of H429F modified mAbs, each of which detected a different epitope on the same molecular target, showed functional improvements over their separate components at the level of C1q binding (see FIG. 29), CDC killing potency (see FIG. 30C), and DR5-induced cell death (see FIG. 38-43). Furthermore, improved CDC was achieved by combinations of H429 modified mAbs that recognize different antigens, i.e., different molecular targets such as CD20 and CD38 (FIG. 30B). Here, experiments in mAb-mediated cell death were performed to evaluate the potency of mixtures of H429F modified mAbs directed against different molecular targets (e.g., CD38 and DR5). Isatuximab mAbs containing WT or H429F mutated IgG H chains were used herein and were as described in Example 7. In particular, Ramos lymphoma cells expressing CD38 and DR5 (Figure 46) were treated individually with the anti-CD38 mAb Isatuximab containing the WT H chain, wild type Isatuximab (Isa-WT), or the anti-DR5 mAb BDR5-1 containing the WT H chain (BDR5-1WT). Treatment with these mAbs alone caused little change in cell viability compared to untreated cells (absorbance at 450 nm = 0.720). Also, treatment with a 1:1 mixture of Isa-WT and BDR5-1WT mAbs (Isa-WT + BDR5-1WT; Figure 46) caused only a slight reduction in cell viability (absorbance at 450 nm = 0.576). Similar reductions in viability were achieved by treatment with the individual H429F-modified mAbs, Isa-HF (absorbance 450 nm = 0.550), or BDR5-1HF (absorbance 450 nm = 0.564) mAbs. In contrast, however, a mixture of Isa-HF with BDR5-1HF mAb (Isa-HF + BDR5-1HF, Figure 46), both of which contain heavy chains bearing the H429F modification, was clearly more effective in reducing cell viability by inducing cell death (absorbance 450 nm = 0.372).
[0244] Consideration The results obtained in this example clearly demonstrate that the substitution of histidine 429 in the IgG heavy chain increases the ability of the mAb to induce cell death in target cells expressing the target antigen. In particular, the H429F modification of the CH3 domain was found to substantially improve the killing potency of the anti-death receptor mAb compared to a mAb with a wild-type H chain (i.e., lacking any modification at position 429). Importantly, the improvement in killing potency was found to be independent of the epitope on the target, independent of the IgG heavy chain subclass to which the H429 modification was made, and independent of the cellular target, and notably, the H429F modification overcame the poor killing ability of the WT mAb directed against a different epitope. In addition, improved killing by BDR5 and TDR5 mAbs containing the H429F modification was achieved when they were formatted as either IgG1 and IgG2 scaffolds, and was found to be further increased by combining two BDR5 and TDR5 mAbs regardless of subclass format, i.e., when two DR5 clones were formatted as H429F modified mAbs of the same IgG subclass (IgG1 or IgG2), or when one clone was IgG1 and the second clone IgG2. In summary, the effect of the H429 modification of the Fc was robust and independent of IgG subclass association, enhancing the receptor agonism of the mAbs individually or in combination, as measured in these examples by DR5-induced apoptosis. Collectively, these results are highly significant in that they confirm the broader utility of the H429 modification for other antibodies, antibody-like molecules, and antibody derivatives, since H429 is conserved, for example, in human, non-human primate, and mouse IgG subclasses (see sequence comparisons provided in Figures 3 and 4). Furthermore, H429 is also found at equivalent positions in the heavy chains of other human Ig classes (i.e., IgA, IgE, and IgM) that are structurally distinct from IgG and would not be expected to mimic the Fc-associated properties attributable to the IgG Fc portion.Nevertheless, using IgA as an example, DR5-specific mAbs used in the IgG studies have instead been generated to contain wild-type IgA H chains or IgA H chains containing the H429F modification and have been found to exhibit enhanced cell killing capabilities.
[0245] Interestingly, the improved killing by individual mAbs carrying the H429F modification was substantially further improved by culturing the target cells in a mixture of mAbs binding different epitopes of the target antigen (e.g., different epitopes of DR5). In particular, it was found that combining TDR5-2HF and BDR5-2HF antibodies achieved more potent killing levels than the individual mAbs (containing the H429F modification), to the extent that the mixture of mAbs even at a ratio of 90:10 resulted in almost complete killing of the cells. Finally, the results of this example also showed that the improved killing achieved with mAbs containing the H429 modification, whether used as individual mAbs or in a mixture, was not restricted to the target cell type; indeed, DR5-specific antibodies exhibited similar levels of enhanced killing of colorectal and lymphoma cell types, regardless of whether they contained IgG1 or IgG2 H chains modified with H429.
[0246] A method to more effectively focus the killing mechanism of action on the intended target cells is desirable for improved immunotherapy with mAbs. The properties of H429-modified mAbs and Fc fusion proteins in forming oligomeric platforms (e.g., for optimal CDC) provide a route to combine mAbs with different specificities for increased cell targeting specificity. Thus, specific cell killing efficacy can be achieved by using one mAb that targets a molecule present on a wide range of cell types but mixed with mAbs that target molecules of limited cellular expression. For example, DR5 and CD38 have different cellular and tissue distributions, but they are co-expressed on some cell types, especially hematopoietic cells (Zola et al., supra, 2007). The results shown in Figure 46 validate this approach, demonstrating that individual H429F-modified DR5 mAbs or individual H429F-modified CD38 mAbs induce modest apoptosis, but lymphoma killing is enhanced by their combination where their antigens are co-expressed on the target cells. This enhanced killing by the combination of H429F-modified mAbs detecting different molecular targets may be due to several mechanisms that depend on the H429F modification of Fc, such as the formation of hetero-oligomers in which different cell surface targets are incorporated into signaling clusters by interactions between H429F-modified H chains of different mAbs, including, for example, both CD38:anti-CD38 and DR5:anti-DR5 oligomeric complexes. Such enhancement may also reflect the integration of signals propagated by the combined engagement and cross-linking of DR5 and CD38 by these mAbs, whether as homo- or hetero-oligomers, or a combination of these effects. Thus, the combined use of H429F-modified mAbs detecting separate molecular target molecules combines target cell specificity with killing potency. Such a combination of effects is desirable in overcoming often limiting factors in therapy, including lack of specificity and undesirable toxicity.
[0247] Example 9 H429 Modifications Confer Enhanced CDC to Further Examples of Anti-CD38 Monoclonal Antibodies Mezagitamab is a monoclonal antibody that recognizes the human CD38 cell surface molecule and exhibits functional properties distinct from those of several other anti-CD38 mAbs, such as daratumumab (Deckert J et al., 2014 supra). We assessed the effect of H429 modification on the CDC activity of mezagitamab against cells resistant to CDC killing.
[0248] Methods and Materials Antibodies and antibody constructs The mezagitamab-WT mAb used in this example comprises a CD38-specific heavy chain polypeptide having the amino acid sequence shown as SEQ ID NO: 74, which comprises, in N-terminal to C-terminal order, the CD38-specific VH domain of mezagitamab mAb fused to the CH1-hinge-CH2-CH3 domain of human IgG1, and is encoded by the codon-optimized polynucleotide sequence shown as SEQ ID NO: 75. The polypeptide of the anti-CD38 mAb mezagitamab light chain comprises the amino acid sequence shown as SEQ ID NO: 76 (which comprises the CD38-specific VL domain of mezagitamab mAb fused to a human lambda constant domain), and is encoded by the codon-optimized polynucleotide sequence shown as SEQ ID NO: 77.
[0249] Synthesis of unmodified and mutated heavy chains Antibody expression vectors and Fc variants containing a replacement of H429 with phenylalanine in the heavy chain of CD38 mAb (H429F) are generated by standard methods known to those of skill in the art and are described elsewhere herein for therapeutic mAbs (e.g., As described in Example 3).
[0250] Expression of antibody constructs Expression of the antibodies was carried out using transient transfection of Expi293F cells (Thermo Fisher Scientific) under the same conditions as those described above for the other therapeutic mAbs described herein. For the mAbs, cell cultures were harvested after transfection, centrifuged at 2500 rpm for 20-30 min, and the supernatants were filtered through a 0.2 μm high-flow filter (Sartorius AG) prior to purification. The presence of the expected antibodies in the supernatants was confirmed by SDS-PAGE analysis.
[0251] Purification of mAbs and evaluation of antigen binding Mezagitamab-H429F and mezagitamab-WT mAbs were purified from the supernatant of transfected Expi293F cells using protein A affinity chromatography followed by size exclusion chromatography. SEC-purified mAbs showed the expected H2L2 format of monomeric IgG confirmed by SDS-PAGE analysis. After purification, binding to CD38-positive cells was confirmed by flow cytometry analysis (data not shown).
[0252] Complement-dependent lysis of cells mAb-mediated CDC of target cells was measured after opsonization of the cells with mAbs by flow cytometry using the Zombie Green Fixable Viability kit (BioLegend) as described elsewhere herein (e.g., Example 3).
[0253] Results and Discussion The ability of mezagitamab-H429F mAb to mediate CDC killing of cells was compared to that by its wild-type counterpart mezagitamab-WT mAb (Figure 47). Each mAb was individually titrated by serial two-fold dilutions in the presence of normal human serum as a source of complement. CDC potency (% killing) was assessed on Ramos cells expressing the CD38 antigen. As can be seen from Figure 47, Ramos cells resisted CDC killing by mezagitamab-WT mAb, showing only a maximum killing level of 27.61% at the highest concentration (5 μg / ml), but were easily killed by mezagitamab-H429F mutant mAb, showing a maximum killing percentage of 89.74%, and even at high dilution (0.16 μg / ml), showing CDC killing of 29%, similar to the maximum killing achieved by the wild-type form (27.61%). Thus, substitutions at position H429 in the CH3 domain of mezagitamab not only enhance CDC against certain cellular targets, but can also confer potent CDC against targets that are resistant to lysis. Importantly, the enhanced level of cell killing conferred by the H429F modification in mezagitamab-H429F further demonstrates that the H429 modification can be effectively applied to unrelated mAbs to enhance cell killing, including cells that are poorly killed by unmodified WT mAb (i.e., cells that are resistant to lysis), as seen, for example, with daratumumab-H429F (Figures 25, 26) and isatuximab-H429F (Figure 34).
[0254] Example 10 H429F modification of Fc region components can produce hetero-oligomers The H429F modification of IgG Fc enhances complement-mediated cytotoxicity (CDC). The K439E and S440K mutations of IgG are known to suppress IgG hexamer formation and inhibit CDC function, but full activity is restored when the two mutant IgGs are used together as a mixture (Diebolder CA et al., 2014 supra). Therefore, the effect of the K439E and S440K mutations on the properties of H429-modified IgG was evaluated in this example using the CD20-specific mAb, rituximab.
[0255] Methods and Materials Antibodies and antibody constructs Used in this example are the Rituximab IgG1 WT heavy chain and the H429F mutant heavy chain described in Example 3 above. Two additional antibodies were synthesized that contained H429F + additional point mutations in the H chain, as described in Table 4. The first additional mAb contained an H chain containing the H429F modification + additional mutation of K439E (Rituximab-H429F / K439E). The second additional mAb contained an H chain containing the H429F modification + additional mutation of S440K (Rituximab-H429F / S440K).
[0256] Synthesis of unmodified and mutated heavy chains Antibody expression constructs and Fc variants containing replacement of H429 with phenylalanine (H429F), replacement of K439 with glutamic acid (K439E), and replacement of S440 with lysine (S440K) in the heavy chain of rituximab mAb were generated by standard methods known to those of skill in the art.
[0257] Expression of antibody constructs Expression of antibodies was performed using transient transfection of Expi293F cells (Thermo Fisher Scientific) under the same conditions described above for the other therapeutic mAbs. For mAbs, cell cultures were harvested after transfection and centrifuged at 2500 rpm for 20-30 min, and the supernatants were then filtered through a 0.2 μm high-flow filter (Sartorius AG) before purification. The presence of the expected antibodies in the supernatants was confirmed by SDS-PAGE.
[0258] Purification of mAbs and evaluation of antigen binding mAbs were purified from the supernatant of transfected Expi293F cells by Protein A affinity chromatography as described elsewhere, such as in Example 3. Following Protein A affinity purification, size exclusion chromatography (SEC) was used to further purify and characterize the antibodies described herein. Purified antibodies were then tested for antigen binding to CD20 positive cells by flow cytometry prior to functional analysis.
[0259] Complement-dependent lysis of cells mAb-mediated CDC of target cells was measured by flow cytometry using the Zombie Green Fixable Viability kit (BioLegend) after opsonization of the cells with mAbs. [Table 4]
[0260] Results and Discussion Rituximab-WT, rituximab-H429F, and the additional C-terminal mutants H429F / K439E and H429F / S440K showed comparable elution from the Protein A affinity column, and further purification by SEC also yielded a single IgG peak for each of the mAbs at 150 kDa by SDS-PAGE, containing approximately 50 kDa heavy chain and 25 kDa light chain species after reduction with dithiothreitol, as described for the same therapeutic mAb in Example 3.
[0261] The CDC potency of Rituximab-H429F was compared to Rituximab-WT (Figure 48A). Each mAb was individually titrated by serial two-fold dilutions in the presence of normal human serum as a source of complement. CDC potency (% killing) was assessed on CD20-expressing Ramos cells. As shown by Figure 48A, Ramos cells were resistant to CDC killing by Rituximab-WT, but were easily killed by the Rituximab-H429F mutant. However, both double mutants, Rituximab-H429F / K439E and Rituximab-H429F / S440K, showed significantly reduced killing compared to Rituximab-H429F. Thus, substitutions at positions 439 or 440 strongly inhibit the CDC enhancing effect of the H429F mutation. Others have shown that K439E and S440K mutations inhibit Fc:Fc interactions, oligomerization (including hexamers), and subsequent CDC by introducing charge repulsion (Diebolder CA et al., 2014 supra). However, when Rituximab-H429F / K439E and Rituximab-H429F / S440K mAbs are used together as a mixture, the fully enhanced CDC activity is restored, comparable to that of Rituximab-H429F. It should be noted that all mAbs conferred nearly identical binding to CD20 (Figure 48B). Thus, the difference in CDC potency conferred by the mutations K439E and S440K was not related to differences in binding to target cells. Without wishing to be bound by theory, it is believed that using these two mutants together as a mixture allows to avoid charge repulsion by heterotypic interactions between K439E and S440K mutant Fc.
[0262] The full CDC activity of the combination of rituximab-H429F / K439E and rituximab-H429F / S440K as a mixture demonstrates that hetero-oligomers (e.g., hexamers) are efficiently formed. This can be exploited to produce hetero-oligomers from two mAbs with different specificities to target two different epitopes on the same antigen, or two completely different antigens. Such heterotypic oligomers, including heterohexamers, are expected to have advantages for specificity, for example, when it is desired that effector functions be directed only or selectively against targets expressing two specificities that are individually recognized by each of the two mAbs. Furthermore, cross-linking of different receptors selected by the different specificities of the two mAbs in hetero-oligomers including heterohexamers is also expected to be efficient. More heterogeneous oligomers (which may nevertheless have highly selective directing of effector functions towards targets or may be capable of multiple cross-linking ...
Claims
1. 1. An immunotherapeutic protein comprising one or more immunoglobulin heavy chain polypeptides comprising an Fc region component comprising at least a constant heavy chain domain 3 (CH3) domain (or at least a constant heavy chain domain 4 (CH4) domain), wherein said one or more polypeptides comprise an amino acid substitution at a position corresponding to H429 (Eu numbering) of the amino acid sequence of a human IgG1 heavy chain.
2. 2. The immunotherapeutic protein of claim 1, wherein the Fc region component comprises constant weight domain 3 (CH3) and constant weight domain 2 (CH2) of an immunoglobulin heavy chain, optionally in combination with lower, core, and / or upper hinge sequences.
3. The immunotherapeutic protein of claim 1 , wherein the Fc region component comprises only constant heavy domain 3 (CH3).
4. The immunotherapeutic protein of any one of claims 1 to 3, wherein the Fc region component is derived from an IgG or IgA heavy chain polypeptide.
5. The immunotherapeutic protein of any one of claims 1 to 4, wherein the immunotherapeutic protein is an immunoglobulin molecule comprising first and second immunoglobulin heavy chain polypeptides comprising an Fc region component comprising CH2 and CH3 domains, such that the first and second polypeptides form an Fc fragment or an Fc-like fragment upon dimerization.
6. The immunotherapeutic protein of claim 4 , wherein the Fc region component is derived from an IgG1 heavy chain polypeptide.
7. The immunotherapeutic protein of claim 4 , wherein the Fc region component is derived from an IgG2 heavy chain polypeptide.
8. The immunotherapeutic protein of claim 4 , wherein the Fc region component is derived from an IgG3 heavy chain polypeptide.
9. The immunotherapeutic protein of claim 4 , wherein the Fc region component is derived from an IgG4 heavy chain polypeptide.
10. The immunotherapeutic protein of claim 4 , wherein the Fc region component is derived from an IgA heavy chain polypeptide.
11. The immunotherapy protein of claim 1, wherein the immunotherapy protein is an immunoglobulin molecule comprising first and second immunoglobulin heavy chain polypeptides comprising an Fc region component comprising CH2 and CH4 domains, such that the first and second polypeptides dimerize to form an Fc fragment or an Fc-like fragment.
12. The immunotherapeutic protein of claim 5 or 11, wherein the immunoglobulin protein is an antibody, an antibody-like molecule, or an antibody derivative.
13. The immunotherapeutic protein of claim 12, wherein the immunoglobulin protein comprises at least one antigen recognition structure capable of specifically binding to a therapeutically important antigen or epitope.
14. The immunotherapeutic protein of claim 13, wherein the at least one antigen recognition structure specifically binds to a cancer-associated antigen, a self-antigen, an allergen, an antigen associated with an inflammatory disease, an antigen from a transplanted tissue or organ, or an antigen of an infectious agent such as an antigen of a bacterial or viral pathogen.
15. The immunotherapeutic protein of claim 14, wherein the at least one antigen recognition structure specifically binds to a cancer-associated antigen selected from CD20, CD38, and CD52.
16. 15. The immunotherapeutic protein of claim 14, wherein the at least one antigen recognition structure specifically binds to an antigen of SARS-CoV-2 virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Respiratory Syncytial Virus (RSV), or Dengue virus.
17. The immunotherapeutic protein of claim 14, wherein the at least one antigen recognition structure specifically binds to an antigen of a viral pathogen selected from an antigen of a coronavirus.
18. The immunotherapeutic protein of claim 13, wherein the at least one antigen recognition structure specifically binds to a cell surface molecule known to induce cell activation or cell proliferation and / or stimulate an inhibitory pathway to inhibit or reduce a cellular response.
19. The immunotherapeutic protein of claim 13, wherein the at least one antigen recognition structure specifically binds to a cell surface molecule known to induce a cellular response selected from stimulating an inhibitory pathway to inhibit or reduce the response.
20. The immunotherapeutic protein of claim 13 or 15, wherein the at least one antigen recognition structure specifically binds to an immune checkpoint molecule.
21. The immune checkpoint molecules include 4-1BB (CD137), cluster of differentiation (CD40, CD154), OX40 receptor (TNFRSF4, CD134), tumor necrosis factor receptor type II (TNFR2, CD120b), glucocorticoid-inducible TNFR-related protein (GITR, TNFRSF18, CD357), cluster of differentiation 27 (CD27), T cell immunoglobulin and mucin domain-containing-3 (TIM-3), B and T lymphocyte attenuation factor (BTLA, CD272), and lymphocyte activator activator 2 (IL-2, CD273).
21. The immunotherapeutic protein of claim 20, selected from the group consisting of lymphocyte activation gene-3 (LAG3, CD223), cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152), inducible costimulatory T cell (ICOS, CD278), cluster of differentiation 28 (CD28), TT cell immunoreceptor with Ig and ITIM domains (IGIT, Vstm3), programmed death ligand 1 (PDL-1, CD274), and programmed cell death protein 1 (PD-1, CD279).
22. The immunotherapeutic protein of claim 13, wherein the at least one antigen recognition structure specifically binds to a cell surface molecule and induces cell death when the cell surface molecule is engaged by a ligand or the immunotherapeutic protein.
23. 23. The immunotherapeutic protein of claim 22, wherein the cell surface molecule is selected from the group consisting of tumor necrosis receptor 1 (TNFR1), Fas (CD95), death receptor 3, death receptor 4, death receptor 5, death receptor 6, and cluster of differentiation (CD38).
24. The immunotherapeutic protein of any one of claims 12 to 23, wherein the immunotherapeutic protein is an antibody that forms oligomers through self-association in solution at physiological pH.
25. 25. The immunotherapeutic protein of claim 24, wherein the immunotherapeutic protein is a hexamer.
26. 26. The immunotherapeutic protein of claim 24 or 25, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide is a H→Y substitution.
27. The immunotherapeutic protein according to any one of claims 12 to 23, wherein the immunotherapeutic protein is an antibody that forms oligomers upon binding to an associated target through "on-target" oligomerization.
29. The immunotherapeutic protein of claim 28, wherein the immunotherapeutic protein forms a hexamer upon binding to an associated target through "on-target" oligomerization.
30. 29. The immunotherapeutic protein of claim 28, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide is an H→F substitution.
31. 29. The immunotherapeutic protein of claim 28, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG2 heavy chain polypeptide is an H→F substitution.
32. 29. The immunotherapeutic protein of claim 28, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG3 heavy chain polypeptide is an H→F substitution.
33. 33. The immunotherapeutic protein of any one of claims 30 to 32, wherein the Fc region component comprises at least a constant heavy domain 3 (CH3) domain (or at least a constant heavy domain 4 (CH4) domain) and a constant heavy domain 2 (CH2) domain, wherein the CH2 comprises a L234A and / or a L235A amino acid substitution.
34. The immunotherapeutic protein of any one of claims 1 to 4, wherein the immunotherapeutic protein comprises a fusion protein or protein conjugate comprising a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a constant heavy domain 4 (CH4) domain).
35. The immunotherapeutic protein of claim 34, wherein the partner polypeptide is a cell surface receptor polypeptide (or a fragment thereof) or a co-receptor polypeptide (or a fragment thereof).
36. The immunotherapeutic protein of claim 34, wherein the partner polypeptide is a cell surface receptor polypeptide (or a fragment thereof) capable of binding to a viral structural protein such that the immunotherapeutic protein can act as a "decoy" to block viral interaction and viral cellular entry into a host cell.
37. 35. The immunotherapeutic protein of claim 34, wherein the partner polypeptide is angiotensin-converting enzyme 2 (ACE2) ectodomain, dipeptidyl peptidase 4 (DPP4, CD26), Hsp70, Hepatitis A virus cellular receptor 1 (HAVCR1 / TIM-1), cluster of differentiation 155 (CD155), glucose transporter 1 (GLUT1), proto-oncogene tyrosine protein kinase MER (MERTK), TYRO3 protein tyrosine kinase (TYRO3), AXL, or cluster of differentiation 4 receptor (CD4 receptor).
38. The immunotherapeutic protein of claim 34, wherein the partner polypeptide is a co-receptor polypeptide (or a fragment thereof).
39. 39. The immunotherapeutic protein of claim 38, wherein the co-receptor polypeptide (or fragment thereof) is C-X-C chemokine receptor type 4 (CXCR4), C-C chemokine receptor type 5 (CCR5), a tetraspanin, or occludin.
40. 35. The immunotherapeutic protein of claim 34, wherein the partner polypeptide is cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (or a soluble extracellular fragment thereof), interleukin-1 receptor (IL-1R), interleukin-6 receptor (IL-6R), tumor necrosis factor receptor-2 (TNFR2, also known as CD120b), or a receptor for a cytokine of the TGF-β superfamily.
41. The immunotherapeutic protein of claim 34, wherein the partner polypeptide is a ligand for a cell surface molecule known to induce cell activation and / or proliferation and / or stimulate an inhibitory pathway to inhibit or reduce a cellular response.
42. The immunotherapeutic protein of claim 41 , wherein the partner polypeptide is a ligand for an immune checkpoint molecule.
43. 43. The immunotherapeutic protein of claim 42, wherein the immune checkpoint molecule is selected from the group consisting of 4-1BB (CD137), CD40 (CD154), OX40 (TNFRSF4, CD134), TNFR2 (CD120b), GITR (TNFRSF18, CD357), CD27, TIM-3, BTLA (CD272), LAG3 (CD223), CTLA4 (CD152), ICOS (CD278), CD28, TIGIT (Vstm3), PDL-1 (CD274), and PD-1 (CD279).
44. 35. The immunotherapeutic protein of claim 34, wherein the partner polypeptide is a ligand for a cell surface molecule that induces cell death when engaged by the ligand.
45. 45. The immunotherapeutic protein of claim 44, wherein the partner polypeptide is a ligand for a cell surface molecule selected from the group consisting of TNFR1, Fas, death receptor 3, death receptor 4, death receptor 5, death receptor 6, and CD38.
46. 46. The immunotherapeutic protein of claim 45, wherein the partner polypeptide is TNF-related apoptosis-inducing ligand (TRAIL).
47. The immunotherapeutic protein of any one of claims 34 to 46, wherein the immunotherapeutic protein is a fusion protein that forms oligomers through self-association in solution at physiological pH.
48. 48. The immunotherapeutic protein of claim 47, wherein the immunotherapeutic protein is a hexamer.
49. 49. The immunotherapeutic protein of claim 47 or 48, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide is a H→Y substitution.
50. The immunotherapeutic protein of any one of claims 34 to 46, wherein the immunotherapeutic protein is a fusion protein that forms oligomers upon binding to an associated target through "on-target" oligomerization.
51. The immunotherapeutic protein of claim 50, wherein the immunotherapeutic protein forms a hexamer upon binding to an associated target through "on-target" oligomerization.
52. 52. The immunotherapeutic protein of claim 50 or 51, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide is an H→F substitution.
53. The immunotherapeutic protein comprises two fusion proteins each comprising an immunoglobulin heavy chain polypeptide comprising an Fc region component comprising at least a constant heavy domain 3 (CH3) domain (or at least a constant heavy domain 4 (CH4) domain) and comprising an amino acid substitution at a position corresponding to H429 (Eu numbering) of the amino acid sequence of a human IgG1 heavy chain, and a partner polypeptide linked to the Fc region component comprising at least a CH3 domain (or at least a constant heavy domain 4 (CH4) domain). 2 Or H 2 L 2 The immunotherapeutic protein according to any one of claims 34 to 52, which is an antibody-like molecule of the form
54. The immunotherapeutic protein of claim 53, wherein the partner polypeptides of the two fusion proteins are the same or different.
55. The immunotherapeutic protein is 2 L 2 55. The immunotherapy protein of claim 53 or 54, which is an antibody-like molecule of the type comprising two fusion proteins each comprising an immunoglobulin light chain polypeptide and a partner polypeptide linked thereto, which may be the same or different.
56. The immunotherapeutic protein of any one of claims 53 to 55, wherein the partner polypeptides are each target recognition structures.
57. 57. Use of an immunotherapeutic protein according to any one of claims 1 to 56 for treating or preventing a disease or condition in a subject, said disease or condition being selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases and proliferative diseases.
58. 57. Use of an immunotherapeutic protein according to any one of claims 1 to 56 in the manufacture of a medicament for treating or preventing a disease or condition, said disease or condition being selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases and proliferative diseases.
59. 57. A method for treating or preventing a disease or condition comprising administering to a subject an effective amount of an immunotherapeutic protein of any one of claims 1 to 56, wherein the disease or condition is selected from autoimmune diseases and conditions, other inflammatory diseases, infectious diseases, and proliferative diseases.
60. 60. The method of claim 59, wherein the immunotherapeutic protein comprises a fusion protein comprising a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a constant heavy domain 4 (CH4) domain), the partner polypeptide being a cell surface receptor polypeptide (or fragment thereof) capable of binding to a viral structural protein such that the immunotherapeutic protein can act as a "decoy" to block viral interaction and viral cellular entry into a host cell, and the method further comprises administering an antibody directed against the virus.
61. 60. The method of claim 59, wherein the immunotherapeutic protein comprises a fusion protein comprising a partner polypeptide linked to an Fc region component comprising at least a CH3 domain (or at least a constant heavy domain 4 (CH4) domain), the partner polypeptide being directed against a therapeutically important target, the method further comprising administering an antibody directed against the target.
62. A pharmaceutical composition or medicament comprising an immunotherapeutic protein according to any one of claims 1 to 56 and a pharma- ceutically acceptable carrier, diluent and / or excipient.
63. 63. A pharmaceutical composition or medicament according to claim 62, wherein the carrier is saline at physiological pH.
64. 63. A pharmaceutical composition or medicament as described in claim 62, wherein the carrier is saline at a pH below 6.
5.
65. 53. A pharmaceutical composition or medicament comprising an immunotherapeutic protein according to claim 51 or 52 and a pharma- ceutically acceptable carrier, diluent and / or excipient, wherein the pH of the composition or medicament is weakly acidic.
66. A pharmaceutical composition or medicament comprising a mixture of two or more different immunotherapeutic proteins according to any one of claims 1 to 56, and a pharma- ceutically acceptable carrier, diluent and / or excipient.
67. 67. The pharmaceutical composition or medicament of claim 66, wherein said mixture of two or more immunotherapeutic proteins binds to different molecular targets.
68. 68. The pharmaceutical composition or medicament of claim 67, wherein the immunotherapeutic protein consists of a first immunoglobulin molecule having a first antigen recognition structure directed to a first antigen and a second immunoglobulin molecule having a second antigen recognition structure directed to a second antigen, wherein the first antigen is a cancer antigen present on the surface of a cancerous cell and the second antigen is a death receptor.
69. 68. The pharmaceutical composition or medicament of claim 67, wherein the immunotherapeutic proteins bind to different epitopes on a single molecular target.
70. A kit of parts comprising at least one immunotherapeutic protein according to any one of claims 1 to 56.
71. A method for producing an immunotherapeutic protein according to any one of claims 1 to 56, comprising culturing a host cell containing a construct encoding said protein under conditions suitable for the expression of said protein, (i) a mildly acidic pH to recover the immunotherapeutic protein in monomeric form, or (ii) recovering the immunotherapeutic protein from the culture supernatant under substantially neutral pH conditions to recover said protein in oligomeric form.
72. 57. A method for producing an immunotherapeutic protein according to any one of claims 1 to 56, comprising culturing a host cell comprising a construct encoding said protein under conditions suitable for expression of said protein, and recovering said protein from the culture supernatant using a method comprising affinity chromatography using an elution buffer comprising an arginine concentration of less than 130 mM and at a pH of 5.0 or less.
73. 72. The method of claim 71, wherein said recovery of the expressed immunotherapeutic protein comprises recovery by size exclusion chromatography (SEC).
Citation Information
Patent Citations
fc mutants with altered binding to fcrn
JP2008519860A
